Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient

TECHNICAL FIELD

[0001] The present invention relates to a carboxylic acid derivative and a peroxisome proliferator activated receptor regulator containing carboxylic acid derivative as active ingredient.

[0002] More particularly, the present invention relates to a peroxisome proliferator activated regulator containing a compound of formula (I)

[0003] (wherein all symbols are as hereinafter described), a non-toxic salt thereof and a hydrate thereof as active ingredient, a novel carboxylic acid derivative of formula (I), a non-toxic salt thereof, a hydrate thereof and a process for the preparation thereof.

BACKGROUND

[0004] Recently in the study of transcription factors concerned with genes expression in adipocytes differentiation, peroxisome proliferator activated receptor (abbreviated as PPAR hereinafter) has been focused. cDNAs of PPAR were cloned from various kinds of animals, and plural isoform genes were found, particularly in mammals three types of isoforms (α, β, γ) are known (see J. Steroid Biochem. Molec. Biol., 51, 157 (1994); Gene Expression, 4, 281 (1995); Biochem Biophys. Res. Commun., 224, 431 (1996); Mol. Endocrinology., 6, 1634 (1992)). PPAR γ isoform is predominantly expressed in adipose tissues, immune cells, adrenal gland, spleen, small intestine. PPAR α isoform is mainly expressed in adipose tissue, liver, retina, and δ isoform shows the expression with no tissue specificity, which is widely expressed (see Endocrinology., 137, 354 (1996)).

[0005] On the other hand, the following thiazolidine derivatives are known as agents for the treatment of non-insulin dependent diabetes mellitus (NIDDM) and are hypoglycemic agents which are used for the improvement of hyperglycemia in the patients suffering from diabetes. They are also effective for the improvement of hyperinsulinemia, glucose tolerance and decrease of serum lipid and therefore they are thought to be considerably hopeful as agents for the treatment of insulin resistance.

[0006] One of the target proteins in the cells of these thiazolidine derivatives is exactly PPAR γ and it is resolved that they enhance the transcription activity of PPAR γ (see Endocrinology., 137, 4189 (1996); Cell., 83, 803 (1995); Cell., 83, 813 (1995); J. Biol. Chem., 270, 12953 (1995)). Therefore, a PPAR activator (agonist) which enhances its transcription activity is thought to be hopeful as a hypoglycemic agent and/or a hypolipidemic agent. Furthermore, since a PPAR γ agonist is known to promote the expression of PPAR γ protein itself (Genes & Development., 10, 974 (1996)), an agent which increases the expression of PPAR γ protein itself as well as PPAR γ activating agent is also clinically useful.

[0007] Among all of nuclear receptors, PPAR γ is related to adipocytes differentiation (see J. Biol. Chem., 272, 5637 (1997) and Cell., 83, 803 (1995)). It is known that thiazolidine derivatives which activate this receptor promote adipocytes differentiation. Recently it was reported that thiazolidine derivatives increase fat mass and cause man to gain weight and to become obese (see Lancet., 349, 952 (1997)). Therefore, it is also thought that antagonists which inhibit PPAR γ activity and agents that decrease the expression of PPAR γ protein itself are also clinically applicable. On the other hand, a compound that phosphorylates PPAR γ protein and decreases its activity is reported (Science., 274, 2100 (1996)). This implies that an agent which does not bind on PPAR γ protein as a ligand, but inhibits its activity is also clinically applicable.

[0008] From these, PPAR γ activators (agonists) and PPAR γ regulators for its expression that can increase the expression of the protein itself are expected to be useful as hypoglycemic agents, hypolipidemic agents, preventives and/or remedies for diseases associated with metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, etc.

[0009] On the other hand, antagonists that inhibit the transcription activity of PPAR γ or PPAR γ regulators that inhibit the expression of the protein itself are expected to be useful as hypoglycemic agents, preventives and/or remedies for diseases associated with metabolic disorders (diabetes, obesity, syndrome X, etc.), hyperlipidemia, atherosclerosis, hypertension, overeating, etc.

[0010] The following fibrate compound (e.g. chlofibrate) is known as a hypolipidemic agent.

[0011] It is also resolved that one of the target proteins in the cells of fibrate compounds is PPAR α (See Nature., 347, 645 (1990); J. Steroid Biochem. Molec. Biol., 51, 157 (1994); Biochemistry., 32, 5598 (1993)). From these facts, PPAR α regulators, which can be activated by fibrate compounds are thought to have a hypolipidemic effect, and so they are expected to be useful as preventives and/or remedies for hyperlipidemia etc.

[0012] Besides, it was recently reported that biological activation of PPAR α linked anti-obese effect in the specification of WO 9736579. It was reported that the elevation of high density lipoprotein (HDL) cholesterol and the reduction of low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol and triglyceride were induced by PPAR α activation (J. Lipid Res., 39, 17 (1998)). It was also reported that improvement of fatty acid composition in the blood, hypertension and insulin resistance by the treatment of bezafibrate (one of fibtrate compounds) (Diabetes., 46, 348 (1997)). Therefore, agonists that activate PPAR α and PPAR α regulators that promote expression of PPAR α protein itself are useful as hypolipidemic agents and remedies for hyperlipidemia, and are expected to have HDL cholesterol-elevating effect, LDL cholesterol and/or VLDL cholesterol-lowering effect, inhibition on the progress of atherosclerosis and anti-obese effect. Therefore, they are thought to be hopeful agents for the treatment and/or prevention of diabetes as hypoglycemic agents, for the improvement of hypertension, for the relief from risk factor of syndrome X and for the prevention of occurrence of coronary heart diseases.

[0013] On the other hand, few reports are found on ligands that activate PPAR δ significantly or on biological activities associated with PPAR δ.

[0014] PPAR δ is sometimes called PPAR β, or it is also called NUC1 in human. So far it was shown that in the specification of WO 9601430 hNUC1B (PPAR subtype whose structure is different from that of human NUC1 in one amino acid)(inhibited the transcription activities of human PPAR α and thyroid hormone receptor. Recently in the specification of WO 9728149, it was reported that compounds bound to PPAR δ protein with high affinity activated PPAR δ significantly (i.e. agonists) and they had HDL (high density lipoprotein) cholesterol-elevating activity. Therefore, agonists that activate PPAR δ are expected to have HDL cholesterol-elevating effect, and so they are expected to be useful for the inhibition on the progress of atherosclerosis and its treatment, as hypolipidemic agents and/or hypoglycemic agents, for the treatment of hyperlipidemia, as hypoglycemic agents, for the treatment of diabetes, for the relief from risk factor of syndrome X, and for the prevention of occurrence of coronary heart diseases.

[0015] The following PPAR regulators have been reported.

[0016] (1) For example, in the specification of WO 9728115, it is described that a compound of formula (A)

[0017] (wherein R1A is selected from hydrogen, C3˜10 cycloalkyl, etc., R2A is selected from hydrogen, C5˜10 aryl, C5˜10 heteroaryl, etc., R4A is selected from R2A etc., (ZA-WA-) is ZA-CR6AR7A or ZA-CR6AR7A—R8A—, etc., R8A is selected from CR6AR7A, O, S(O)pA, etc., R6A and R7A are each independently, selected from hydrogen, C1˜6 alkyl, etc., X1A and X2A are each independently, hydrogen, C1˜15 alkyl, halogen, etc., YA is selected from S(O)pA, —O—, etc., Y1A is selected from O, C, etc., ZA is selected from CO2R3A etc., tA and vA are each independently 0 or 1, tA+vA is 1, QA is saturated or unsaturated 2˜4 straight-chained hydrocarbon, pA is 0˜2, R3A is hydroxy, C1˜15 alkoxy, etc.) or a pharmaceutically acceptable salt thereof is a PPAR δ modulator (necessary part is extracted in the explanation of the group). In the specifications of WO 9727857 and WO 9728137, it is described that analogous compounds therewith are also PPAR δ modulators.

[0018] (2) In the specification of WO 9731907, it is described that a compound of formula (B)

[0019] (wherein AB is phenyl, said phenyl may be substituted by one or more of halogen, C1˜6 alkyl, C1˜3 alkoxy, C1˜3 fluoroalkoxy, nitrile or —NR7BR8B (R7B and R8B are each independently hydrogen or C1˜3 alkyl);

[0020] BB is 5 or 6-membered hetero ring —C1˜6 alkylene-, said hetero ring may be substituted by C1˜3 alkyl;

[0021] AlkB is C1˜3 alkylene;

[0022] R1B is hydrogen or C1˜3 alkyl;

[0023] ZB is selected from —(C1˜3 alkylene)phenyl or —NR3BR4B) or a pharmaceutically acceptable salt thereof has PPAR γ agonist activity (necessary part is extracted in the explanation of the group).

[0024] (3) In the specification of JP Kokai Hei 9˜323982, it is described that a propionic acid derivative of formula (C)

[0025] (wherein R′C is an optionally substituted aromatic hydrocarbon, an optionally substituted cyclic aliphatic hydrocarbon, an optionally substituted hetero ring or an optionally substituted fused hetero ring and R5C is lower alkyl), R4C is hydrogen or lower alkyl, R6C is hydrogen or taken together with R9C to form a double bond, R7′C is hydrogen, hydroxy, carboxy, acyl, optionally substituted alkoxycarbonyl, optionally substituted lower alkyl, optionally substituted carbamoyl, optionally substituted aryloxycarbonyl, optionally substituted aralkyloxycarbonyl or a group represented by formula —YC—R8C (wherein YC is —NH— or oxygen, R8C is optionally substituted acyl, optionally substituted alkoxycarbonyl, aryloxycarbonyl or aralkyloxycarbonyl), R9C is hydrogen, optionally substituted lower alkyl or optionally substituted lower alkoxycarbonyl, R10C is hydroxy, optionally substituted amino, optionally substituted lower alkoxy, optionally substituted lower alkyl, optionally substituted aryloxy or optionally substituted aralkyloxy) or a pharmaceutical composition containing a pharmaceutically acceptable salt thereof has hypoglycemic effect and hypolipidemic effect. In the specifications of JP Kokai Hei 8˜325264, JP Kokai Hei 8-325250, WO 9638415 and WO 9800137, it is described that analogous compounds, therewith have hypoglycemic effect and hypolipidemic effect.

[0026] (4) In the specification of JP Kokai Hei 8˜104688, it is described that a compound of formula (D)

[0027] (wherein RD is an optionally substituted hydrocarbon residue or a hetero ring which may be bound through carbon chain(s), nD is 0 or 1, XD is CH or N, YD is a bivalent hydrocarbon residue. R1D and R2D are the same or different to represent hydrogen, halogen, optionally substituted hydroxyl or an optionally substituted hydrocarbon residue, and either of R1D or R2D may be taken attached to a part of YD to form a ring) or a salt thereof has hypoglycemic effect and hypolipidemic effect. In the specification of JP Kokai Sho 61-85372, it is described that analogous compounds therewith also have hypoglycemic effect and hypolipidemic effect.

[0028] (5) In the specification of JP Kokai Hei 1-143856, it is described that a compound of formula (E)

[0029] (wherein XE is —CR4E═ or —N═, YE is —CR4E═N—, —N═CR4E—, —CR4E═CR4E—, —O—, —S— or —NR4E—, ZE is —(CH2)nEO—, —(CH2)nES—, etc., R1E is —(CHR7E)nECOOR6E etc., nE is each independently 0˜5, R2E is each hydrogen, lower alkyl, lower alkoxy, trifluoromethyl, nitro, cyano or halogen, etc., R3E is

[0030] WE is a bond or —O—, —S— or —NR4E—, mE is 1˜15, R4E is each independently hydrogen or lower alkyl, R7E is hydrogen or methyl) or a pharmaceutically acceptable salt thereof has an inhibitory activity against lipoxygenase and a competitive activity against leucotriene.

[0031] (6) In the specification of JP Kohyo Hei 8-504194, it is described that a compound of formula (F)

XF—YF-ZF—“ArylF”—AF-BF (F)

[0032] (wherein “Aryl F” is a monocyclic 6-membered hetero ring system containing 0, 1, 2, 3 or 4 of N atom and having no substituents or substituted by R5F;

[0033] XF is a mono- or multi-cyclic aromatic or non-aromatic 4˜10 membered ring system etc. containing 0, 1, 2, 3 or 4 of hetero atom selected from N, O and S and having no substituents or substituted by R1F, R2F, R3F or R4F

[0034] R1F, R2F, R3F and R4F are independently selected from a group of hydrogen, C1˜10 alkyl, C3˜8 cycloalkyl, aryl C0˜8 alkyl, amino C0˜8 alkyl, C1˜6 alkylamino C0˜8 alkyl, C1˜6 dialkylamino C0˜8 alkyl, C1˜4 alkoxy C0˜6 alkyl, etc.;

[0035] YF is C0˜8 alkyl, C0˜8 alkyl-O—C0˜8 alkyl, C0˜8 alkyl-SOnF—C0˜8 alkyl, etc., wherein nF is an integer of 0˜2,

[0036] ZF and AF are independently selected from (CH2)mF, (CH2)mFO(CH2)nF, (CH2)mFSO2(CH2)nF, (CH2)mFS(CH2)nF, (CH2)mFSO(CH2)nF, etc., wherein mF and nF are integers independently selected from 0˜6, with the proviso that when AF is (CH2)mF, “Aryl F” which is attached to ZF and AF must contain at least 1 hetero atom;

[0037] R5F is hydrogen, C1˜6 alkyl, C0˜6 alkyloxy C0˜6 alkyl, or halogen, etc., BF is

[0038] wherein R6F, R7F, R8F, R9F, R10F and R11F are independently selected from hydrogen, C1˜8 alkyl, etc.,

[0039] R12F is selected from hydroxy, C1˜8 alkyloxy, etc.) and a pharmaceutically acceptable salt have fibrinogen receptor antagonist activity (necessary part is extracted in the explanation of the group).

DISCLOSURE OF THE INVENTION

[0040] As a result of energetic investigations in order to find compounds which possess PPAR regulating activity, the present inventors have found that the purpose is accomplished by the compound of formula (I).

[0041] Part of the compounds of formula (I) is known by the said specifications of JP Kokai Hei 1-143856 and JP Kohyo Hei 8-504194. The effects of these compounds, that is to say, lipoxygenase inhibitory activity, leucotriene competitive activity and fibrinogen receptor antagonist activity are also known, but PPAR regulating effect of these compounds is not easily expected from these facts.

[0042] The other part of the compounds of formula (I) is novel which has never been known so far.

[0043] The present invention relates to

[0044] 1) a peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I)

[0045] (wherein A1 is C1˜4 alkylene or C2˜4 alkenylene,

[0046] A2 is —O— or —S—,

[0047] A3 is CH or N,

[0048] n is 1˜5,

[0049] R1 is

[0050] (i) hydrogen,

[0051] (ii) C1˜8 alkyl,

[0052] (iii) halogen,

[0053] (iv) C1˜4 alkoxy,

[0054] (v) nitro,

[0055] (vi) trihalomethyl,

[0056] (vii) trihalomethoxy,

[0057] (viii) trihalomethylthio,

[0058] (ix) cyano,

[0059] (x) C1˜4 alkylthio,

[0060] (xi) NR5R6 (wherein R5 and R6 are each independently, hydrogen or C1˜4 alkyl),

[0061] (xii) carbocyclic ring or

[0062] (xiii) hetero ring,

[0063] R2 is

[0064] (i) hydrogen,

[0065] (ii) C1˜4 alkyl,

[0066] (iii) halogen or

[0067] (iv) trihalomethyl,

[0068] Cyc1 is

[0069] Cyc2 is

[0070] (i) carbocyclic ring or

[0071] (ii) hetero ring,

[0072] R1 is

[0073] (i) hydrogen,

[0074] (ii) C1˜8 alkyl,

[0075] (iii) halogen,

[0076] (iv) C1˜4 alkoxy,

[0077] (v) nitro,

[0078] (vi) trihalomethyl,

[0079] (vii) trihalomethoxy,

[0080] (viii) trihalomethylthio,

[0081] (ix) cyano or

[0082] (x) C1˜4 alkylthio,

[0083] R4 is

[0084] or

[0085] (ii) 2,4-thiazolidindion-5-yl,

[0086] A4 is

[0087] (i) bond,

[0088] (ii) C1˜4 alkylene,

[0089] (iii) —C1˜4 alkylene-O— or

[0090] (iv) —C1˜4 alkylene-S—,

[0091] R7, R8 and R9 are each independently hydrogen or C1˜4 alkyl, with the proviso that

[0092] (1) R4 is attached to 2- or 3-position and

[0093] (2) when R4 is attached to 3-position, A4 is bond or methylene, A3 is CH and Cyc1 is benzene, then A1 is methylene, ethylene or vinylene.), its non-toxic salt or hydrate thereof as active ingredient,

[0094] 2) a carboxylic acid derivative of formula (I)

[0095] (wherein A1 is C1˜4 alkylene or C2˜4 alkenylene,

[0096] A2 is —O— or —S—,

[0097] A3 is CH or N,

[0098] n is 1˜5,

[0099] R1 is

[0100] (i) hydrogen,

[0101] (ii) C1˜8 alkyl,

[0102] (iii) halogen,

[0103] (iv) C1˜4 alkoxy,

[0104] (v) nitro,

[0105] (vi) trihalomethyl,

[0106] (vii) trihalomethoxy,

[0107] (viii) trihalomethylthio,

[0108] (ix) cyano,

[0109] (x) C1˜4 alkylthio,

[0110] (xi) NR5R6 (wherein R5 and R6 are each independently hydrogen or C1˜4 alkyl),

[0111] (xii) carbocyclic ring or

[0112] (xiii) hetero ring,

[0113] R2 is

[0114] (i) hydrogen,

[0115] (ii) C1˜4 alkyl,

[0116] (iii) halogen or

[0117] (iv) trihalomethyl,

[0118] Cyc1 is

[0119] Cyc2 is

[0120] (i) a carbocyclic ring or

[0121] (ii) a hetero ring,

[0122] R3 is

[0123] (i) hydrogen,

[0124] (ii) C1˜8 alkyl,

[0125] (iii) halogen,

[0126] (iv) C1˜4 alkoxy,

[0127] (v) nitro,

[0128] (vi) trihalomethyl,

[0129] (vii) trihalomethoxy,

[0130] (viii) trihalomethylthio,

[0131] (ix) cyano or

[0132] (x) C1˜4 alkylthio,

[0133] R4 is

[0134] or

[0135] (ii) 2,4-thiazolidindion-5-yl,

[0136] A4 is

[0137] (i) bond,

[0138] (ii) C1˜4 alkylene,

[0139] (iii) —C1˜4 alkylene-O— or

[0140] (iv) —C1˜4 alkylene-S—,

[0141] R7, R8 and R9 are each independently hydrogen or C1˜4 alkyl, with the proviso that

[0142] (1) R4 is attached to 2- or 3-position and

[0143] (2) when R4 is attached to 3-position, A4 is a bond or methylene, A3 is CH and Cyc1 is benzene, A1 is methylene, ethylnene or vinylene.), a non-toxic acid thereof or a hydrate thereof and

[0144] (3) a method for the preparation of a compound of formula (I).

DETAILED EXPLANATION OF THE INVENTION

[0145] Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylene, alkenylene and alkynylene include straight-chain and branched-chain ones. Moreover, the isomers in the structure of double bond, ring, fused ring (E, Z, cis, trans), the isomers generated by the presence of asymmetric carbon atom(s) etc. (R, S isomers, α, β isomers, enantiomers, diastereomers) optically active isomers having optical rotation (D, L, d, l isomers), isomers separated by chromatography (more polar or less polar isomers), equilibrium compounds, compounds of arbitrary ratio of these compounds.

[0146] In the present invention, C1˜4 alkyl is methyl, ethyl, propyl, butyl and isomers thereof.

[0147] C1˜8 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomers thereof.

[0148] C1˜4 alkoxy is methoxy, ethoxy, propoxy, butoxy and isomers thereof.

[0149] C1˜4 alkylthio is methylthio, ethylthio, propylthio, butylthio and isomers thereof.

[0150] C1˜4 alkylene is methylene, ethylene, trimethylene, tetramethylene and isomers thereof.

[0151] C2˜4 alkenylene is ethenylene, propenylene, butenylene and isomers thereof.

[0152] Halogen is iodine, bromine, fluorine and chlorine.

[0153] Trihalomethyl is methyl group which is tri-substituted by iodine, bromine, fluorine or chlorine.

[0154] Trihalomethoxy is methoxy group which is tri-substituted by iodine, bromine, fluorine or chlorine.

[0155] Trihalomethylthio is methylthio group which is tri-substituted by iodine, bromine, fluorine or chlorine.

[0156] Carbocyclic ring represents C3˜15 mono-, bi-, or tri-cyclic carbon ring and bridged carbocyclic ring. C3˜15 mono-, bi-, or tri-cyclic carbon ring and bridged carbocyclic ring contains, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, benzene, pentalene, indene, naphthalene, azulene, fluorene, phenanthrene, anthracene, acenaphthylene, biphenylene, perhydronaphthalene, indane (dihydroindene), perhydroindene, dihydronaphthalene, tetrahydronaphthalene, perhydronaphthalene, perhydroazulene, perhydrofluorene, perhydrophenanthrene, perhydroanthracene, perhydroacenaphthylene, perhydrophenylene, bicyclopentane, bicyclohexane, bicycloheptane ([2.2.1]bicycloheptane), bicyclooctane, bicyclononane, bicyclodecane, adamantane, etc.

[0157] Hetero ring includes a 4˜18 membered mono-, di- or tri-cyclic hetero aryl, or partially or completely saturated one containing 1˜4 of nitrogen, 1˜2 of oxygen and/or 1 of sulfur.

[0158] Said 4˜18 membered mono-, di- or tri-cyclic hetero aryl containing 1˜4 of nitrogen, 1˜2 of oxygen and/or 1 of sulfur includes pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepin, oxazepin, thiophene, thiain (thiopyran), thiepin, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, ozadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzoimidazole, carbazole, acridine, etc.

[0159] Said 4˜18 membered mono-, di- or tri-cyclic hetero aryl or partially or completely saturated one containing 1˜4 of nitrogen, 1˜2 of oxygen and/or 1 of sulfur includes pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyridine, dihydropyrazine, dihydropyrimidine, dihydropyridazine, piperidine, piperazine, tetrahydropyrimidine, tetrahydropyridazine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiaine (dihydrothiopyran), tetrahydrothiaine (tetrahydrothiopyran), dihydroxazole, tetrahydroxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, morpholine, thiomorpholine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, benzoxazepine, benzoxadiazepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, indoloxazepine, indolotetrahydroxazepine, indoloxadiazepine, indolotetrahydroxadiazepine, indolothiazepine, indolotetrahydrothiazepine, indolothiadiazepine, indolotetrahydrothiadiazepine, indolazepine, indolotetrahydroazepine, indolodiazepine, indolotetrahydrodiazepine, benzofurazane, benzothiadiazole, benzotriazole, camphor, imidazothiazole, dihydrocarbazole, tetrahydrocarbazole, perhydrocarbazole, dihydroacridine, tetrahydroacridine, perhydroacridine, 1,3-dioxaindane, 1,4-dioxaindane ring, etc.

[0160] In the formula (I), R2 is preferably C1˜4 alkyl, more preferably methyl and ethyl.

[0161] In the formula (I), Cyc1 is preferably,

[0162] (wherein the bond in the right hand is attached to A1), more preferably

[0163] (wherein the bond in the right hand is attached to A1.).

[0164] In the formula (I), A1 is preferably C1˜4 alkylene, more preferably C1˜2 alkylene (—CH2—, —(CH2)2—).

[0165] In the formula (I), A2 is preferably —O—.

[0166] In the formula (I), A3 is preferably CH.

[0167] In the formula (I), R4 is preferably attached to 3-position.

[0168] In the formula (I), R4 is preferably

[0169] In the formula (I), A4 is preferably a bond, —C1˜4 alkylene-O— or —C1˜4 alkylene-S—, more preferably a bond or —CH2—S—.

[0170] In the formula (I), R8 and R9 are preferably hydrogen or methyl, more preferably hydrogen.

[0171] In the formula (I), R1 is preferably hydrogen, C1˜8 alkyl, halogen, trihalomethoxy or trihalomethylthio, more preferably hydrogen, halogen or trihalomethoxy.

[0172] In the formula (I), a carbocyclic ring represented by Cyc2 is, preferably C3˜10 mono- or bi-cyclic carbon ring, more preferably cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane or benzene, particularly preferably, cyclopropane, cyclopentane, cyclohexane or benzene.

[0173] In the formula (I), a hetero ring represented by Cyc2 is preferably 3˜10 membered mono- or bi-cyclic hetero aryl containing 1˜2 of nitrogen, 1˜2 of oxygen and/or 1 of sulfur or partly or totally saturated one, more preferably furan, thiophene, pyridine, quinoline, thiadiazole (1,2,3-thiadiazole), piperazine or dioxaindane (1,3-dioxaindane), particularly preferably dioxaindane (1,3-dioxaindane).

[0174] In the formula (I), a carbocyclic ring represented by R1 is preferably C3˜10 mono- or bi-cyclic carbon ring, more preferably cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane or benzene, particularly preferably cyclopropane, cyclopentane, cyclohexane or benzene.

[0175] In the formula (I), a hetero ring represented by R1 is preferably a 5˜10 membered mono- or bi-cyclic hetero aryl or partially or completely saturated one containing 1˜2 of nitrogen, 1˜2 of oxygen and/or 1 of sulfur, more preferably furan, thiophene, pyridine, thiadiazole (1,2,3-thiazole), piperazine or dioxaindane (1,3-dioxaindane), particularly preferably thiadiazole (1,2,3-thiadiazole).

[0176] In the present invention, PPAR regulator includes all the regulators of PPAR α, γ, δ, α+γ, α+δ, γ+δ and α+γ+δ. Preferable regulatory fashion is, PPAR α regulator, PPAR δ regulator, PPAR α+γ regulator, PPAR α+δ regulator, more preferably PPAR α+γ regulator or PPAR δ regulator.

[0177] PPAR regulator also includes PPAR agonist and PPAR antagonist, preferably PPAR agonist, more preferably PPAR α agonist, PPAR δ agonist, PPAR α+γ agonist or PPAR α+γ agonist or PPAR α+δ agonist, particularly preferably PPAR α+γ agonist or PPAR δ agonist.

[0178] Among the compounds of formula (I), preferable ones are, a compound of formula (I-a)

[0179] (wherein all symbols are as hereinbefore described), a compound of formula (I-b)

[0180] (wherein all symbols are as hereinbefore described), a compound of formula (I-c)

[0181] (wherein all symbols are as hereinbefore described), a compound of formula (I-d)

[0182] (wherein all symbols are as hereinbefore described), a compound of formula (I-e)

[0183] (wherein all symbols are as hereinbefore described), a compound of formula (I-f)

[0184] (wherein all symbols are as hereinbefore described), a compound of formula (I-g)

[0185] (wherein all symbols are as hereinbefore described), a compound of formula (I-h)

[0186] (wherein all symbols are as hereinbefore described), a compound of formula (I-j)

[0187] (wherein all symbols are as hereinbefore described), a compound of formula (I-k)

[0188] (wherein all symbols are as hereinbefore described), a compound of formula (I-l)

[0189] (wherein all symbols are as hereinbefore described), a compound of formula (I-m)

[0190] a non-toxic salt thereof and a hydrate thereof.

[0191] Concrete compounds include the ones described in the following tables 1˜20, non-toxic salts thereof and hydrates thereof.

[0192] In the following tables, Me represents methyl, Et represents ethyl, t-Bu represents t-butyl and the other symbols are as hereinbefore described.

1TABLE 1(I-a-1)

No.

[0193]

2

TABLE 2

(I-a-2)

No.

100

[0194]

3

TABLE 3

(I-b-1)

101

No.

102

No.

103

No.

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

[0195]

4

TABLE 4

(I-b-2)

135

No.

136

No.

137

No.

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

[0196]

5

TABLE 5

(I-c-1)

169

No.

170

No.

171

No.

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

[0197]

6

TABLE 6

(I-c-2)

203

No.

204

No.

205

No.

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

[0198]

7

TABLE 7

(I-d-1)

237

No.

238

No.

239

No.

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

[0199]

8

TABLE 8

(I-d-2)

271

No.

272

No.

273

No.

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

[0200]

9

TABLE 9

(I-e-1)

305

No.

306

No.

307

No.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

[0201]

10

TABLE 10

(I-e-2)

339

No.

340

No.

341

No.

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

[0202]

11

TABLE 11

(I-f-1)

373

No.

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

[0203]

12

TABLE 13

(I-g-1)

405

No.

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

[0204]

13

TABLE 14

(I-g-2)

437

No.

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

[0205]

14

TABLE 15

(I-h-1)

469

No.

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

[0206]

15

TABLE 16

(I-h-2)

501

No.

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

[0207]

16

TABLE 17

(I-j-1)

533

No.

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

[0208]

17

TABLE 18

(I-k-1)

565

No.

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

[0209]

18

TABLE 19

(I-l-1)

597

No.

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

[0210]

19

TABLE 20

(I-m-1)

629

No.

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

[0211] [Processes for the Preparation of the Compound of the Present Invention]

[0212] (1) Among the compounds of the present invention of formula (I), the compounds wherein R4 is

661

[0213] i.e. the compounds of formula (I-1)

662

[0214] (wherein R1-1 and COOR7-1 are the same meanings as R1 and COOR7 respectively, with the proviso that amino group represented by R1-1 is protected if necessary, COOH group represented by COOR7-1 is protected if necessary.

[0215] Protective groups for amino include, for example, benzyloxycarbonyl, t-butoxycarbonyl, trifluoroacetyl, etc., protective groups for COOH include, for example, methyl, ethyl, t-butyl, benzyl, etc. The other symbols are as hereinbefore described) may be prepared by subjecting to a reaction a compound of formula (II)

663

[0216] (wherein all symbols are as hereinbefore described) and a compound of formula (III)

664

[0217] (wherein all symbols are as hereinbefore described) or subjecting to a reaction a compound of formula (IV)

665

[0218] (wherein R10 is halogen or methanesulfonyloxy and the other symbols are as hereinbefore described) and a compound of formula (V)

666

[0219] (wherein R11 is hydroxy or mercapto and the other symbols are as hereinbefore described).

[0220] The reaction of a compound of formula (II) and a compound of formula (III) is known, for example, it is carried out in an organic solvent (dichloromethane, ether, tetrahydrofuran, acetonitrile, benzene, toluene, etc.) in the presence of azo compound (azodicarboxylic acid diethyl, azodicarboxylic acid diisopropyl, 1,1′-(azodicarbonyl)dipiperidine, 1,1′-azobis(N,N-dimethylformamide), etc.) and phosphine compound (triphenylphosphine, tributylphosphine, trimethylphosphine, etc.) at a temperature of from 0° C. to 60° C. for 3˜20 hours.

[0221] The reaction of a compound of formula (IV) and a compound of formula (V) is known, for example, it is carried out in an inert organic solvent (tetrahydrofuran (THF), diethyl ether, dichloromethane, chloroform, carbon tetrachloride, pentane, hexane, benzene, toluene, dimethylformamide (DMF), dimethylsulfoxide (DMSO), hexamethylphosphoramide (HMPA), etc.) in the presence of base (sodium hydride, potassium carbonate, triethylamine, pyridine, cesium carbonate, etc.), optionally using an additive (sodium iodide, potassium iodide, etc.) at a temperature of from 0° C. to 80° C.

[0222] (2) Among the compounds of formula (I), the compounds wherein R4 is 2,4-thiazolidindion-5-yl, i.e. the compounds of formula (I-2)

667

[0223] (wherein all symbols are as hereinbefore described) may be prepared by subjecting to a reaction a compound of formula (VI)

668

[0224] (wherein X is halogen and the other symbols are as hereinbefore described) and thiourea.

[0225] The above reaction is known, for example, it is carried out in an organic solvent (methanol, ethanol, propanol, etc.) subjecting to a reaction a compound of formula (VI) and thiourea at a temperature of from 0° C. to refluxing temperature for 3˜20 hours, followed by addition of acid (concentrated sulfuric acid etc.) and then subjecting to a reaction at a temperature of 0° C. to refluxing temperature for another 3˜20 hours.

[0226] (3) Among the compounds of formula (I), the compounds wherein at least one of R1 and COOR7 is COOH or amino, i.e. the compounds of formula (I-3)

669

[0227] (wherein R1-2 and COOR7-2 are the same meanings as R1 and COOR7, with the proviso that at least one of R1-2 and COOR7-2 is amino or COOH and the other symbols are as hereinbefore described) may be prepared by subjecting a compound of formula (I-1) to alkali hydrolysis, deprotection reaction under acidic conditions or deprotection reaction by hydration.

[0228] Deprotection reaction by alkali hydrolysis is known, for example, it is carried out in an organic solvent (methanol, ethanol, tetrahydrofuran, dioxane, etc.) using hydroxide of alkali metal (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), hydroxide of alkaline earth metal (barium hydroxide, calcium hydroxide, etc.) or carbonate (sodium carbonate, potassium carbonate, etc.) or an aqueous solution thereof or a mixture thereof at a temperature of from 0° C. to 40° C.

[0229] Deprotection reaction under acidic conditions is known, for example, it is carried out in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate, anisole, etc.), in organic acid (acetic acid, trifluoroacetic acid, methanesulfonic acid, trimethylsilyl iodide etc.) or inorganic acid (hydrochloric acid, sulfuric acid, etc.) or a mixture thereof (hydrobromic acid-acetic acid etc.) at a temperature of from 0° C. to 100° C.

[0230] Deprotection reaction by hydration is known, for example, it is carried out in an inert solvent [ether (e.g. tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether, etc.), alcohol (e.g. methanol, ethanol, etc.), benzene (e.g. benzene, toluene, etc.), ketone (e.g. acetone, methylethylketone, etc.), nitrile (e.g. acetonitrile etc.), amide (e.g. dimethylformamide etc.), water, ethyl acetate, acetic acid or a mixture of two or more thereof], in the presence of hydrating catalyst (e.g. palladium-carbon, palladium black, palladium, palladium hydroxide, platinum hydroxide, platinum dioxide, nickel, Raney-nickel, ruthenium chloride, etc.) in the presence or absence of inorganic acid (e.g. hydrochloric acid, sulfuric acid, hypochlorous acid, boronic acid, tetrafluoroboronic acid, etc.) or organic acid (e.g. acetic acid, p-toluenesulfonic acid, oxalic acid, trifluoroacetic acid, formic acid etc.), under normal atmosphere or suppressed atmosphere of hydrogen or in the presence of ammonium formate, at a temperature of from 0° C. to 200° C. In use of acid, its salt may be used.

[0231] (4) Among the compounds of formula (I), the compounds wherein R1 is 2,4-thiazolidinedion-5-yl and at least one of R1 is amino, i.e. the compounds of formula (I-4)

670

[0232] (wherein R1-3 is the same meaning as R1, with the proviso that at least one of R1-3 is amino, and the other symbols are the same meaning as hereinbefore described) may be prepared by subjecting the said compound of formula (I-2) to deprotection reaction under acidic conditions or deprotection reaction by hydration.

[0233] Deprotection reaction under acidic conditions or deprotection reaction by hydration is carried out by the same procedure as hereinbefore described.

[0234] In the present invention deprotection reaction means a comprehensive deprotection reaction easily understood by those skilled in the art, for example, alkali hydrolysis, deprotection reaction under acidic condition, deprotection reaction by hydration. The desired compounds of the present invention can be easily prepared by these reactions.

[0235] As should be easily understood by those skilled in the art, methyl, ethyl, t-butyl and benzyl are included in the protective groups for carboxyl, but other groups that can be easily and selectively eliminated may also be used instead. For example, the groups described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1991 may be used.

[0236] Benzyloxycarbonyl, t-butoxycarbonyl and trifluoroacetyl are included in the protective groups for amino, but other groups that can be easily and selectively eliminated may also be used instead. For example, the groups described in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1991 may be used.

[0237] The compounds of formula (II), (III), (IV), (V) and (VI) are known per se or may be easily prepared by known methods.

[0238] For example, among the compounds of formula (II), 2-(5-methyl-2-phenyloxazol-4-yl)ethanol can be prepared by the method described in J. Med. Chem., 41, 5037-5054 (1998).

[0239] For example, the compounds of formula (IV), (V) and (VI) may be prepared by the method described in the following reaction schemes.

[0240] The symbols in the reaction schemes represent the followings and the other symbols are as hereinbefore described.

[0241] R11-1: protected hydroxy or mercapto;

[0242] A4-1: a bond or C1˜4 alkylene;

[0243] A4-2: —C1˜4 alkylene-O— or —C1˜4 alkylene-S—;

[0244] TMSCN: trimethylsilylcyanide;

[0245] Ph3P: triphenylphosphine;

[0246] ADDP: 1,1′-(azodicarbonyl)dipiperidine.

671

672

673

674

[0247] The starting materials in the reaction schemes are known per se or may be prepared by known methods.

[0248] The reactions of the reaction schemes may be carried out by known methods.

[0249] The other starting materials and reagents in the present invention are known per se or may be prepared by known methods.

[0250] In each reaction described in the present specification, reaction products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, by washing or by recrystallization, etc. Purification may be carried out after each reaction, or after a series of reactions.

[0251] The compounds described in the present specification may be converted to corresponding salts by known methods. Non-toxic and water-soluble salts are preferable. Suitable salts include a salt of alkali metal (potassium, sodium, etc.), a salt of alkali earth metal (calcium, magnesium, etc.), an ammonium salt, a pharmaceutically acceptable salt of organic amine (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane, lysine, arginine, N-methyl-D-glucamine, etc.)

[0252] The compounds of formula (I) may be converted to corresponding acid addition salts by known methods. Non-toxic and water-soluble acid addition salts are preferable. Suitable acid addition salts include salts of inorganic acid (e.g. salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid) and salts of organic acid (e.g. salts of acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid), etc.

[0253] The compounds of the present invention described in the present specification or salts thereof may be converted to hydrates by a known method.

[0254] [Pharmacological Activity]

[0255] It was confirmed that a compound of the present invention of formula (I) has PPAR regulating activities by the following experiments.

[0256] Measurement of PPAR α, PPAR γ and PPAR δ agonist activities

[0257] 1) Preparation of Materials Using Human PPAR α, γ or δ in Luciferase Assay

[0258] The whole operation was based on basic gene engineering techniques, and in the operation conventional methods in yeast One-hybrid or Two-hybrid-system were used.

[0259] As a luciferase gene expression vector under the control of thymidine kinase (TK) promotor, luciferase structural gene was excised from PicaGene Basic Vector 2 (A Brand Name, Toyo Ink Inc., catalogue No. 309˜04821), to prepare luciferase gene expression vector pTK-Luc. under the control of TK promotor (−105/+51) as a minimum essential promotor activity from pTKβ having TK promotor (Chrontech Inc., catalogue No. 6179˜1). In the upper stream of TK promotor, four times repeated UAS sequence was inserted, which is the response element of Gal4 protein, a basic transcription factor in yeast, to construct 4× UAS-TK-Luc. as reporter gene. The following is the enhancer sequence used (Sequence No. 1).

[0260] Sequence No. 1: Enhancer sequence repeating Gal4 response element four-times tandemly

[0261] 5′-T(CGACGGAGTACTGTCCTCCG)x4 AGCT-3′

[0262] A vector was prepared as described hereafter which expresses chimeric receptor protein wherein in carboxyl terminus of yeast Gal4 protein DNA binding domain was fused to ligand binding domain of human PPAR α, γ or δ. That is to say, PicaGene Basic Vector 2 (a Brand Name; Toyo Ink Inc., catalogue No. 309˜04821) was used as a basic expression vector, the structural gene was exchanged for that of chimeric receptor protein, while promotor and enhancer domains were kept as they were.

[0263] DNA encoding a fused protein composed of Gal4 DNA binding domain, amino acids 1˜147 linked to the ligand binding domain of human PPAR α, γ in frame was inserted to the downstream of promotor/enhancer in PicaGene Basic Vector 2(a Brand Name). Here the DNA was aligned as follows; in the amino terminus of human PPAR α, γ or δ ligand binding domain, nuclear translocation signal originated from SV-40 T-antigen, Ala Pro Lys Lys Lys Arg Lys Val Gly (sequence No. 2) was added to make fusion protein localizing intranuclearly. On the other hand, in the carboxy terminus of them, influenza hemagglutinin epitope, Tyr Pro Tyr Asp Val Pro Asp Tyr Ala (sequence No. 3) and stop codon for translation was added in this order, to detect an expressed fused protein tagged epitope sequence.

[0264] The portion of structural gene used as ligand binding domain of human PPAR α, γ or δ is as follows:

[0265] human PPAR α ligand binding domain: Ser167-Tyr468

[0266] human PPAR γ ligand binding domain: Ser176-Tyr478

[0267] human PPAR δ ligand binding domain: Ser139-Tyr441

[0268] in comparison with human PPAR δ 1 and human PPAR γ2, Ser204-Tyr506 in human γ2 is corresponding and identical to Ser176-Tyr478 in human PPAR γ1), according to the comparison of human PPAR structures described in the literatures by R. Mukherjee at al. (See J. Steroid Biochem. Molec. Biol., 51, 157 (1994)), M. E. Green et al., (See Gene Expression., 4, 281 (1995)), A. Elbrecht et al. (See Biochem Biophys. Res. Commun., 224, 431 (1996)) or A. Schmidt et al. (See Mol. Endocrinology., 1634 (1992)). In order to measure basal level of transcription, an expression vector containing DNA binding domain of Gal4 protein lacking in PPAR ligand binding domain, which is exclusively encoding the amino acids of No. 1˜No. 147 in Gal4 protein was also prepared.

[0269] 2) Luciferase Assay Using Human PPAR α, γ or δ

[0270] CV-1 cells used as host cells were cultured by a conventional technique. That is to say, Dulbecco's modified Eagle medium (DMEM) supplemented 10% bovine fetal serum (GIBCO BRL Inc., catalogue No. 26140-061) and 50 U/ml of penicillin G and 50 μg/ml of streptomycin sulfate were used to culture CV-1 cells under the atmosphere of 5% carbon dioxide gas at 37° C.

[0271] 2×106 cells were seeded in a 10 cm dish, and once washed with the medium without serum, followed by addition of the medium (10 ml) thereto. Reporter gene (10 μg), Gal4-PPAR expression vector (0.5 μg) and 50 μl of LipofectAMINE (a Brand Name, GIBRO BRL Inc., catalogue No. 18324-012) were well mixed and added to the culture to introduce these DNAs into the cells. They were cultured at 37° C. for 5˜6 hours, and thereto was added 10 ml of medium containing 20% of dialyzed bovine fetal serum (GIBRO BRL Inc., catalogue No. 26300-061), and then cultured at 37° C. overnight. The cells were dispersed by trypsin, and they were again seeded in 96-well plates in a density of 8000 cells/100 ml of DMEM-10% dialyzed serum/well. Several hours after the cultivation, cells were attached to the plastic ware, then 100 μl of DMEM-10% dialyzed serum containing the compounds of the present invention, whose concentration is twice as high as the final concentration of them. The culture was settled at 37° C. for 42 hours and the cells were dissolved, to measure luciferase activity according to manufacturer's instruction.

[0272] As to PPAR α agonist activity, the relative activity of the compounds of the present invention (0.3 μM) was shown in table 21, under the condition that luciferase activity was defined as 1.0 when a positive control compound carbacyclin made a final concentration of 10 μM, which apparently activated PPAR α (See Eur. J. Biochem., 233, 242 (1996); Genes & Development., 10, 974 (1996)).

[0273] As to PPAR γ agonist activity, the relative activity of the compounds of the present invention (1.0 μM) was shown in table 22, under the condition that luciferase activity was defined as 1.0 when a positive control compound troglitazone made a final concentration of 10 μM, which significantly activated PPAR γ (See Cell., 83, 863 (1995); Endocrinology., 137, 4189 (1996) and J. Med. Chem., 39, 665 (1996)) and has already launched.

[0274] As to PPAR δ agonist activity, the relative activity of the compounds of the present invention was shown in table 23, under the condition that luciferase activity was defined as 1.0 when solvent containing no compound was added.

[0275] Furthermore, the reproducibility was very good in each point examined in triplicate. And dose dependent activation of PPARs thereof was also confirmed.

20TABLE 21PPAR α agonist activityCompound No.Relative ActivityExample 22.1Example 2 (5)0.8Example 2 (11)3.2Example 2 (12)1.7

[0276]

21

TABLE 22

PPAR γ agonist activity

Compound No.
Relative Activity

Example 2 (12)
1.4

[0277]

22

TABLE 23

PPAR δ agonist activity

Concentration (μM)

Compound No.
0
1.0
10.0

Example 2 (22)
1.0
9.3
66.7

Example 2 (93)
1.0
36.1
54.7

Example 6
1.0
11.0
61.6

[0278] Hypoglycemic and Hypolipidemic Effects in KKAy Mice:

[0279] Male, 7-weeks old KKAy/Ta mice weighed from 35 to 40 g (seven mice per group) were pre-breaded for approximately one week and acclimatized for three days on milled diet. On the first day of the experiment (Day 0), mice were divided into some groups by weight, plasma glucose and triglyceride (TG) levels to minimize the differences among groups. From the next day for two days they were given compounds by food mixture containing 0.03% (w/w) of the compound of the present invention or by milled diet only. At 13:00 of the third day, blood samples were collected and glucose and TG were measured. These results are shown in table 24. Additionally, there was no significant difference in the food intake between control group (milled diet only) and compounds-treated group (milled diet containing 0.03% compounds).

23TABLE 24glycemic value (mg/dl)TG value (mg/dl)Compound No.3 days3 dayscontrol495 ± 35558 ± 107food containing compound 214 ± 19*221 ± 66*of Example 2 (12) 38.9 mg/kg/day (converted)*p < 0.01 v.s. control (seven mice per group)

[0280] Hypocholesterolemic and Hypolipidemic Effects in Normal Rats:

[0281] Male, six-weeks old SD rats (seven rats per group) were left to take milled diet and water ad libitum and were acclimatized for 1 week.

[0282] At 9:00 on the first day of the experiment (Day 0) blood sampling was done from tail vein. The rats were divided into some groups by body weight, triglyceride(TG), non-esterified fatty acid (NEFA), total cholesterol (TC) values to minimize differences of the parameters among the groups. At 17:00 of the day the compound of the present invention suspended in 0.5% aqueous solution of carboxymethylcellulose (CMC) was orally administered at a dose of 10 mg/kg, and thereafter, with hypercholesterolemic food (5.5% peanut oil, 1.5% cholesterol and 0.5% cholic acid were mixed with milled CRF-1 diet, Charles River Inc.) was given to the rats.

[0283] At 9:00 of the next day, blood sampling was done from tail vein. The lipid values in blood (TG, NEFA and TC values) were measured. The results are shown in table 25.

[0284] There was no significant difference of the food intake between the control group (provided only 0.5% CMC) and the group treated with the compounds of the present invention.

24TABLE 25TC valueTG valueNEFA valueCompound No.(mg/dl)(mg/dl)(μEq/l)control188 ± 5147 ± 9489 ± 66Example 2 (12) 70 ± 5**100 ± 14*178 ± 14***p < 0.05 vs control (seven rats per group) **p < 0.01 vs control (seven rats per group)

[0285] The hypoglycemic or hypolipidemic effects observed in KKAy mice imply the possibility of preventives and/or remedies for diabetes and hyperlipidemia, etc. Cholesterol-lowering and free fatty acid-lowering effects observed in high cholesterol diet-fed rats imply that the compounds of the present invention are useful as preventives and/or remedies of atherosclerosis etc.

INDUSTRIAL APPLICABILITY

[0286] [Effect]

[0287] The compounds of formula (I), non-toxic salts thereof and hydrates thereof have PPAR regulating effect, and therefore are expected to be applied as hypoglycemic agents, hypolipidemic agents, preventives and/or remedies for diseases associated with metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., HDL cholesterol-elevating agents, LDL cholesterol and/or VLDL cholesterol-lowering agents and agents for relieving risk factors of diabetes or syndrome X.

[0288] The compounds of formula (I), non-toxic salts thereof and hydrates thereof have particularly PPAR α agonist and/or PPAR γ agonist effect, and therefore are thought to be useful as hypoglycemic agents, hypolipidemic agents, preventives and/or remedies for diseases associated with metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, etc. coronary heart diseases, etc. Since they are expected to have HDL cholesterol-elevating effect, LDL cholesterol and/or VLDL cholesterol-lowering effect, inhibition of progress of atherosclerosis and its treatment, and inhibitory effect against obesity, they are also expected to be useful for the treatment and/or prevention of diabetes as hypoglycemic agents, for the amelioration of hypertension, for the relief from risk factors of syndrome X, and as preventives against occurrence of coronary heart diseases.

[0289] Since the compounds of formula (I), non-toxic salts thereof and hydrates thereof also have PPAR δ agonist activity, they are expected to have HDL cholesterol-elevating effect, and therefore, they are expected to be useful as agents for the inhibition of progress of atherosclerosis and its treatment, hypolipidemic agents and/or hypoglycemic agents. Furthermore, they are also expected to be useful for the treatment of hyperglycemia, as hypoglycemic agents, for the treatment of diabetes, for the relief from risk factors of syndrome X, and as preventives against occurrence of coronary heart diseases.

[0290] [Toxicity]

[0291] The toxicity of the compounds of the present invention are very low and the compounds are safe enough for pharmaceutical use.

[0292] [Application to Pharmaceuticals]

[0293] For the purpose above described, the compounds of the present invention of formula (I), non-toxic salts, acid addition salts or hydrates thereof may normally be administered usually systemically or topically, orally or parenterally.

[0294] The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally in the range of from 1 mg to 1000 mg, by oral administration, up to several times per day, and in the range of from 0.1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.

[0295] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0296] The compounds of the present invention may be administered in the form of, for example, solid forms for oral administration, liquid forms for oral administration, injections, liniments or suppositories for parenteral administration.

[0297] Solid forms for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules, etc. Capsules include hard capsules and soft capsules.

[0298] In these solid forms, one or more of the active compound(s) may be admixed with excipients (e.g. lactose, mannitol, glucose, microcrystalline cellulose, starch), binders (e.g. hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate), disintegrants (e.g. cellulose calcium glycolate), lubricants (e.g. magnesium stearate), stabilizing agents, and adjuvants to assist dissolution (e.g. glutamic acid, aspartic acid) and prepared according to methods well known to those skilled in the art. The solid forms may, if desired, be coated with coating agents (e.g. sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

[0299] Liquid forms for oral administration include pharmaceutically acceptable aqueous solutions, suspensions and emulsions, syrups and elixirs, etc. In such forms, one or more of the active compound(s) may be dissolved, suspended or emulsified into diluent(s) commonly used in the art (e.g. purified water, ethanol or a mixture thereof). Besides such liquid forms may also comprise wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent, etc.

[0300] Injections for parenteral administration include sterile aqueous, suspensions, emulsions and solid forms which are dissolved or suspended into solvent(s) for injection immediately before use. In injections, one or more of the active compound(s) may be dissolved, suspended or emulsified into solvent(s). The solvents may include distilled water for injection, physiological salt solution, vegetable oil, propylene glycol, polyethylene glycol, alcohol, e.g. ethanol, or a mixture thereof.

[0301] Injections may comprise some additives, such as stabilizing agents, solution adjuvants (e.g. glutamic acid, aspartic acid or POLYSORBATE80 (registered trademark)), suspending agents, emulsifying agents, soothing agent, buffering agents, preservatives. They may be sterilized at the final step, or may be prepared and compensated according to sterile methods. They may also be manufactured in the form of sterile solid forms, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.

[0302] Other forms for parenteral administration include liquids for external use, ointments and endermic liniments, inhalations, sprays, suppositories and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known per se. Sprays may comprise additional substances other than diluents, such as stabilizing agents (e.g. sodium sulfate), isotonic buffers (e.g. sodium chloride, sodium citrate or citric acid). For preparation of such sprays, for example, the method described in the U.S. Pat. Nos. 2,868,691 or 3,095,355 may be used.

BEST MODE FOR CARRYING OUT THE INVENTION

[0303] The following Reference Examples and Examples illustrate the present invention, but do not limit the present invention.

[0304] The solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations and TLC.

[0305] Solvents in the parentheses of NMR show the solvents used for measurement.

REFERENCE EXAMPLE 1

[0306] 3-methoxymethoxybenzaldehyde

675

[0307] A solution of 3-hydroxybenzaldehyde (20 g), chloromethylmethyl ether (25 ml) and diisopropylethylamine (114 ml) intetrahydrofuran (300 ml) was stirred at room temperature overnight. To the reaction mixture was added ice water and was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=25:1) to give the title compound (23 g) having the following physical data.

[0308] TLC: Rf 0.65 (hexane:ethyl acetate=3:1)

[0309] NMR (CDCl3): δ 9.98 (s, 1H), 7.42-7.56 (m, 3H), 7.30 (m, 1H), 5.24 (s, 2H), 3.50 (s, 3H).

REFERENCE EXAMPLE 2

[0310] 3-methoxymethoxybenzylalcohol

676

[0311] To a suspension of lithium aluminum hydride (690 mg) in tetrahydrofuran (60 ml), was added a solution of the compound prepared in Reference Example 1 (3.0 g) in tetrahydrofuran (40 ml) and the reaction mixture was stirred at room temperature for 30 minutes. To the reaction mixture were added a saturated aqueous solution of sodium sulfate and magnesium sulfate and the mixture was filtered through Celite. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=3:1) to give the title compound (2.5 g) having the following physical data.

[0312] TLC: Rf 0.39 (hexane:ethyl acetate=3:1);

[0313] NMR (CDCl3): δ 7.25 (t, J=7.5 Hz, 1H), 7.10-6.95 (m, 3H), 5.20 (s, 2H), 4.70 (d, J=6 Hz, 2H), 3.50 (s, 3H), 1.75 (t, J=6 Hz, 1H).

REFERENCE EXAMPLE 3

[0314] 3-methoxymethoxybenzyl Bromide

677

[0315] To a solution of the compound prepared in Reference Example 2 (2.48 g) and triphenylphosphine (4.64 g) in dichloromethane (150 ml), carbon tetrabromide (7.34 g) was added and the mixture was stirred at room temperature for 30 minutes. To the reaction mixture was added a saturated aqueous solution of sodium bicarbonate and was extracted with dichloromethane. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=5:1) to give the tittle compound (4.41 g) having the following physical data.

[0316] TLC: Rf 0.71 (hexane:ethyl acetate=2:1)

[0317] NMR (CDCl3): δ 7.25 (t, J=7.5 Hz, 1H), 7.10-6.95 (m, 3H), 5.20 (s, 2H), 4.45 (s, 2H), 3.50 (s, 3H).

REFERENCE EXAMPLE 4

[0318] 2-(3-methoxymethoxyphenylmethylthio)acetic Acid.Methyl Ester

678

[0319] A suspension of the compound prepared in Reference Example 3 (4.41 g), methyl thioglycolate (1.5 ml), potassium carbonate (2.45 g) and potassium iodide (250 mg) in acetonitrile (50 ml) was refluxed for 3 hours. The reaction mixture was filtered. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=5:1) to give the title compound (2.81 g) having the following physical data.

[0320] TLC: Rf 0.57 (hexane:ethyl acetate=2:1)

[0321] NMR (CDCl3): δ 7.25 (t, J=7.5 Hz, 1H), 7.05-6.90 (m, 3H), 5.20 (s, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.50 (s, 3H), 3.10 (s, 2H).

REFERENCE EXAMPLE 5

[0322] 2-(3-hydroxyphenylmethylthio)acetic Acid.Methyl Ester

679

[0323] To a solution of the compound prepared in Reference Example 4 (2.81 g) in methanol (20 ml), was added 4N solution of hydrogen chloride in dioxane (11 ml) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=5:1) to give the title compound (2.16 g) having the following physical data.

[0324] TLC: Rf 0.45 (hexane:ethyl acetate=2:1)

[0325] NMR (CDCl3): δ 7.20 (t, J=7.5 Hz, 1H), 6.90 (d, J=7.5 Hz, 1H), 6.85 (d, J=2 Hz, 1H), 6.75 (dd, J=7.5, 2 Hz, 1H), 5.05 (s, 1H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H).

EXAMPLE 1

[0326] 2-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

680

[0327] The compound prepared in Reference Example 5 (0.30 g) was dissolved in dichloromethane (10 ml) and thereto were added 2-hydroxymethyl-4-(4-methylphenyl)thiazole (0.34 g) and triphenylphosphine (0.44 g) and the mixture was stirred at room temperature for 5 minutes. To the reaction mixture was added 1, 1′-azodicarbonyldipiperidine (0.56 g) and the mixture was stirred at room temperature overnight. To the reaction mixture was added diethyl ether and the mixture was filtered. The filtrate was washed with a saturated aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=10:1) to give the compound of the present invention (0.51 g) having the following physical data.

[0328] TLC: Rf 0.56 (hexane:ethyl acetate=3:1)

[0329] NMR (CDCl3): δ 7.79 (d, J=8.2 Hz, 2H), 7.44 (s, 1H), 7.22-7.30 (m, 3H), 6.91-7.05 (m, 3H), 5.42 (s, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 2.39 (s, 3H).

EXAMPLE 1(1)˜EXAMPLE 1(137)

[0330] The following compounds were obtained by the same procedure as shown in Example 1, using the compound prepared in Reference Example 5 or corresponding derivatives, and 2-hydroxymethyl-4-(4-methylphenyl)thiazole or corresponding derivatives.

EXAMPLE 1(1)

[0331] 6-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)hexanoic Acid.Methyl Ester

681

[0332] TLC: Rf 0.75 (hexane:ethyl acetate=2:1)

[0333] NMR (CDCl3): δ 7.48-7.66 (2H, m), 7.43 (1H, s), 7.28-7.10 (3H, m), 6.88-6.72 (3H, m), 5.41 (2H, s), 3.66 (3H, s), 2.59 (2H, t, J=8.0 Hz), 2.39 (3H, s), 2.30 (2H, t, J=7.5 Hz), 1.74-1.46 (4H, m), 1.45-1.16 (2H, m).

EXAMPLE 1(2)

[0334] 5-(3-(biphenyl-4-ylmethoxy)phenyl)pentanoic Acid.Methyl Ester

682

[0335] TLC: Rf 0.57 (hexane:ethyl acetate=4:1)

[0336] NMR (CDCl3): δ 7.30-7.62 (m, 9H), 7.20 (m, 1H), 6.77-6.83 (m, 3H), 5.08 (s, 2H), 3.64 (s, 3H), 2.60 (t, J=6.8 Hz, 2H), 2.32 (t, J=6.8 Hz, 2H), 1.59-1.66 (m, 4H).

EXAMPLE 1(3)

[0337] 4-(3-(biphenyl-4-ylmethoxy)phenyl)butanoic Acid.Methyl Ester

683

[0338] TLC: Rf 0.65 (hexane:ethyl acetate=3:1);

[0339] NMR (CDCl3): δ 7.57-7.64 (m, 4H), 7.31-7.53 (m, 5H), 7.22 (m, 1H), 6.78-6.87 (m, 3H), 5.09 (s, 2H), 3.66 (s, 3H), 2.64 (t, J=7.5 Hz, 2H), 2.33 (t, J=7.5 Hz, 2H), 1.96 (tt, J=7.5, 7.5 Hz, 2H).

EXAMPLE 1(4)

[0340] 4-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)butanoic Acid.Methyl Ester

684

[0341] TLC: Rf 0.59 (hexane:ethyl acetate=3:1)

[0342] NMR (CDCl3): δ 7.79 (d, J=8.0 Hz, 2H), 7.44 (s, 1H), 7.18-7.26 (m, 3H), 6.81-6.87 (m, 3H), 5.41 (s, 2H), 3.66 (s, 3H), 2.64 (t, J=7.5 Hz, 2H), 2.39 (s, 3H), 2.33 (t, J=7.5 Hz, 2H), 1.95 (tt, J=7.5, 7.5 Hz, 2H).

EXAMPLE 1(5)

[0343] 4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)butanoic Acid.Methyl Ester

685

[0344] TLC: Rf 0.39 (hexane:ethyl acetate=3:1)

[0345] NMR (CDCl3): δ 7.98 (m, 2H), 7.38-7.46 (m, 3H), 7.17 (m, 1H), 6.72-6.77 (m, 3H), 4.23 (t, J=7.0 Hz, 2H), 3.66 (s, 3H), 2.98 (t, J=7.0 Hz, 2H), 2.60 (t, J=7.5 Hz, 2H), 2.38 (s, 3H), 2.32 (t, J=7.5 Hz, 2H), 1.93 (tt, J=7.5, 7.5 Hz, 2H).

EXAMPLE 1(6)

[0346] 6-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)hexanoic Acid.Methyl Ester

686

[0347] TLC: Rf 0.51 (hexane:ethyl acetate=3:1)

[0348] NMR (CDCl3): δ 8.04-7.92 (2H, m), 7.50-7.36 (3H, m), 7.16 (1H, t, J=8.0 Hz), 6.80-6.60 (3H, m), 4.23 (2H, t, J=7.0 Hz), 3.65 (3H, s), 2.98 (2H, t, J=7.0 Hz), 2.56 (2H, t, J=7.5 Hz), 2.38 (3H, s), 2.29 (2H, t, J=7.0 Hz), 1.75-1.52 (4H, m), 1.44-1.26 (2H, m).

EXAMPLE 1(7)

[0349] 5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pentanoic Acid.Methyl Ester

687

[0350] TLC: Rf 0.28 (hexane:ethyl acetate=5:1)

[0351] NMR (CDCl3): δ 8.03-7.94 (2H, m), 7.49-7.36 (3H, m), 7.23-7.12 (1H, m), 6.78-6.68 (3H, m), 4.23 (2H, t, J=7.0 Hz), 3.65 (3H, s), 2.98 (2H, t, J=7.0 Hz), 2.64-2.52 (2H, m), 2.38 (3H, s), 2.38-2.26 (2H, m), 1.75-1.58 (4H, m).

EXAMPLE 1(8)

[0352] 2-(3-(3-(biphenyl-4-ylmethoxy)phenyl)propylthio)acetic Acid.Methyl Ester

688

[0353] TLC: Rf 0.73 (hexane:ethyl acetate=2:1)

[0354] NMR (CDCl3): δ 7.57-7.64 (m, 4H), 7.31-7.53 (m, 5H), 7.22 (dd, J=9.0, 7.6 Hz, 1H), 6.79-6.86 (m, 3H), 5.10 (s, 2H), 3.72 (s, 3H), 3.23 (s, 2H), 2.71 (t, J=7.4 Hz, 2H), 2.65 (t, J=7.4 Hz, 2H), 1.93 (tt, J=7.4, 7.4 Hz, 2H).

EXAMPLE 1(9)

[0355] 2-(3-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)propylthio)acetic Acid.Methyl Ester

689

[0356] TLC: Rf 0.68 (hexane:ethyl acetate=2:1)

[0357] NMR (CDCl3): δ 7.79 (d, J=8.0 Hz, 2H), 7.44 (s, 1H), 7.18-7.26 (m, 3H), 6.82-6.88 (m, 3H), 5.41 (s, 2H), 3.72 (s, 3H), 3.22 (s, 2H), 2.71 (t, J=7.5 Hz, 2H), 2.64 (t, J=7.5 Hz, 2H), 2.39 (s, 3H), 1.92 (tt, J=7.5, 7.5 Hz, 2H).

EXAMPLE 1(10)

[0358] 6-(2-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)hexanoic Acid.Methyl Ester

690

[0359] TLC: Rf 0.51 (hexane:ethyl acetate=5:1)

[0360] NMR (CDCl3): δ 7.95-8.00 (m, 2H), 7.40-7.45 (m, 3H), 7.02-7.17 (m, 2H), 6.81-6.89 (m, 2H), 4.25 (t, J=6.4 Hz, 2H), 3.65 (s, 3H), 2.99 (t, J=6.4 Hz, 2H), 2.56 (t, J=7.8 Hz, 2H), 2.38 (s, 3H), 2.26 (t, J=7.8 Hz, 2H), 1.46-1.76 (m, 4H), 1.22-1.45 (m, 2H).

EXAMPLE 1(11)

[0361] 2-(3-(biphenyl-4-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

691

[0362] TLC: Rf 0.56 (hexane:ethyl acetate=3:1)

[0363] NMR (CDCl3): δ 7.57-7.63 (m, 4H), 7.34-7.52 (m, 5H), 7.24 (dd, J=8.1, 7.7 Hz, 1H), 6.87-7.00 (m, 3H), 5.10 (s, 2H), 3.80 (s, 2H), 3.71 (s, 3H), 3.07 (s, 2H).

EXAMPLE 1(12)

[0364] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

692

[0365] TLC: Rf 0.36 (hexane:ethyl acetate=3:1);

[0366] NMR (CDCl3): δ 7.95-8.00 (m, 2H), 7.37-7.44 (m, 3H), 7.20 (dd, J=8.0, 8.0 Hz, 1H), 6.87-6.90 (m, 2H), 6.80 (dd, J=8.0, 2.5 Hz, 1H), 4.24 (t, J=6.7 Hz, 2H), 3.77 (s, 2H), 3.70 (s, 3H), 3.07 (s, 2H), 2.98 (t, J=6.7 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(13)

[0367] 5-(2-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pentanoic Acid.Methyl Ester

693

[0368] TLC: Rf 0.59 (hexane:ethyl acetate=2:1)

[0369] NMR (CDCl3): δ 8.05-7.95 (m, 2H), 7.45-7.35 (m, 3H), 7.20-7.05 (m, 2H), 6.90-6.80 (m, 2H), 4.25 (t, J=6.5 Hz, 2H), 3.65 (s, 3H), 3.00 (t, J=6.5 Hz, 2H), 2.60 (t, J=7 Hz, 2H), 2.40 (s, 3H), 2.25 (t, J=7 Hz, 2H), 1.80-1.45 (m, 4H).

EXAMPLE 1(14)

[0370] 6-(2-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)hexanoic Acid.Methyl Ester

694

[0371] TLC: Rf 0.55 (hexane:ethyl acetate=5:1);

[0372] NMR (CDCl3): δ 7.79 (d, J=8.0 Hz, 2H), 7.44 (s, 1H), 7.24 (d, J=8.0 Hz, 2H), 7.15-7.22 (m, 2H), 6.91-6.98 (m, 2H), 5.42 (s, 2H), 3.65 (s, 3H), 2.73 (t, J=7.6 Hz, 2H), 2.39 (s, 3H), 2.32 (t, J=7.4 Hz, 2H), 1.61-1.77 (m, 4H), 1.38-1.50 (m, 2H).

EXAMPLE 1(15)

[0373] 2-(3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propylthic)acetic Acid.Methyl Ester

695

[0374] TLC: Rf 0.29 (hexane:ethyl acetate=4:1)

[0375] NMR (CDCl3): δ 7.95-8.00 (m, 2H), 7.40-7.46 (m, 3H), 7.17 (dd, J=8.1, 8.1 Hz, 1H), 6.72-6.77 (m, 3H), 4.23 (t, J=6.8 Hz, 2H), 3.71 (s, 3H), 3.22 (s, 2H), 2.98 (t, J=6.8 Hz, 2H), 2.67 (t, J=6.8 Hz, 2H), 2.63 (t, J=6.8 Hz, 2H), 2.38 (s, 3H), 1.90 (tt, J=6.8, 6.8 Hz, 2H).

EXAMPLE 1(16)

[0376] 2-(3-(2-(biphenyl-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

696

[0377] TLC: Rf 0.48 (hexane:ethyl acetate=3:1)

[0378] NMR (CDCl3): δ 7.53-7.61 (m, 4H), 7.30-7.47 (m, 5H), 7.22 (dd, J=8.2, 8.2 Hz, 1H), 6.78-6.92 (m, 3H), 4.21 (t, J=7.0 Hz, 2H), 3.79 (s, 2H), 3.71 (s, 3H), 3.14 (t, J=7.0 Hz, 2H), 3.09 (s, 2H).

EXAMPLE 1(17)

[0379] 2-(4-chloro-3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

697

[0380] TLC: Rf 0.41 (hexane:ethyl acetate=2:1)

[0381] NMR (CDCl3): δ 8.00 (m, 2H), 7.50-7.35 (m. 3H), 7.27 (d, J=8.0 Hz, 1H), 6.94 (d, J=2.0 Hz, 1H), 6.83 (dd, J=8.0, 2.0 Hz, 1H), 4.30 (t, J=6.5 Hz, 2H), 3.75 (s, 2H), 3.71 (s, 3H), 3.05 (s, 2H), 3.05 (t, J=6.5 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 1(18)

[0382] 2-(4-chloro-3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

698

[0383] TLC: Rf 0.61 (hexane:ethyl acetate=2:1)

[0384] NMR (CDCl3): δ 7.78 (d, J=8.0 Hz, 2H), 7.45 (s. 1H), 7.34 (d, J=8.0 Hz, 1H), 7.23 (d, J=8.0 Hz, 2H), 7.11 (d, J=2.0 Hz, 1H), 6.93 (dd, J=8.0, 2.0 Hz, 1H), 5.49 (s, 2H), 3.77 (s, 2H), 3.69 (s, 3H), 3.01 (s, 2H), 2.38 (s, 3H).

EXAMPLE 1(19)

[0385] 2-(3-(biphenyl-4-ylmethoxy)-4-chlorophenylmethylthio)acetic Acid.Methyl Ester

699

[0386] TLC Rf 0.62 (hexane:ethyl acetate=2:1)

[0387] NMR (CDCl3): δ 7.70-7.35 (m, 5H), 7.58 (d, J=8.0 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H), 7.33 (d, J=8.0 Hz, 1H), 7.03 (d, J=2.0 Hz, 1H), 6.88 (dd, J=8.0, 2.0 Hz, 1H), 5.22 (s, 2H), 3.77 (s, 2H), 3.70 (s, 3H), 3.00 (s, 2H).

EXAMPLE 1(20)

[0388] 2-(3-((2E)-3-(biphenyl-4-yl)propenyloxy)phenylmethylthio)acetic Acid.Methyl Ester

700

[0389] TLC Rf 0.63 (hexane:ethyl acetate=3:1)

[0390] NMR (CDCl3): δ 7.53-7.63 (m, 4H), 7.15-7.50 (m, 6H), 6.74-6.93 (m, 4H), 6.45 (dt, J=16.2, 5.7 Hz, 1H), 4.73 (dd, J=5.7, 1.4 Hz, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H).

EXAMPLE 1(21)

[0391] 2-(3-(3-(biphenyl-4-yl)propoxy)phenylmethylthio)acetic Acid.Methyl Ester

701

[0392] TLC: Rf 0.66 (hexane:ethyl acetate=4:1)

[0393] NMR (CDCl3): δ 7.19-7.61 (m, 10H), 6.79-6.92 (m, 3H), 4.00 (t, J=6.2 Hz, 2H), 3.80 (s, 2H), 3.72 (s, 3H), 3.10 (s, 2H), 2.86 (t, J=7.7 Hz, 2H), 2.14 (m, 2H).

EXAMPLE 1(22)

[0394] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

702

[0395] TLC: Rf 0.50 (hexane:ethyl acetate=2:1);

[0396] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.50-7.35 (m, 3H), 7.20 (m, 1H), 6.90-6.75 (m, 3H), 4.25 (t, J=7 Hz, 2H), 3.70 (s, 3H), 3.60 (s, 2H), 3.00 (t, J=7 Hz, 2H), 2.40 (3H, s).

EXAMPLE 1(23)

[0397] 2-(3-(biphenyl-4-ylmethoxy)pyridin-5-ylmethylthio)acetic Acid.Methyl Ester

703

[0398] TLC: Rf 0.22 (ethyl acetate:hexane=1:2)

[0399] NMR (CDCl3): δ 8.32 (d, J=3.0 Hz, 1H), 8.18 (d, J=2.0 Hz, 1H), 7.70-7.30 (m, 10H), 5.16 (s, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.06 (s, 2H).

EXAMPLE 1(24)

[0400] 2-(3-(4′-propylbiphenyl-4-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

704

[0401] TLC: Rf 0.65 (hexane:ethyl acetate=3:1)

[0402] NMR (CDCl3): δ 7.60 (d, J=8.4 Hz, 2H), 7.51 (d, J=8.2 Hz, 2H), 7.49 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.2 Hz, 2H), 7.24 (dd, J=7.7, 7.7 Hz, 1H), 6.87-7.00 (m, 3H), 5.10 (s, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 2.63 (t, J=7.4 Hz, 2H), 1.68 (tq, J=7.4, 7.4 Hz, 2H), 0.98 (t, J=7.4 Hz, 3H).

EXAMPLE 1(25)

[0403] 2-(3-(4-(pyridin-4-yl)phenylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

705

[0404] TLC: Rf 0.50 (ethyl acetate)

[0405] NMR (CDCl3): δ 8.67 (d, J=4.5 Hz, 1H), 8.66 (d, J=4.5 Hz, 1H), 7.67 (d, J=8.6 Hz, 2H), 7.50-7.58 (m, 4H), 7.26 (dd, J=8.0, 8.0 Hz, 1H), 6.80-7.01 (m, 3H), 5.13 (s, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H).

EXAMPLE 1(26)

[0406] 2-(3-(4-(pyridin-3-yl)phenylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

706

[0407] TLC: Rf 0.77 (hexane:ethyl acetate=1:9)

[0408] NMR (CDCl3): δ 8.86 (d, J=2.4 Hz, 1H), 8.60 (dd, J=5.0, 1.6 Hz, 1H), 7.89 (ddd, J=8.0, 2.4, 1.6 Hz, 1H), 7.62 (d, J=8.2 Hz, 2H), 7.55 (d, J=8.2 Hz, 2H), 7.38 (dd, J=8.0, 5.0 Hz, 1H), 7.26 (dd, J=8.0, 8.0 Hz, 1H), 6.87-7.01 (m, 3H), 5.13 (s, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H).

EXAMPLE 1(27)

[0409] 2-(3-(4-(1,3-dioxaindan-5-yl)phenylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

707

[0410] TLC: Rf 0.48 (hexane:ethyl acetate=3:1)

[0411] NMR (CDCl3): δ 7.54 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H), 7.25 (dd, J=7.9, 7.9 Hz, 1H), 6.86-7.08 (m, 6H), 6.00 (s, 2H), 5.09 (s, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H).

EXAMPLE 1(28)

[0412] 2-(3-(4-(pyridin-2-yl)phenylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

708

[0413] TLC: Rf 0.47 (hexane:ethyl acetate=2:1)

[0414] NMR (CDCl3): δ 8.70 (d, J=4.6 Hz, 1H), 8.01 (d, J=8.6 Hz, 2H), 7.74-7.77 (m, 3H), 7.54 (d, J=8.6 Hz, 2H), 7.24 (m, 1H), 6.75-7.00 (m, 3H), 5.13 (s, 2H), 3.80 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H).

EXAMPLE 1(29)

[0415] 2-(5-(biphenyl-4-ylmethoxy)-2-nitrophenylmethylthio)acetic Acid.Methyl Ester

709

[0416] TLC: Rf 0.38 (hexane:ethyl acetate=4:1)

[0417] NMR (CDCl3): δ 8.14 (d, J=9.0 Hz, 1H), 7.57-7.65 (m, 4H), 7.45-7.52 (m, 3H), 7.36-7.45 (m, 2H), 7.08 (d, J=2.8 Hz, 1H), 6.97 (dd, J=9.0, 2.8 Hz, 1H), 5.22 (s, 2H), 4.22 (s, 2H), 3.71 (s, 3H), 3.07 (s, 2H).

EXAMPLE 1(30)

[0418] 2-(3-(biphenyl-4-ylmethoxy)-4-nitrophenylmethylthio)acetic Acid.Methyl Ester

710

[0419] TLC: Rf 0.34 (hexane:ethyl acetate=4:1)

[0420] NMR (CDCl3): δ 7.85 (d, J=5.5 Hz, 1H), 7.53-7.63 (m, 6H), 7.42-7.48 (m, 2H), 7.33-7.38 (m, 1H), 7.20 (d, J=1.0 Hz, 1H), 7.01 (dd, J=5.5, 1.0 Hz, 1H), 5.31 (s, 2H), 3.83 (s, 2H), 3.71 (s, 3H), 3.00 (s, 2H).

EXAMPLE 1(31)

[0421] 2-(3-(4-(1,3-dioxaindan-4-yl)phenylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

711

[0422] TLC: Rf 0.52 (hexane:ethyl acetate=3:1)

[0423] NMR (CDCl3): δ 7.74 (d, J=8.4 Hz, 2H), 7.50 (d, J=8.4 Hz, 2H), 7.24 (dd, J=7.8, 7.8 Hz, 1H), 6.80-7.09 (m, 6H), 6.02 (s, 2H), 5.11 (s, 2H), 3.80 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H).

EXAMPLE 1(32)

[0424] 2-(3-(2-phenylthiazol-4-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

712

[0425] TLC: Rf 0.38 (hexane:ethyl acetate=4:1)

[0426] NMR (CDCl3): δ 7.92-7.99 (m, 2H), 7.43-7.48 (m, 3H), 7.32 (t, J=1.0 Hz, 1H), 7.26 (dd J=7.9, 7.9 Hz, 1H), 6.90-7.04 (m, 3H), 5.27 (d, J=1.0 Hz, 2H), 3.81 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H).

EXAMPLE 1(33)

[0427] 2-(3-(2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

713

[0428] TLC: Rf 0.81 (hexane:ethyl acetate=1:1)

[0429] NMR (CDCl3): δ 7.86 (d, J=8.2 Hz, 2H), 7.25-7.16 (m, 3H), 6.90-6.76 (m, 3H), 4.24 (t, J=6.7 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.7 Hz, 2H), 2.39 (s, 3H), 2.37 (s, 3H).

EXAMPLE 1(34)

[0430] 2-(3-(2-(2-phenylthiazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

714

[0431] TLC: Rf 0.39 (hexane:ethyl acetate=4:1)

[0432] NMR (CDCl3): δ 7.92-7.96 (m, 2H), 7.41-7.46 (m, 3H), 7.23 (dd, J=8.4, 8.4 Hz, 1H), 7.07 (s, 1H), 6.81-6.93 (m, 3H), 4.37 (t, J=6.6 Hz, 2H), 3.79 (s, 2H), 3.71 (s, 3H), 3.31 (t, J=6.6 Hz, 2H), 3.09 (s, 2H).

EXAMPLE 1(35)

[0433] 2-(3-(2-(5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

715

[0434] TLC: Rf 0.22 (hexane:ethyl acetate=2:1)

[0435] NMR (CDCl3) δ 8.09 (d, J=7.6 Hz, 2H), 7.69 (d, J=7.6 Hz, 2H), 7.19 (m, 1H), 6.89 (m, 2H), 6.8 (d, J=7.2 Hz, 1H), 4.25 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 2.99 (t, J=6.5 Hz, 2H), 2.41 (s, 3H).

EXAMPLE 1(36)

[0436] 2-(3-(2-(2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

716

[0437] TLC: Rf 0.40 (hexane:ethyl acetate=3:1)

[0438] NMR (CDCl3): δ 8.00-8.05 (m, 2H), 7.58 (s, 1H), 7.41-7.46 (m, 3H), 7.23 (dd, J=8.0, 8.0 Hz, 1H), 6.81-6.93 (m, 3H), 4.29 (t, J=6.5 Hz, 2H), 3.79 (s, 2H), 3.72 (s, 3H), 3.09 (t, J=6.5 Hz, 2H), 3.09 (s, 2H).

EXAMPLE 1(37)

[0439] 2-(3-(2-(5-methyl-2-(4-fluorophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

717

[0440] TLC: Rf 0.62 (hexane:ethyl acetate=1:1)

[0441] NMR (CDCl3): δ 7.96 (m, 2H), 7.06-7.24 (m, 3H), 6.91-6.74 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.77 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 1(38)

[0442] 2-(3-(2-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

718

[0443] TLC: Rf 0.84 (hexane:ethyl acetate=1:1)

[0444] NMR (CDCl3): δ 7.52 (dd, J=8.0, 1.4 Hz, 1H), 7.43 (d, J=1.4 Hz, 1H), 7.19 (d, J=8.0 Hz, 1H), 6.91-6.77 (m, 4H), 6.01 (s, 2H), 4.23 (t, J=6.7 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.95 (t, J=6.7 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 1(39)

[0445] 5-(3-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenyl)pentanoic Acid.Methyl Ester

719

[0446] TLC Rf 0.64 (hexane:ethyl acetate=2:1);

[0447] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.50-7.35 (m, 3H), 7.20 (dd, J=8, 7.5 Hz, 1H), 6.80-6.70 (m, 3H), 4.00 (t, J=6 Hz, 2H), 3.65 (s, 3H), 2.70 (t, J=6 Hz, 2H), 2.60 (m, 2H), 2.35 (m, 2H), 2.30 (s, 3H), 2.15 (m, 2H), 1.70-1.50 (m, 4H).

EXAMPLE 1(40)

[0448] 2-(3-(2-(5-methyl-2-(4-chlorophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

720

[0449] TLC: Rf 0.83 (hexane:ethyl acetate=2:1)

[0450] NMR (CDCl3): δ 7.93 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 7.27 (t, J=7.9 Hz, 1H), 7.06 (m, 1H), 6.92 (d, J=8.0 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 4.27 (t, J=7.8 Hz, 2H), 3.88 (s, 2H), 3.70 (s, 3H), 3.15 (s, 2H), 2.97 (t, J=7.8 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 1(41)

[0451] 2-(3-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

721

[0452] TLC: Rf 0.56 (hexane:ethyl acetate=2:1)

[0453] NMR (CDCl3): δ 8.05-8.00 (m, 2H), 7.50-7.40 (m, 3H), 7.25 (dd, J=8, 8 Hz, 1H), 7.05-6.90 (m, 3H), 5.00 (s, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H), 2.50 (s, 3H).

EXAMPLE 1(42)

[0454] 2-(3-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenylmethylthio)acetic Acid.Methyl Ester

722

[0455] TLC: Rf 0.53 (hexane:ethyl acetate=2:1)

[0456] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.25 (dd, J=7.5, 7.5 Hz, 1H), 6.95-6.75 (m, 3H), 4.00 (t, J=6 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H), 2.70 (t, J=7 Hz, 2H), 2.30 (s, 3H), 2.15 (m, 2H).

EXAMPLE 1(43)

[0457] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-methylpropanoic Acid.Methyl Ester

723

[0458] TLC: Rf 0.48 (hexane:ethyl acetate=3:1);

[0459] NMR (CDCl3): δ 7.97-8.02 (m, 2H), 7.41-7.46 (m, 3H), 7.22 (dd, J=8.0, 8.0 Hz, 1H), 6.76-6.81 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.64 (s, 3H), 2.99 (t, J=6.5 Hz, 2H), 2.38 (s, 3H), 1.55 (S, 6H).

EXAMPLE 1(44)

[0460] 2-(3-(2-(5-methyl-2-(2-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

724

[0461] TLC: Rf 0.70 (hexane:ethyl acetate=2:1)

[0462] NMR (CDCl3): δ 7.91 (m, 1H), 7.25-7.15 (m, 4H), 6.90-6.77 (in, 3H), 4.25 (t, J=6.7 Hz, 2H), 3.77 (s, 2H), 3.68 (s, 3H), 3.06 (s, 2H), 2.98 (t, J=6.7 Hz, 2H), 2.65 (s, 3H), 2.36 (s, 3H).

EXAMPLE 1(45)

[0463] 2-(3-(2-(5-methyl-2-(3-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

725

[0464] TLC: Rf 0.64 (hexane:ethyl acetate=2:1)

[0465] NMR (CDCl3) δ 7.81 (s, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.32-7.14 (m, 3H), 6.89-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.75 (s, 2H), 3.67 (s, 3H), 3.06 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.37 (s, 3H), 2.35 (s, 3H).

EXAMPLE 1(46)

[0466] 2-(3-(2-(5-methyl-2-(4-methoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

726

[0467] TLC: Rf 0.43 (hexane:ethyl acetate=3:1);

[0468] NMR (CDCl3): δ 7.92 (d, J=9.0 Hz, 2H), 7.21 (dd, J=8.1, 8.1 Hz, 1H), 6.94 (d, J=9.0 Hz, 2H), 6.88-6.98 (m, 2H), 6.81 (m, 1H), 4.24 (t, J=6.7 Hz, 2H), 3.85 (s, 3H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.7 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 1(47)

[0469] 2-(3-(2-(5-methyl-2-(4-nitrophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

727

[0470] TLC: Rf 0.32 (hexane:ethyl acetate=3:1)

[0471] NMR (CDCl3): δ 8.30 (d, J=9.0 Hz, 2H), 8.14 (d, J=9.0 Hz, 2H), 7.22 (dd, J=8.0, 8.0 Hz, 1H), 6.77-6.91 (m, 3H), 4.26 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.43 (s, 3H).

EXAMPLE 1(48)

[0472] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-5-chlorophenylmethylthio)acetic Acid.Methyl Ester

728

[0473] TLC: Rf 0.45 (hexane:ethyl acetate=3:1)

[0474] NMR (CDCl3): δ 7.96-8.00 (m, 2H), 7.40-7.46 (m, 3H), 6.91 (m, 1H), 6.77-6.81 (m, 2H), 4.23 (t, J=6.6 Hz, 2H), 3.73 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 1(49)

[0475] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-methylphenylmethylthio)acetic Acid.Methyl Ester

729

[0476] TLC: Rf 0.48 (hexane:ethyl acetate=5:1)

[0477] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.46-7.39 (m, 3H), 7.07 (t, J=7.9 Hz, 1H), 6.85-6.77 (m, 2H), 4.24 (t, J=6.5 Hz, 2H), 3.83 (s, 2H), 3.73 (s, 3H), 3.11 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.38 (s, 3H), 2.21 (s, 3H).

EXAMPLE 1(50)

[0478] 2-(1-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)ethylthio)acetic Acid.Methyl Ester

730

[0479] TLC: Rf 0.68 (hexane:ethyl acetate=4:1)

[0480] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.46-7.39 (m, 3H), 7.21 (t, J=8.2 Hz, 1H), 6.94-6.89 (m, 2H), 6.82-6.76 (m, 1H), 4.25 (t, J=6.7 Hz, 2H), 4.10 (q, J=7.2 Hz, 1H), 3.67 (s, 3H), 3.02 (s, 2H), 2.98 (t, J=6.7 Hz, 2H), 2.39 (s, 3H), 1.55 (d, J=7.2 Hz, 3H).

EXAMPLE 1(51)

[0481] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)-1-methylethoxy)phenylmethylthio)acetic Acid.Methyl Ester

731

[0482] TLC: Rf 0.72 (hexane:ethyl acetate=2:1).

EXAMPLE 1(52)

[0483] 2-(3-(2-(5-trifluoromethyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

732

[0484] TLC: Rf 0.37 (hexane:ethyl acetate=4:1)

[0485] NMR (CDCl3): δ 8.10-8.00 (m., 2H), 7.55-7.41 (m., 3H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.94-6.75 (m, 3H), 4.31 (t, J=6.5 Hz, 2H), 3.77 (s, 2H), 3.71 (s, 3H), 3.25-3.14 (m, 2H), 3.08 (s, 2H).

EXAMPLE 1(53)

[0486] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenylmethylthio)acetic Acid.Methyl Ester

733

[0487] TLC: Rf 0.54 (hexane:ethyl acetate=3:1)

[0488] NMR (CDCl3): δ 8.00-7.94 (m, 2H), 7.44-7.37 (m, 3H), 7.29 (t, J=8.2 Hz, 1H), 6.89-6.86 (m, 2H), 6.79 (dd, J=8.4, 2.0 Hz, 1H), 4.17-4.03 (m, 2H), 3.77 (s, 2H), 3.71 (s, 3H), 3.26-3.15 (m, 1H), 3.08 (s, 2H), 2.37 (s, 3H), 1.41 (d, J=6.8 Hz, 3H).

EXAMPLE 1(54)

[0489] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)propanoic Acid.Ethyl Ester

734

[0490] TLC: Rf 0.75 (hexane:ethyl acetate=7:1);

[0491] NMR (CDCl3): δ 8.00-7.94 (m, 2H), 7.46-7.38 (m, 3H), 7.20 (t, J=8.2 Hz, 1H), 6.90 (m, 2H), 6.82-6.75 (m, 1H), 4.24 (t, J=6.8 Hz, 2H), 4.17 (q, J=7.2 Hz, 2H), 3.82 (d, J=13.4 Hz, 1H), 3.74 (d, J=13.4 Hz, 1H), 3.28 (q, J=7.0 Hz, 1H), 2.98 (t, J=6.8 Hz, 2H), 2.38 (s, 3H), 1.38 (d, J=7.0 Hz, 3H), 1.28 (t, J=7.2 Hz, 3H).

EXAMPLE 1(55)

[0492] 2-(3-(2-(5-methyl-2-(4-ethylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

735

[0493] TLC Rf 0.57 (ethyl acetate:hexane=1:2)

[0494] NMR (CDCl3): δ 7.88 (d, J=8.0 Hz, 2H), 7.25 (d, J=8.0 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 4.24 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.5 Hz, 2H), 2.68 (q, J=7.5 Hz, 2H), 2.37 (s, 3H), 1.25 (t, J=7.5 Hz, 3H).

EXAMPLE 1(56)

[0495] 2-(3-(2-(5-methyl-2-(2,2-difluoro-1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

736

[0496] TLC: Rf 0.59 (ethyl acetate:hexane=1:2)

[0497] NMR (CDCl3): δ 7.75 (dd, J=8.0, 1.0 Hz, 1H), 7.69 (d, J=1.0 Hz, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J=8.0 Hz, 1H), 4.23 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.09 (s, 2H), 2.96 (t, J=6.5 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 1(57)

[0498] 2-(3-(2-(5-methyl-2-(4-propylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

737

[0499] TLC: Rf 0.63 (ethyl acetate:hexane=1:2)

[0500] NMR (CDCl3): δ 7.88 (d, J=8.5 Hz, 2H), 7.23 (d, J=8.5 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 4.24 (t, J=7.0 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=7.0 Hz, 2H), 2.62 (t, J=7.5 Hz, 2H), 2.37 (s, 3H), 1.65 (m, 2H), 0.94 (t, J=7.5 Hz, 3H).

EXAMPLE 1(58)

[0501] 2-(3-(2-(5-methyl-2-(4-isopropylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

738

[0502] TLC: Rf 0.60 (ethyl acetate:hexane=1:2)

[0503] NMR (CDCl3): δ 7.89 (d, J=8.5 Hz, 2H), 7.28 (d, J=8.5 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 4.24 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.5 Hz, 2H), 2.94 (m, 1H), 2.37 (s, 3H), 1.26 (d, J=7.0 Hz, 6H).

EXAMPLE 1(59)

[0504] 2-(3-(2-(5-methyl-2-phenylthiazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

739

[0505] TLC: Rf 0.54 (hexane:ethyl acetate=3:1)

[0506] NMR (CDCl3) δ 7.89-7.83 (m, 2H), 7.45-7.36 (m, 3H), 7.21 (t, J=8.0 Hz, 1H), 6.91-6.77 (m, 3H), 4.33 (t, J=6.8 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.19 (t, J=6.8 Hz, 2H), 3.08 (s, 2H), 2.47 (s, 3H).

EXAMPLE 1(60)

[0507] 2-(3-(2-(5-methyl-2-(4-butylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

740

[0508] TLC: Rf 0.59 (hexane:ethyl acetate=2:1)

[0509] NMR (CDCl3): δ 7.90 (d, J=7 Hz, 2H), 7.25-7.15 (m, 3H), 6.90-6.75 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.75 (s, 2H), 3.70 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.65 (t, J=7.5 Hz, 2H), 2.40 (s, 3H), 1.60 (m, 2H), 1.35 (m, 2H), 0.95 (t, J=7 Hz, 3H).

EXAMPLE 1(61)

[0510] 2-(3-(2-(5-ethyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

741

[0511] TLC: Rf 0.27 (hexane:ethyl acetate=3:1)

[0512] NMR (CDCl3): δ 7.96-8.01 (m, 2H), 7.40-7.48 (m, 3H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.87-6.90 (m, 2H), 6.79 (m, 1H), 4.24 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.99 (t, J=6.6 Hz, 2H), 2.75 (q, J=7.6 Hz, 2H), 1.31 (t, J=7.6 Hz, 3H).

EXAMPLE 1(62)

[0513] 2-(3-(2-(5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid. Methyl Ester

742

[0514] TLC Rf 0.45 (hexane:ethyl acetate=4:1)

[0515] NMR (CDCl3): δ 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.94-6.75 (m, 3H), 4.25 (t, J=6.4 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 3.03 (t, J=6.4 Hz, 2H), 2.42 (s, 3H), 2.36-2.30 (m, 3H).

EXAMPLE 1(63)

[0516] 2-(3-(2-(5-methyl-2-(4-pentylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

743

[0517] TLC: Rf 0.66 (hexane:ethyl acetate=2:1)

[0518] NMR (CDCl3): δ 7.90 (d, J=8 Hz, 2H), 7.25-7.20 (m, 3H), 6.95-6.75 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.80 (s, 2H), 3.70 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.65 (t, J=7.5 Hz, 2H), 2.40 (s, 3H), 1.60 (m, 2H), 1.40-1.25 (m, 4H), 0.90 (t, J=6.5 Hz, 3H).

EXAMPLE 1(64)

[0519] 2-(3-(2-(5-methyl-2-(3-chloro-4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

744

[0520] TLC: Rf 0.47 (hexane:ethyl acetate=3:1)

[0521] NMR (CDCl3) δ 7.96 (d, J=1.8 Hz, 1H), 7.75 (dd, J=7.8, 1.8 Hz, 1H), 7.28 (d, J=7.8 Hz, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.88-6.91 (m, 2H), 6.79 (m, 1H), 4.24 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.41 (s, 3H), 2.38 (s, 3H).

EXAMPLE 1(65)

[0522] 2-(3-(2-(5-methyl-2-cyclohexyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

745

[0523] TLC: Rf 0.65 (hexane:ethyl acetate=2:1)

[0524] NMR (CDCl3): δ 7.20 (m, 1H), 6.95-6.70 (m, 3H), 4.15 (t, J=7.5 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.15 (s, 2H), 2.90 (t, J=7.5 Hz, 2H), 2.70 (m, 1H), 2.25 (s, 3H), 2.10-1.20 (m, 10H).

EXAMPLE 1(66)

[0525] 2-(3-(2-(5-methyl-2-(4-(2-methylpropyl)phenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

746

[0526] TLC: Rf 0.58 (hexane:ethyl acetate=2:1)

[0527] NMR (CDCl3): δ 7.90 (d, J=8 Hz, 2H), 7.25-7.20 (m, 3H), 6.90-6.75 (m, 3H), 4.25 (t, J=7 Hz, 2H), 3.80 (s, 2H), 3.70 (s, 3H), 3.10 (s, 2H), 2.95 (t, J=7 Hz, 2H), 2.50 (d, J=8 Hz, 2H), 2.40 (s, 3H), 1.90 (m, 1H), 0.90 (d, J=7 Hz, 6H).

EXAMPLE 1(67)

[0528] 2-(3-(2-(5-methyl-2-(4-t-butylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

747

[0529] TLC: Rf 0.50 (hexane:ethyl acetate=2:1)

[0530] NMR (CDCl3): 7.90 (d, J=8 Hz, 2H), 7.45 (d, J=8 Hz, 2H), 7.20 (dd, J=8, 8 Hz, 1H), 6.90-6.75 (m, 3H), 4.25 (t, J=7 Hz, 2H), 3.80 (s, 2H), 3.70 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=7 Hz, 2H), 2.40 (s, 3H), 1.35 (s, 9H).

EXAMPLE 1(68)

[0531] 2-(3-(2-(5-methyl-2-(4-cyclohexylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

748

[0532] TLC: Rf 0.42 (hexane:ethyl acetate=4:1)

[0533] NMR (CDCl3): δ 7.88 (d, J=8.3 Hz, 2H), 7.26 (d, J=8.3 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.87-6.90 (m, 2H), 6.80 (m, 1H), 4.23 (t, J=6.8 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.8 Hz, 2H), 2.53 (m, 1H), 2.37 (s, 3H), 1.70-1.94 (m, 4H), 1.30-1.53 (m, 6H).

EXAMPLE 1(69)

[0534] 2-(3-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

749

[0535] TLC: Rf 0.50 (hexane:ethyl acetate=4:1)

[0536] NMR (CDCl3) δ 7.55 (dd, J=8.0, 1.8 Hz, 1H), 7.47 (d, J=1.8 Hz, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 7.08-7.02 (m, 1H), 6.96-6.82 (m, 3H), 6.02 (s, 2H), 5.00 (s, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.11 (s, 2H), 2.43 (s, 3H).

EXAMPLE 1(70)

[0537] 2-(3-(5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)phenylmethylthio)acetic Acid.Methyl Ester

750

[0538] TLC: Rf 0.50 (hexane:ethyl acetate=4:1)

[0539] NMR (CDCl3) δ 7.93 (dd, J=8.5, 2.0 Hz, 2H), 7.35-7.18 (m, 3H), 7.09-7.03 (m, 1H), 6.96-6.84 (m, 2H), 5.02 (s, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.11 (s, 2H), 2.94 (sep., J=7.0 Hz, 1H), 2.43 (s, 3H), 1.27 (d, J=7.0 Hz, 6H).

EXAMPLE 1(71)

[0540] 2-(3-(2-(4-methyl-2-phenyloxazol-5-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

751

[0541] TLC: Rf 0.37 (hexane:ethyl acetate=3:1)

[0542] NMR (CDCl3): δ 8.01-7.96 (m, 2H), 7.46-7.39 (m, 3H), 7.22 (t, J=8.2 Hz, 1H), 6.97-6.88 (m, 2H), 6.80 (m, 1H), 4.23 (t, J=6.8 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.16 (t, J=6.8 Hz, 2H), 3.08 (s, 2H), 2.22 (s, 3H).

EXAMPLE 1(72)

[0543] 2-(3-(2-(5-methyl-2-(3,4-dimethoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

752

[0544] TLC: Rf 0.18 (hexane:ethyl acetate=3:1)

[0545] NMR (CDCl3): δ 7.56 (dd, J=8.3, 2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.21 (dd, J=8.1, 8.1 Hz, 1H), 6.91 (d, J=8.3 Hz, 1H), 6.87-6.91 (m, 2H), 6.80 (ddd, J=8.1, 2.5, 1.0 Hz, 1H), 4.24 (t, J=6.7 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.78 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 2.97 (t, J=6.7 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(73)

[0546] 2-(3-(2-(5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

753

[0547] TLC: Rf 0.62 (hexane:ethyl acetate=2:1)

[0548] NMR (CDCl3): δ 8.00 (d, J=8 Hz, 2H), 7.30-7.15 (m, 3H), 6.95-6.75 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(74)

[0549] 2-(3-(2-(5-methyl-2-(3,4,5-trimethoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

754

[0550] TLC: Rf 0.24 (hexane:ethyl acetate=2:1)

[0551] NMR (CDCl3): δ 7.25-7.15 (m, 3H), 6.95-6.75 (m, 3H), 4.25 (t, J=7.5 Hz, 2H), 3.95 (s, 6H), 3.90 (s, 3H), 3.80 (s, 2H), 3.70 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=7.5 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(75)

[0552] 2-(3-(2-(5-methyl-2-(4-methylpiperazin-1-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

755

[0553] TLC: Rf 0.12 (ethyl acetate)

[0554] NMR (CDCl3): δ 7.20 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 4.20 (t, J=7.0 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.42 (t, J=5.0 Hz, 4H), 3.09 (s, 2H), 2.95 (t, J=7.0 Hz, 2H), 2.50 (t, J=5.0 Hz, 4H), 2.34 (s, 3H), 2.26 (s, 3H).

EXAMPLE 1(76)

[0555] 2-(3-(2-(5-methyl-2-(4-methylthiophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

756

[0556] TLC: Rf 0.46 (ethyl acetate:hexane=1:2)

[0557] NMR (CDCl3): δ 7.88 (d, J=8.5 Hz, 2H), 7.27 (d, J=8.5 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 4.24 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.5 Hz, 2H), 2.52 (s, 3H), 2.37 (s, 3H).

EXAMPLE 1(77)

[0558] 2-(3-(2-(5-methyl-2-(pyridin-2-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

757

[0559] TLC: Rf 0.60 (hexane:ethyl acetate=1:2);

[0560] NMR (CDCl3): δ 8.71 (m, 1H), 8.05 (m, 1H), 7.73 (m, 1H), 7.32 (m, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.76-6.92 (m, 3H), 4.27 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 3.01 (t, J=6.6 Hz, 2H), 2.44 (s, 3H).

EXAMPLE 1(78)

[0561] 2-(3-(2-(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

758

[0562] TLC: Rf 0.40 (hexane:ethyl acetate=3:1)

[0563] NMR (CDCl3): δ 7.58 (dd, J=3.6, 1.3 Hz, 1H), 7.37 (dd, J=5.0, 1.3 Hz, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 7.08 (dd, J=5.0, 3.6 Hz, 1H), 6.87-6.91 (m, 2H), 6.79 (m, 1H), 4.22 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 1(79)

[0564] 2-(3-(2-(5-methyl-2-(3-nitro-4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

759

[0565] TLC: Rf 0.42 (hexane:ethyl acetate=2:1)

[0566] NMR (CDCl3): δ 8.55 (d, J=1 Hz, 1H), 8.10 (dd, J=8, 1 Hz, 1H), 7.40 (d, J=8 Hz, 1H), 7.20 (dd, J=8, 8 Hz, 1H), 6.95-6.80 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.65 (s, 3H), 2.40 (s, 3H).

EXAMPLE 1(80)

[0567] 2-(3-(2-(5-methyl-2-(4-dimethylaminophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

760

[0568] TLC: Rf 0.43 (ethyl acetate:hexane=1:2)

[0569] NMR (CDCl3): δ 7.83 (d, J=9.0 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 6.71 (d, J=9.0 Hz, 2H), 4.23 (t, J=7.0 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 3.01 (s, 6H), 2.96 (t, J=7.0 Hz, 2H), 2.34 (s, 3H).

EXAMPLE 1(81)

[0570] 2-(3-(2-(5-methyl-2-cyclopentyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

761

[0571] TLC Rf 0.46 (hexane:ethyl acetate=2:1)

[0572] NMR (CDCl3): δ 7.20 (m, 1H), 6.95-6.70 (m, 3H), 4.15 (t, J=6.5 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.15 (m, 3H), 2.90 (t, J=6.5 Hz, 2H), 2.25 (s, 3H), 2.20-1.50 (m, 8H).

EXAMPLE 1(82)

[0573] 2-(3-(2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

762

[0574] TLC: Rf 0.54 (hexane:ethyl acetate=2:1)

[0575] NMR (CDCl3): δ 7.86 (d, J=8.0 Hz, 2H), 7.28-7.15 (m, 3H), 6.88-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.39 (s, 3H), 2.36 (s, 3H).

EXAMPLE 1(83)

[0576] 2-(3-(2-(5-methyl-2-(4-ethylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

763

[0577] TLC: Rf 0.56 (hexane:ethyl acetate=2:1)

[0578] NMR (CDCl3) δ 7.90 (d, J=8.0 Hz, 2H), 7.30-7.16 (m, 3H), 6.88-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.68 (q, J=7.6 Hz, 2H), 2.37 (s, 3H), 1.26 (t, J=7.6 Hz, 3H).

EXAMPLE 1(84)

[0579] 2-(3-(2-(5-methyl-2-(4-propylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

764

[0580] TLC: Rf 0.59 (hexane:ethyl acetate=2:1)

[0581] NMR (CDCl3): δ 7.88 (d, J=8.4 Hz, 2H), 7.27-7.15 (m, 3H), 6.88-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.62 (t, J=7.5 Hz, 2H), 2.36 (s, 3H), 1.66 (m, 2H), 0.94 (t, J=7.5 Hz, 3H).

EXAMPLE 1(85)

[0582] 2-(3-(2-(5-methyl-2-(4-isopropylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

765

[0583] TLC: Rf 0.66 (hexane:ethyl acetate=2:1)

[0584] NMR (CDCl3): δ 7.89 (d, J=8.4 Hz, 2H), 7.34-7.15 (m, 3H), 6.88-6.75 (m, 3H), 4.23 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.8 Hz, 2H), 3.04-2.86 (m, 1H), 2.36 (s, 3H), 1.28 (s, 3H), 1.25 (s, 3H).

EXAMPLE 1(86)

[0585] 2-(3-(2-(5-methyl-2-(4-(2-methylpropyl)phenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

766

[0586] TLC: Rf 0.60 (hexane:ethyl acetate=2:1)

[0587] NMR (CDCl3): δ 7.88 (d, J=8.2 Hz, 2H), 7.27-7.15 (m, 3H), 6.90-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.51 (d, J=5.4 Hz, 2H), 2.36 (s, 3H), 2.00-1.76 (m, 1H), 0.92 (s, 3H), 0.89 (s, 3H).

EXAMPLE 1(87)

[0588] 2-(3-(2-(5-methyl-2-(4-t-butylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

767

[0589] TLC: Rf 0.57 (hexane:ethyl acetate=2:1)

[0590] NMR (CDCl3): δ 7.90 (d, J=8.6 Hz, 2H), 7.44 (d, J=8.6 Hz, 2H), 7.21 (m, 1H), 6.88-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.37 (s, 3H), 1.34 (s, 9H).

EXAMPLE 1(88)

[0591] 2-(3-(2-(5-methyl-2-cyclopropyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

768

[0592] TLC: Rf 0.47 (ethyl acetate:hexane=1:1)

[0593] NMR (CDCl3): δ 7.20 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.75 (m, 3H), 4.15 (t, J=7.0 Hz, 2H), 3.79 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 2.84 (t, J=7.0 Hz, 2H), 2.22 (s, 3H), 1.97 (m, 1H), 1.05-0.90 (m, 4H).

EXAMPLE 1(89)

[0594] 2-(3-(2-(5-methyl-2-(4-(1,2,3-thiadiazol-4-yl)phenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

769

[0595] TLC Rf 0.75 (hexane:ethyl acetate=2:1)

[0596] NMR (CDCl3): δ 8.72 (s, 1H), 8.13 (s, 4H), 7.22 (t, J=8.0 Hz, 1H), 6.93-6.77 (m, 3H), 4.27 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.09 (s, 2H), 3.00 (t, J=6.6 Hz, 2H), 2.41 (s, 3H).

EXAMPLE 1(90)

[0597] 2-(3-(2-(5-methyl-2-(4-(4-methyl-1,2,3-thiadiazol-5-yl)phenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

770

[0598] TLC: Rf 0.89 (hexane:ethyl acetate=2:1)

[0599] NMR (CDCl3): δ 7.21 (t, J=7.4 Hz, 1H), 6.94-6.74 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 3.02 (s, 3H), 2.99 (t, J=6.6 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 1(91)

[0600] 2-(3-(2-(5-methyl-2-(4-methoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

771

[0601] TLC: Rf 0.38 (hexane:ethyl acetate=2:1)

[0602] NMR (CDCl3): δ 7.91 (d, J=9.0 Hz, 2H), 7.20 (m, 1H), 6.94 (d, J=9.0 Hz, 2H), 6.88-6.77 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.85 (s, 3H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 1(92)

[0603] 2-(3-(2-(5-methyl-2-(3,4-dimethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

772

[0604] TLC: Rf 0.17 (hexane:ethyl acetate=2:1)

[0605] NMR (CDCl3+CD3OD): δ 7.56 (dd, J=8.2, 2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.21 (m, 1H), 6.91 (d, J=8.2 Hz, 1H), 6.89-6.77 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(93)

[0606] 2-(3-(2-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

773

[0607] TLC: Rf 0.44 (hexane:ethyl acetate=2:1)

[0608] NMR (CDCl3): δ 7.52 (dd, J=8.2, 1.8 Hz, 1H), 7.44 (d, J=1.8 Hz, 1H), 7.21 (m, 1H), 6.99-6.76 (m, 4H), 6.01 (s, 2H), 4.22 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 1(94)

[0609] 2-(3-(2-(5-methyl-2-(3,4,5-trimethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

774

[0610] TLC: Rf 0.28 (hexane:ethyl acetate=2:1)

[0611] NMR (CDCl3): δ 7.28-7.17 (m, 3H), 6.89-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.94 (s, 6H), 3.89 (s, 3H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 1(95)

[0612] 2-(3-(2-(5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

775

[0613] TLC: Rf 0.61 (hexane:ethyl acetate=2:1)

[0614] NMR (CDCl3): δ 8.01 (d, J=8.6 Hz, 2H), 7.32-7.16 (m, 3H), 6.89-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 1(96)

[0615] 2-(3-(2-(5-methyl-2-(2,2-difluoro-1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

776

[0616] TLC: Rf 0.52 (hexane:ethyl acetate=2:1)

[0617] NMR (CDCl3): δ 7.75 (dd, J=8.4, 1.8 Hz, 1H); 7.68 (d, J=1.8 Hz, 1H), 7.21 (m, 1H), 7.10 (d, J=8.4 Hz, 1H), 6.89-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(97)

[0618] 2-(3-(2-(5-methyl-2-(4-trifluoromethylthiophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

777

[0619] TLC: Rf 0.45 (hexane:ethyl acetate=3:1)

[0620] NMR (CDCl3): δ 8.02 (d, J=8.4 Hz, 2H), 7.70 (d, J=8.4 Hz, 2H), 7.21 (t, J=7.8 Hz, 1H), 6.91-6.73 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.71 (s, 3H), 3.08 (s, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(98)

[0621] 2-(3-(2-(5-methyl-2-(4-cyanophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

778

[0622] TLC: Rf 0.35 (hexane:ethyl acetate=2:1)

[0623] NMR (CDCl3): δ 8.08 (d, J=8.4 Hz, 2H), 7.71 (d, J=8.4 Hz, 2H), 7.21 (m, 1H), 6.75-6.94 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.09 (s, 2H), 2.99 (t, J=6.6 Hz, 2H), 2.41 (s, 3H).

EXAMPLE 1(99)

[0624] 2-(3-(2-(5-methyl-2-(furan-2-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

779

[0625] TLC: Rf 0.32 (hexane:ethyl acetate=2:1)

[0626] NMR (CDCl3): δ 7.52 (m, 1H), 7.21 (m, 1H), 6.86-6.96 (m, 3H), 6.79 (m, 1H), 6.51 (m, 1H), 4.24 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.72 (s, 3H), 3.08 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(100)

[0627] 2-(3-(5-methyl-2-phenyloxazol-4-yl)methoxy)phenyl)acetic Acid.Methyl Ester

780

[0628] TLC: Rf 0.69 (hexane:ethyl acetate=2:1);

[0629] NMR (CDCl3): δ 7.98-8.10 (m, 2H), 7.40-7.54 (m, 3H), 7.26 (m, 1H), 6.86-7.00 (m, 3H), 4.99 (s, 2H), 3.68 (s, 3H), 3.61 (s, 2H), 2.44 (s, 3H).

EXAMPLE 1(101)

[0630] 2-(3-(2-(5-methyl-2-phenylthiazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

781

[0631] TLC: Rf 0.56 (hexane:ethyl acetate=2:1)

[0632] NMR (CDCl3): δ 7.90-7.81 (m, 2H), 7.46-7.35 (m, 3H), 7.25-7.16 (m, 1H), 6.87-6.78 (m, 3H), 4.32 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.19 (t, J=6.8 Hz, 2H), 2.46 (s, 3H).

EXAMPLE 1(102)

[0633] 2-(3-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenyl)acetic Acid.Methyl Ester

782

[0634] TLC: Rf 0.42 (hexane:ethyl acetate=2:1)

[0635] NMR (CDCl3): δ 7.94-8.04 (m, 2H), 7.36-7.50 (m, 3H), 7.22 (m, 1H), 6.76-6.90 (m, 3H), 3.98 (t, J=6.2 Hz, 2H), 3.69 (s, 3H), 3.59 (s, 2H), 2.70 (t, J=7.0 Hz, 2H), 2.28 (s, 3H), 2.15 (m, 2H).

EXAMPLE 1(103)

[0636] 2-(3-(2-(2-phenyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

783

[0637] TLC: Rf 0.53 (hexane:ethyl acetate=2:1)

[0638] NMR (CDCl3): δ 7.96-8.08 (m, 2H), 7.57 (s, 1H), 7.40-7.52 (m, 3H), 7.24 (m, 1H), 6.80-6.92 (m, 3H), 4.28 (t, J=6.6 Hz, 2H), 3.69 (s, 3H), 3.59 (s, 2H), 3.09 (t, J=6.6 Hz, 2H).

EXAMPLE 1(104)

[0639] 2-(3-(2-(5-methyl-2-(4-cyclohexylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

784

[0640] TLC: Rf 0.67 (hexane:ethyl acetate=2:1)

[0641] NMR (CDCl3): δ 7.88 (d, J=8.4 Hz, 2H), 7.26 (d, J=8.4 Hz, 2H), 7.21 (m, 1H), 6.77-6.86 (m, 3H), 4.23 (t, J=7.0 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96 (t, J=7.0 Hz, 2H), 2.55 (m, 1H), 2.36 (s, 3H), 1.73-7.87 (m, 4H), 1.30-1.60 (m, 6H).

EXAMPLE 1(105)

[0642] 2-(3-(2-(5-methyl-2-(3-chloro-4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

785

[0643] TLC: Rf 0.53 (hexane:ethyl acetate=2:1)

[0644] NMR (CDCl3): δ 7.96 (d, J=1.8 Hz, 1H), 7.75 (dd, J=8.0, 1.8 Hz, 1H), 7.28 (d, J=8.0 Hz, 1H), 7.22 (m, 1H), 6.78-6.86 (m, 3H), 4.23 (t, J=6.7 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96 (t, J=6.7 Hz, 2H), 2.40 (s, 3H), 2.37 (s, 3H).

EXAMPLE 1(106)

[0645] 2-(3-(2-(5-methyl-2-(4-dimethylaminophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

786

[0646] TLC: Rf 0.31 (hexane:ethyl acetate=2:1)

[0647] NMR (CDCl3): δ 7.84 (d, J=9.0 Hz, 2H), 7.21 (m, 1H), 6.78-6.87 (m, 3H), 6.71 (d, J=9.0 Hz, 2H), 4.23 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.01 (s, 6H), 2.95 (t, J=6.8 Hz, 2H), 2.34 (s, 3H).

EXAMPLE 1(107)

[0648] 2-(3-(2-(5-ethyl-2-phenyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

787

[0649] TLC: Rf 0.61 (hexane:ethyl acetate=2:1)

[0650] NMR (CDCl3): δ 7.94-8.04 (m, 2H), 7.37-7.50 (m, 3H), 7.21 (m, 1H), 6.76-6.89 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.75 (q, J=7.6 Hz, 2H), 1.31 (t, J=7.6 Hz, 3H).

EXAMPLE 1(108)

[0651] 2-(3-(2-(5-methyl-2-(4-butylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

788

[0652] TLC: Rf 0.62 (hexane:ethyl acetate=2:1)

[0653] NMR (CDCl3): δ 7.88 (d, J=8.6 Hz, 2H), 7.16-7.28 (m, 3H), 6.76-6.90 (m, 3H), 4.23 (t, J=6.8 Hz, 2H), 3.69 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.8 Hz, 2H), 2.64 (t, J=7.0 Hz, 2H), 2.36 (s, 3H), 1.62 (m, 2H), 1.34 (m, 2H), 0.93 (t, J=7.4 Hz, 3H).

EXAMPLE 1(109)

[0654] 2-(3-(2-(5-methyl-2-(4-chlorophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

789

[0655] TLC: Rf 0.54 (hexane:ethyl acetate=2:1)

[0656] NMR (CDCl3) δ 7.91 (d, J=8.6 Hz, 2H), 7.40 (d, J=8.6 Hz, 2H), 7.21 (m, 1H), 6.75-6.89 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96(t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(110)

[0657] 2-(3-(2-(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

790

[0658] TLC Rf 0.43 (hexane:ethyl acetate=2:1)

[0659] NMR (CDCl3): δ 7.58 (dd, J=3.7, 1.2 Hz, 1H), 7.36 (dd, J=5.2, 1.2 Hz, 1H), 7.22 (m, 1H), 7.08 (dd, J=5.2, 3.7 Hz, 1H), 6.77-6.88 (m, 3H), 4.22 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 1(111)

[0660] 2-(3-(2-(5-methyl-2-(furan-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

791

[0661] TLC: Rf 0.33 (hexane:ethyl acetate=2:1);

[0662] NMR (CDCl3): δ 7.51 (m, 1H), 7.21 (m, 1H), 6.92 (d, J=3.4 Hz, 1H), 6.78-6.87 (m, 3H), 6.50 (dd, J=3.4, 1.8 Hz, 1H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.57 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 1(112)

[0663] 2-(3-(2-(5-methyl-2-(pyridin-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

792

[0664] TLC: Rf 0.57 (ethyl acetate)

[0665] NMR (CDCl3): δ 8.70 (m, 1H), 8.05 (m, 1H), 7.78 (ddd, J=7.8, 7.8, 1.6 Hz, 1H), 7.31 (m, 1H), 7.21 (m, 1H), 6.76-6.86 (m, 3H), 4.25 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.57 (s, 2H), 3.00 (t, J=6.6 Hz, 2H), 2.43 (s, 3H).

EXAMPLE 1(113)

[0666] 2-(3-(2-(5-methyl-2-(2-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

793

[0667] TLC: Rf 0.76 (hexane:ethyl acetate=2:1)

[0668] NMR (CDCl3): δ 7.91 (m, 1H), 7.19-7.34 (m, 4H), 6.78-6.87 (m, 3H), 4.25 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.98 (t, J=6.8 Hz, 2H), 2.65 (s, 3H), 2.37 (s, 3H).

EXAMPLE 1(114)

[0669] 2-(3-(2-(5-methyl-2-(3-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

794

[0670] TLC: Rf 0.55 (hexane:ethyl acetate=2:1)

[0671] NMR (CDCl3): δ 7.75-7.82 (m, 2H), 7.17-7.35 (m, 3H), 6.78-6.86 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.40 (s, 3H), 2.37 (s, 3H).

EXAMPLE 1(115)

[0672] 2-(3-(2-(5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

795

[0673] TLC: Rf 0.57 (hexane:ethyl acetate=2:1)

[0674] NMR (CDCl3): δ 8.09 (d, J=8.4 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 7.21 (m, 1H), 6.75-6.90 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.99(t, J=6.6 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(116)

[0675] 2-(3-(2-(5-methyl-2-(4-fluorophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

796

[0676] TLC: Rf 0.51 (hexane:ethyl acetate=2:1)

[0677] NMR (CDCl3) δ 7.91-8.04 (m, 2H), 7.05-7.24 (m, 3H), 6.75-6.92 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 1(117)

[0678] 2-(3-(2-(5-methyl-2-(4-cyanophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

797

[0679] TLC: Rf 0.37 (hexane:ethyl acetate=2:1)

[0680] NMR (CDCl3): δ 8.07 (d, J=8.8 Hz, 2H), 7.71 (d, J=8.8 Hz, 2H), 7.22 (m, 1H), 6.78-6.87 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(118)

[0681] 2-(3-(2-(5-methyl-2-(4-methyl-1,2,3-thiadiazol-5-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

798

[0682] TLC: Rf 0.49 (hexane:ethyl acetate=2:1)

[0683] NMR (CDCl3): δ 7.22 (m, 1H), 6.78-6.87 (m, 3H), 4.23 (t, J=6.2 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.02 (s, 3H), 2.98 (t, J=6.2 Hz, 2H), 2.41 (s, 3H).

EXAMPLE 1(119)

[0684] 2-(3-(2-(5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

799

[0685] TLC Rf 0.58 (hexane:ethyl acetate=2:1)

[0686] NMR (CDCl3): δ 7.20 (m, 1H), 6.75-6.90 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.02 (t, J=6.6 Hz, 2H), 2.41 (s, 3H), 2.33 (s, 3H).

EXAMPLE 1(120)

[0687] 2-(3-(2-(5-methyl-2-(3-nitro-4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

800

[0688] TLC: Rf 0.33 (hexane:ethyl acetate=2:1)

[0689] NMR (CDCl3): δ 8.55 (d, J=1.6 Hz, 1H), 8.09 (dd, J=8.0, 1.6 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.19 (m, 1H), 6.70-6.88 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.64 (s, 3H), 2.40 (s, 3H).

EXAMPLE 1(121)

[0690] 2-(3-(2-(5-methyl-2-cyclohexyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

801

[0691] TLC: Rf 0.50 (hexane:ethyl acetate=2:1)

[0692] NMR (CDCl3) δ 7.21 (m, 1H), 6.76-6.86 (m, 3H), 4.15 (t, J=6.7 Hz, 2H), 3.69 (s, 3H), 3.58 (s, 2H), 2.87 (t, J=6.7 Hz, 2H), 2.69 (m, 1H), 2.24 (s, 3H), 1.96-2.08 (m, 2H), 1.20-1.86 (m, 8H).

EXAMPLE 1(122)

[0693] 2-(3-(2-(5-methyl-2-cyclopentyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

802

[0694] TLC: Rf 0.50 (hexane:ethyl acetate=2:1)

[0695] NMR (CDCl3): δ 7.21 (m, 1H), 6.76-6.86 (m, 3H), 4.15 (t, J=6.7 Hz, 2H), 3.69 (s, 3H), 3.58 (s, 2H), 3.11 (m, 1H), 2.86 (t, J=6.7 Hz, 2H), 2.24 (s, 3H), 1.58-2.12 (m, 8H).

EXAMPLE 1(123)

[0696] 2-(3-(2-(5-methyl-2-(4-pentylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

803

[0697] TLC: Rf 0.55 (hexane:ethyl acetate=2:1)

[0698] NMR (CDCl3): δ 7.88 (d, J=8.0 Hz, 2H), 7.29 (d, J=8.0 Hz, 2H), 7.17 (m, 1H), 6.70-6.88 (m, 3H), 4.23 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.57 (s, 2H), 2.96(t, J=6.8 Hz, 2H), 2.63 (t, J=7.6 Hz, 2H), 2.36 (s, 3H), 1.64 (m, 2H), 1.20-1.42 (m, 4H), 0.89 (t, J=6.6 Hz, 3H).

EXAMPLE 1(124)

[0699] 2-(3-(2-(5-methyl-2-(pyridin-4-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

804

[0700] TLC: Rf 0.22 (hexane:ethyl acetate=1:1)

[0701] NMR (CDCl3): δ 8.90 (d, J=6 Hz, 2H), 7.85 (d, J=6 Hz, 2H), 7.20 (dd, J=8, 8 Hz, 1H), 6.95-6.80 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.45 (s, 3H).

EXAMPLE 1(125)

[0702] 2-(3-(2-(5-methyl-2-(pyridin-3-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

805

[0703] TLC: Rf 0.33 (hexane:ethyl acetate=1:3);

[0704] NMR (CDCl3): δ 9.22-9.18 (m, 1H), 8.61 (dd, J=5.0 Hz, 1.8 Hz, 1H), 8.25-8.19 (m, 1H), 7.37-7.16 (m, 2H), 6.85-6.76 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.66 (s, 3H), 3.56 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 1(126)

[0705] 2-(3-(2-(5-methyl-2-(pyridin-4-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

806

[0706] Rf 0.25 (hexane:ethyl acetate=1:3)

[0707] NMR (CDCl3): δ 8.71-8.67 (m, 2H), 7.83-7.80 (m, 2H), 7.26-7.17 (m, 1H), 6.86-6.79 (m, 3H), 4.24 (t, J=6.4 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.99 (t, J=6.4 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(127)

[0708] 2-(3-(2-(5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

807

[0709] TLC: Rf 0.39 (chloroform:methanol=20:1)

[0710] NMR (CDCl3): δ 7.21 (m, 1H), 6.77-6.85 (m, 3H), 4.19 (t, J=7.1 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.42 (m, 4H), 2.94 (t, J=7.1 Hz, 2H), 2.50 (m, 4H), 2.33 (s, 3H), 2.25 (s, 3H).

EXAMPLE 1(128)

[0711] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethoxy)acetic Acid.t-butyl Ester

808

[0712] TLC: Rf 0.79 (ethyl acetate:hexane=1:1)

[0713] NMR (CDCl3): δ 7.98 (m, 2H), 7.50-7.35 (m, 3H), 7.24 (dd, J=8.0, 8.0 Hz, 1H), 6.95-6.80 (m, 3H), 4.58 (s, 2H), 4.25 (t, J=6.5 Hz, 2H), 3.96 (s, 2H), 2.98 (t, J=6.5 Hz, 2H), 2.38 (s, 3H), 1.47 (s, 9H).

EXAMPLE 1(129)

[0714] 2-(3-(2-(5-methyl-2-(pyridin-3-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Methyl Ester

809

[0715] TLC: Rf 0.14 (hexane:ethyl acetate=1:2)

[0716] NMR (CDCl3): δ 9.20 (d, J=2 Hz, 1H), 8.65 (dd, J=5, 2 Hz, 1H), 8.25 (m, 1H), 7.35 (m, 1H), 7.20 (dd, J=8, 8 Hz, 1H), 6.95-6.75 (m, 3H), 4.25 (t, J=6.5 Hz, 2H), 3.80 (s, 2H), 3.75 (s, 3H), 3.10 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 1(130)

[0717] 2-(3-(2-(5-methyl-2-(4-methylthiophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

810

[0718] TLC: Rf 0.39 (hexane:ethyl acetate=2:1)

[0719] NMR (CDCl3): δ 7.88 (d, J=8.6 Hz, 2H), 7.27 (d, J=8.6 Hz, 2H), 7.17 (dd, J=7.8, 7.6 Hz, 1H), 6.70-6.88 (m, 3H), 4.22 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.51 (s, 3H), 2.37 (s, 3H).

EXAMPLE 1(131)

[0720] 2-(3-(2-(5-methyl-2-cyclopropyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

811

[0721] TLC Rf 0.39 (hexane:ethyl acetate=1:1)

[0722] NMR (CDCl3): δ 7.26-7.16 (m, 1H), 6.85-6.76 (m, 3H), 4.14 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.57 (s, 2H), 2.83 (t, J=6.8 Hz, 2H), 2.21 (s, 3H), 2.04-1.90 (m, 1H), 1.01-0.89 (m, 4H).

EXAMPLE 1(132)

[0723] 2-(3-(2-(5-methyl-2-(4-nitrophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

812

[0724] TLC Rf 0.57 (hexane:ethyl acetate=4:3)

[0725] NMR (CDCl3): δ 8.29 (d, J=9.0 Hz, 2H), 8.13 (d, J=9.0 Hz, 2H), 7.22 (m, 1H), 6.77-6.87 (m, 3H), 4.25 (t, J=6.6 Hz, 2H), 3.86 (s, 3H), 3.58 (s, 2H), 3.00 (t, J=6.6 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 1(133)

[0726] 2-(3-(2-(5-methyl-2-(quinolin-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

813

[0727] TLC: Rf 0.38 (hexane:ethyl acetate=4:3)

[0728] NMR (CDCl3): δ 8.17-8.29 (m, 3H), 7.83 (m, 1H), 7.75 (m, 1H), 7.57 (m, 1H), 7.22 (m, 1H), 6.78-6.86 (m, 3H), 4.29 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.05 (t, J=6.6 Hz, 2H), 2.49 (s, 3H).

EXAMPLE 1(134)

[0729] 2-(3-(2-(5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

814

[0730] TLC: Rf 0.46 (hexane:ethyl acetate=2:1)

[0731] NMR (CDCl3): δ 7.91 (dt, J=7.8, 1.2 Hz, 1H), 7.85-7.82 (m, 1H), 7.45 (t, J=7.8 Hz, 1H), 7.28-7.17 (m, 2H), 6.88-6.77 (m, 3H), 4.24 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 1(135)

[0732] 2-(3-(2-(5-methyl-2-(2-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

815

[0733] TLC: Rf 0.43 (hexane:ethyl acetate=2:1)

[0734] NMR (CDCl3): δ 8.11-8.04 (m, 1H), 7.49-7.31 (m, 3H), 7.27-7.16 (m, 1H), 6.88-6.76 (m, 3H), 4.25 (t, J=6.6 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 2.99 (t, J=6.6 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 1(136)

[0735] 2-(3-(2-(4-methyl-2-phenyloxazol-5-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

816

[0736] TLC: Rf 0.37 (hexane:ethyl acetate=2:1)

[0737] NMR (CDCl3): δ 8.02-7.95 (m, 2H), 7.49-7.38 (m, 3H), 7.28-7.18 (m, 1H), 6.90-6.77 (m, 3H), 4.22 (t, J=6.8 Hz, 2H), 3.68 (s, 3H), 3.58 (s, 2H), 3.16 (t, J=6.8 Hz, 2H), 2.22 (s, 3H).

EXAMPLE 1(137)

[0738] 2-(3-(2-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenylmethoxy)acetic Acid.t-butyl Ester

817

[0739] TLC: Rf 0.83 (hexane:ethyl acetate=1:1)

[0740] NMR (CDCl3): δ 7.51 (dd, J=8.0, 1.8 Hz, 1H), 7.43 (d, J=1.8 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H), 6.97-6.79 (m, 4H), 6.01 (s, 2H), 4.58 (s, 2H), 4.23 (t, J=6.8 Hz, 2H), 3.96 (s, 2H), 2.95 (t, J=6.8 Hz, 2H), 2.35 (s, 3H), 1.48 (s, 9H).

EXAMPLE 2

[0741] 2-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenylmethylthio)acetic Acid

818

[0742] The compound prepared in Example 1 (0.51 g) was dissolved in a mixture of methanol-tetrahydrofuran (8 ml, 1:1), and thereto was added 2N aqueous solution of sodium hydroxide (3.2 ml) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was acidified by adding hydrochloric acid and the solution was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized from hexane-ethyl acetate to give the compound of the present invention (0.39 g) having the following physical data.

[0743] TLC: Rf 0.37 (ethyl acetate);

[0744] NMR (CDCl3+4 drop of CD3OD): δ 7.77 (2H, d, J=8.0 Hz), 7.45 (1H, s), 7.23-7.31 (3H, m), 6.91-7.05 (3H, m), 5.42 (2H, s), 3.83 (2H, s), 3.08 (2H, s), 2.39 (3H, s).

EXAMPLE 2(1)˜EXAMPLE 2(137)

[0745] The following compounds of the present invention were obtained by the same procedure as shown in Example 2, using the compounds prepared in Example 1(1)˜Example 1(137) in place of the compound prepared in Example 1, optionally followed by converting them to the corresponding salts by known methods.

EXAMPLE 2(1)

[0746] 6-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)hexanoic Acid

819

[0747] TLC: Rf 0.41 (hexane:ethyl acetate=1:1)

[0748] NMR (CDCl3): δ 7.78 (2H, d, J=8.0 Hz), 7.43 (1H, s), 7.28-7.16 (3H, m), 6.90-6.78 (3H, m), 5.42 (2H, s), 2.60 (2H, t, J=7.5 Hz), 2.39 (3H, s), 2.34 (2H, t, J=7.5 Hz), 1.76-1.54 (4H, m), 1.46-1.24 (2H, m).

EXAMPLE 2(2)

[0749] 5-(3-(biphenyl-4-ylmethoxy)phenyl)pentanoic Acid

820

[0750] TLC: Rf 0.49 (ethyl acetate)

[0751] NMR (CDCl3): δ 7.58-7.64 (4H, m), 7.35-7.53 (5H, m), 7.21 (1H, m), 6.78-6.84 (3H, m), 5.09 (2H, s), 2.62 (2H, t, J=7.0 Hz), 2.38 (2H, t, J=7.0 Hz), 1.64-1.72 (4H, m).

EXAMPLE 2(3)

[0752] 4-(3-(biphenyl-4-ylmethoxy)phenyl)butanoic Acid

821

[0753] TLC: Rf 0.67 (ethyl acetate)

[0754] NMR (d6-DMSO): δ 7.62-7.66 (4H, m), 7.31-7.51 (5H, m), 7.14 (1H, dd, J=7.5, 7.5 Hz), 6.71-6.82 (3H, m), 5.07 (2H, s), 2.52 (2H, t, J=7.0 Hz), 2.06 (2H, t, J=7.0 Hz), 1.74 (2H, tt, J=7.0, 7.0 Hz).

EXAMPLE 2(4)

[0755] 4-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)butanoic Acid

822

[0756] TLC: Rf 0.63 (ethyl acetate)

[0757] NMR (CDCl3): δ 7.78 (2H, d, J=8.0 Hz), 7.43 (1H, s), 7.23 (2H, d, J=8.0 Hz), 7.22 (1H, m), 6.81-6.88 (3H, m), 5.41 (2H, s), 2.66 (2H, t, J=7.5 Hz), 2.38 (3H, s), 2.36 (2H, t, J=7.5 Hz), 1.96 (2H, tt, J=7.5, 7.5 Hz).

EXAMPLE 2(5)

[0758] 4-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)butanoic Acid

823

[0759] TLC: Rf 0.47 (ethyl acetate);

[0760] NMR (CDCl3): δ 7.94-8.02 (2H, m), 7.39-7.48 (3H, m), 7.18 (1H, m), 6.72-6.78 (3H, m), 4.23 (2H, t, J=6.6 Hz), 2.98 (2H, t, J=6.6 Hz), 2.64 (2H, t, J=7.2 Hz), 2.38 (3H, s), 2.35 (2H, t, J=7.2 Hz), 1.95 (2H, tt, J=7.2, 7.2 Hz).

EXAMPLE 2(6)

[0761] 6-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)hexanoic Acid

824

[0762] TLC: Rf 0.41 (chloroform:methanol=15:1)

[0763] NMR (CDCl3): δ 8.02-7.91 (2H, m), 7.49-7.36 (3H, m), 7.16 (1H, t, J=8.0 Hz), 6.78-6.69 (3H, m), 4.24 (2H, t, J=7.0 Hz), 2.98 (2H, t, J=7.0 Hz), 2.58 (2H, t, J=7.5 Hz), 2.38 (3H, s), 2.34 (2H, t, J=7.5 Hz), 1.75-1.54 (4H, m), 1.45-1.25 (2H, m).

EXAMPLE 2(7)

[0764] 5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pentanoic Acid

825

[0765] TLC: Rf 0.36 (chloroform:methanol=15:1)

[0766] NMR (CDCl3): δ 8.04-7.92 (2H, m), 7.49-7.36 (3H, m), 7.17 (1H, t, J=8.0 Hz), 6.78-6.68 (3H, m), 4.24 (2H, t, J=7.0 Hz), 2.98 (2H, t, J=7.0 Hz), 2.68-2.53 (2H, m), 2.45-2.30 (5H, m), 1.79-1.56 (4H, m).

EXAMPLE 2(8)

[0767] 2-(3-(3-(biphenyl-4-ylmethoxy)phenyl)propylthio)acetic Acid

826

[0768] TLC: Rf 0.38 (chloroform:methanol=10:1)

[0769] NMR (CDCl3): δ 7.35-7.64 (9H, m), 7.22 (1H, m), 6.78-6.86 (3H, m), 5.09 (2H, s), 3.25 (2H, s), 2.70 (2H, t, J=7.5 Hz), 2.67 (2H, t, J=7.5 Hz), 1.94 (2H, tt, J=7.5, 7.5 Hz).

EXAMPLE 2(9)

[0770] 2-(3-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)propylthio)acetic Acid

827

[0771] TLC Rf 0.41 (chloroform:methanol=10:1)

[0772] NMR (CDCl3): δ 7.75 (2H, d, J=8.0 Hz), 7.43 (1H, s), 7.18-7.26 (3H, m), 6.80-6.91 (3H, m), 5.44 (2H, s), 3.23 (2H, s), 2.71 (2H, t, J=7.4 Hz), 2.65 (2H, t, J=7.4 Hz), 2.38 (3H, s), 1.93 (2H, tt, J=7.4, 7.4 Hz).

EXAMPLE 2(10)

[0773] 6-(2-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)hexanoic Acid

828

[0774] TLC: Rf 0.50 (chloroform:methanol=10:1)

[0775] NMR (CDCl3): δ 7.95-8.00 (2H, m), 7.39-7.44 (3H, m), 7.07-7.17 (2H, m), 6.81-6.88 (2H, m), 4.23 (2H, t, J=6.7 Hz), 3.00 (2H, t, J=6.7 Hz), 2.57 (2H, t, J=7.3 Hz), 2.37 (3H, s), 2.30 (2H, t, J=7.4 Hz), 1.46-1.69 (4H, m), 1.22-1.40 (2H, m).

EXAMPLE 2(11)

[0776]

829

[0777] 2-(3-(biphenyl-4-ylmethoxy)phenylmethylthio)acetic Acid

[0778] TLC: Rf 0.39 (ethyl acetate)

[0779] NMR (CDCl3) δ 7.60-7.64 (4H, m), 7.22-7.53 (6H, m), 6.89-7.02 (3H, m), 5.11 (2H, s), 3.83 (2H, s), 3.10 (2H, s).

EXAMPLE 2(12)

[0780] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

830

[0781] TLC: Rf 0.33 (ethyl acetate)

[0782] NMR (CDCl3): δ 7.95-8.00 (2H, m), 7.40-7.47 (3H, m), 7.21 (1H, dd, J=8.0, 8.0 Hz), 7.03 (1H, dd, J=2.0, 1.0 Hz), 6.88 (1H, ddd, J=8.0, 3.0, 2.0 Hz), 6.81 (1H, ddd, J=8.0, 3.0, 1.0 Hz), 4.28 (2H, t, J=7.5 Hz), 3.86 (2H, s), 3.16 (2H, s), 2.98 (2H, t, J=7.5 Hz), 2.39 (3H, s).

EXAMPLE 2(13)

[0783] 5-(2-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)pentanoic Acid

831

[0784] TLC: Rf 0.58 (chloroform:methanol=9:1)

[0785] NMR (CDCl3): δ 8.00-7.95 (2H, m), 7.50-7.35 (3H, m), 7.20-7.05 (2H, m), 6.90-6.80 (2H, m), 4.25 (2H, t, J=7 Hz), 3.05 (2H, t, J=7 Hz), 2.60 (2H, t, J=7 Hz), 2.40 (3H, s), 2.35 (2H, t, J=6 Hz), 1.80-1.50 (4H, m).

EXAMPLE 2(14)

[0786] 6-(2-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenyl)hexanoic Acid

832

[0787] TLC: Rf 0.76 (ethyl acetate)

[0788] NMR (CDCl3): δ 7.79 (2H, d, J=8.4 Hz), 7.44 (1H, s), 7.15-7.26 (4H, m), 6.91-6.98 (2H, m), 5.41 (2H, s), 2.73 (2H, t, J=7.4 Hz), 2.38 (3H, s), 2.36 (2H, t, J=7.3 Hz), 1.62-1.78 (4H, m), 1.37-1.52 (2H, m).

EXAMPLE 2(15)

[0789] 2-(3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propylthio)acetic Acid

833

[0790] TLC: Rf 0.42 (chloroform:methanol=10:1)

[0791] NMR (CDCl3): δ 7.94-7.98 (m, 2H), 7.41-7.44 (m, 3H), 7.16 (dd, J=7.7, 7.7 Hz, 1H), 6.89 (m, 1H), 6.72-6.76 (m, 2H), 4.29 (t, J=7.2 Hz, 2H), 3.23 (s, 2H), 3.01 (t, J=7.2 Hz, 2H), 2.72 (t, J=6.7 Hz, 2H), 2.66 (t, J=6.7 Hz, 2H), 2.40 (s, 3H), 1.94 (tt, J=6.7, 6.7 Hz, 2H).

EXAMPLE 2(16)

[0792] 2-(3-(2-(biphenyl-4-yl)ethoxy)phenylmethylthio)acetic Acid

834

[0793] TLC: Rf 0.43 (chloroform:methanol=10:1)

[0794] NMR (CDCl3): δ 7.52-7.61 (m, 4H), 7.34-7.47 (m, 5H), 7.23 (dd, J=8.0, 8.0 Hz, 1H), 6.80-6.92 (m, 3H), 4.21 (t, J=6.8 Hz, 2H), 3.81 (s, 2H), 3.14 (t, J=6.8 Hz, 2H), 3.11 (s, 2H).

EXAMPLE 2(17)

[0795] 2-(4-chloro-3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

835

[0796] TLC: Rf 0.38 (water:methanol:chloroform=1:10:100)

[0797] NMR (CDCl3): δ 7.99 (m, 2H), 7.50-7.40 (m. 3H), 7.28 (d, J=8.0 Hz, 1H), 7.15 (d, J=2.0 Hz, 1H), 6.82 (dd, J=8.0, 2.0 Hz, 1H), 6.30 (br., 1H), 4.38 (t, J=6.5 Hz, 2H), 3.85 (s, 2H), 3.18 (s, 2H), 3.03 (t, J=6.5 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 2(18)

[0798] 2-(4-chloro-3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)phenylmethylthio)acetic Acid

836

[0799] TLC Rf 0.42 (water:methanol:chloroform=1:10:100)

[0800] NMR (CDCl3): δ 7.73 (d, J=8.0 Hz, 2H), 7.44 (s. 1H), 7.33 (d, J=8.0 Hz, 1H), 7.22 (d, J=8.0 Hz, 2H), 7.11 (d, J=2.0 Hz, 1H), 6.91 (dd, J=8.0, 2.0 Hz, 1H), 5.50 (s, 2H), 3.80 (s, 2H), 3.04 (s, 2H), 2.37 (s, 3H).

EXAMPLE 2(19)

[0801] 2-(3-(biphenyl-4-ylmethoxy)-4-chlorophenylmethylthio)acetic Acid

837

[0802] TLC: Rf 0.34 (water:methanol:chloroform=1:10:100)

[0803] NMR (CDCl3): δ 7.65-7.35 (m, 9H), 7.33 (d, J=8.0 Hz, 1H), 7.01 (d, J=2.0 Hz, 1H), 6.87 (dd, J=8.0, 2.0 Hz, 1H), 5.20 (s, 2H), 3.79 (s, 2H), 3.02 (s, 2H).

EXAMPLE 2(20)

[0804] 2-(3-((2E)-3-(biphenyl-4-yl)propenyloxy)phenylmethylthio)acetic Acid

838

[0805] TLC: Rf 0.29 (chloroform:methanol=10:1)

[0806] NMR (CDCl3) δ 7.22-7.62 (m, 10H), 6.74-6.97 (m, 4H), 6.45 (dt, J=16.0, 5.6 Hz, 1H), 4.73 (d, J=5.6 Hz, 2H), 3.84 (s, 2H), 3.12 (s, 2H).

EXAMPLE 2(21)

[0807] 2-(3-(3-(biphenyl-4-yl)propoxy)phenylmethylthio)acetic Acid

839

[0808] TLC: Rf 0.29 (chloroform:methanol=20:1)

[0809] NMR (CDCl3): δ 7.19-7.61 (m, 10H), 6.78-6.93 (m, 3H), 4.00 (t, J=6.1 Hz, 2H), 3.82 (s, 2H), 3.12 (s, 2H), 2.86 (t, J=7.6 Hz, 2H), 2.14 (tt, J=7.6, 6.1 Hz, 2H).

EXAMPLE 2(22)

[0810] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)acetic Acid.Methyl Ester

840

[0811] TLC: Rf 0.52 (chloroform:methanol=9:1)

[0812] NMR (CDCl3) δ 8.00-7.90 (m, 2H), 7.45-7.35 (m, 3H), 7.20 (t, J=7.5 Hz, 1H), 6.90-6.75 (m, 3H), 4.20 (t, J=7 Hz, 2H), 3.60 (s, 2H), 2.95 (t, J=7 Hz, 2H), 2.35(s, 3H).

EXAMPLE 2(23)

[0813] 2-(3-(biphenyl-4-ylmethoxy)pyridin-5-ylmethylthio)acetic Acid

841

[0814] TLC: Rf 0.14 (water:methanol:chloroform=1:10:100)

[0815] NMR (DMSO-d6): δ 8.27 (d, J=3.0 Hz, 1H), 8.12 (d, J=1.5 Hz, 1H), 7.75-7.30 (m, 10H), 5.23 (s, 2H), 3.83 (s, 2H), 3.15 (s, 2H).

EXAMPLE 2(24)

[0816] 2-(3-(4′-propylbiphenyl-4-ylmethoxy)phenylmethylthio)acetic Acid

842

[0817] TLC Rf 0.41 (ethyl acetate)

[0818] NMR (CDCl3): δ 7.60 (d, J=8.3 Hz, 2H), 7.51 (d, J=8.2 Hz, 2H), 7.48 (d, J=8.3 Hz, 2H), 7.26 (dd, J=7.8, 7.8 Hz, 1H), 7.25 (d, J=8.2 Hz, 2H), 6.88-7.01 (m, 3H), 5.10 (s, 2H), 3.83 (s, 2H), 3.10 (s, 2H), 2.63 (t, J=7.4 Hz, 2H), 1.68 (tq, J=7.4, 7.4 Hz, 2H), 0.97 (t, J=7.4 Hz, 3H).

EXAMPLE 2(25)

[0819] 2-(3-(4-(pyridin-4-yl)phenylmethoxy)phenylmethylthio)acetic Acid

843

[0820] TLC: Rf 0.47 (chloroform:methanol=5:1)

[0821] NMR (CDCl3+17 drops of CD3OD) δ 8.53 (d, J=5.8 Hz, 2H), 7.61 (d, J=8.0 Hz, 2H), 7.49-7.52 (m, 4H), 7.18 (dd, J=7.7, 7.7 Hz, 1H), 6.80-6.95 (m, 3H), 5.07 (s, 2H), 3.76 (s, 2H), 3.02 (s, 2H).

EXAMPLE 2(26)

[0822] 2-(3-(4-(pyridin-3-yl)phenylmethoxy)phenylmethylthio)acetic Acid

844

[0823] TLC Rf 0.44 (chloroform:methanol=5:1)

[0824] NMR (DMSO-d6): δ 8.88 (d, J=1.5 Hz, 1H), 8.56 (dd, J=4.8, 1.5 Hz, 1H), 8.05 (m, 1H), 7.72 (d, J=8.0 Hz, 2H), 7.54 (d, J=8.0 Hz, 2H), 7.48 (m, 1H), 7.19 (dd, J=8.0, 8.0 Hz, 1H), 6.86-6.99 (m, 3H), 5.11 (s, 2H), 3.73 (s, 2H), 2.99 (s, 2H).

EXAMPLE 2(27)

[0825] 2-(3-(4-(1,3-dioxaindan-5-yl)phenylmethoxy)phenylmethylthio)acetic Acid

845

[0826] TLC: Rf 0.28 (chloroform:methanol=10:1);

[0827] NMR (CDCl3): δ 7.53 (d, J=8.1 Hz, 2H), 7.47 (d, J=8.1 Hz, 2H), 7.26 (dd, J=7.8, 7.8 Hz, 1H), 6.86-7.07 (m, 6H), 6.00 (s, 2H), 5.09 (s, 2H), 3.83 (s, 2H), 3.10 (s, 2H).

EXAMPLE 2(28)

[0828] 2-(3-(4-(pyridin-2-yl)phenylmethoxy)phenylmethylthio)acetic Acid

846

[0829] TLC Rf 0.50 (chloroform:methanol=10:1)

[0830] NMR (CDCl3+3 drops of CD3OD): δ 8.64 (ddd, J=5.0, 1.6, 1.4 Hz, 1H), 7.90 (d, J=8.6 Hz, 2H), 7.67-7.82 (m, 2H), 7.51 (d, J=8.6 Hz, 2H), 7.18-7.29 (m, 2H), 6.84-6.94 (m, 3H), 5.13 (s, 2H), 3.77 (s, 2H), 3.00 (s, 2H).

EXAMPLE 2(29)

[0831] 2-(5-(biphenyl-4-ylmethoxy)-2-nitrophenylmethylthio)acetic Acid

847

[0832] TLC: Rf 0.40 (chloroform:methanol=10:1)

[0833] NMR (CDCl3): δ 8.16 (d, J=9.0 Hz, 1H), 7.56-7.65 (m, 4H), 7.32-7.51 (m, 5H), 7.04 (d, J=2.8 Hz, 1H), 6.99 (dd, J=9.0, 2.8 Hz, 1H), 5.21 (s, 2H), 4.25 (s, 2H), 3.09 (s, 2H).

EXAMPLE 2(30)

[0834] 2-(3-(biphenyl-4-ylmethoxy)-4-nitrophenylmethylthio)acetic Acid

848

[0835] TLC: Rf 0.25 (chloroform:methanol=10:1)

[0836] NMR (CDCl3): δ 7.85 (d, J=8.4 Hz, 1H), 7.35-7.64 (m, 9H), 7.17 (d, J=1.6 Hz, 1H), 7.00 (dd, J=8.4, 1.6 Hz, 1H), 5.29 (s, 2H), 3.84 (s, 2H), 3.03 (s, 2H).

EXAMPLE 2(31)

[0837] 2-(3-(4-(1,3-dioxaindan-4-yl)phenylmethoxy)phenylmethylthio)acetic Acid

849

[0838] TLC Rf 0.35 (chloroform:methanol=10:1)

[0839] NMR (CDCl3) δ 7.73 (d, J=8.5 Hz, 2H), 7.50 (d, J=8.5 Hz, 2H), 7.25 (dd, J=8.0, 8.0 Hz, 1H), 6.80-7.08 (m, 6H), 6.01 (s, 2H), 5.11 (s, 2H), 3.82 (s, 2H), 3.08 (s, 2H).

EXAMPLE 2(32)

[0840] 2-(3-(2-phenylthiazol-4-ylmethoxy)phenylmethylthio)acetic Acid

850

[0841] TLC: Rf 0.42 (chloroform:methanol=10:1);

[0842] NMR (CDCl3): δ 8.80 (brs, 1H), 7.90-7.96 (m, 2H), 7.40-7.45 (m, 3H), 7.32 (s, 1H), 7.25 (dd, J=7.8, 7.8 Hz, 1H), 6.89-7.03 (m, 3H), 5.27 (s, 2H), 3.82 (s, 2H), 3.09 (s, 2H).

EXAMPLE 2(33)

[0843] 2-(3-(2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

851

[0844] TLC: Rf 0.42 (chloroform:methanol=10:1)

[0845] NMR (CDCl3): δ 7.86 (d, J=8.0 Hz, 2H), 7.25-7.17 (m, 3H), 7.07 (s, 1H), 6.88 (d, J=7.8 Hz, 1H), 6.80 (dd, J=8.0, 1.4 Hz, 1H), 4.29 (t, J=7.7 Hz, 2H), 3.87 (s, 2H), 3.18 (s, 2H), 2.96 (t, J=7.7 Hz, 2H), 2.39 (s, 3H), 2.37 (s, 3H).

EXAMPLE 2(34)

[0846] 2-(3-(2-(2-phenylthiazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

852

[0847] TLC: Rf 0.46 (chloroform:methanol=10:1)

[0848] NMR (CDCl3): δ 7.90-7.95 (m, 2H), 7.39-7.46 (m, 3H), 7.23 (dd, J=7.8, 7.8 Hz, 1H), 7.08 (s, 1H), 6.81-6.98 (m, 3H), 4.38 (t, J=7.0 Hz, 2H), 3.83 (s, 2H), 3.30 (t, J=7.0 Hz, 2H), 3.12 (s, 2H).

EXAMPLE 2(35)

[0849] 2-(3-(2-(5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

853

[0850] TLC: Rf 0.27 (chloroform:methanol=10:1)

[0851] NMR (CDCl3): δ 8.09 (d, J=9.0 Hz, 2H), 7.70 (d, J=9.0 Hz, 2H), 7.22-6.79 (m, 4H), 4.29 (t, J=7.5 Hz, 2H), 3.86 (s, 2H), 3.17 (s, 2H), 2.99 (t, J=7.5 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 2(36)

[0852] 2-(3-(2-(2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

854

[0853] TLC: Rf 0.34 (chloroform:methanol=10:1);

[0854] NMR (CDCl3): δ 7.99-8.04 (m, 2H), 7.58 (s, 1H), 7.42-7.47 (m, 3H), 7.23 (dd, J=7.7, 7.7 Hz, 1H), 6.89-6.95 (m, 2H), 6.83 (dd, J=7.7, 2.5 Hz, 1H), 4.30 (t, J=7.1 Hz, 2H), 3.84 (s, 2H), 3.14 (s, 2H), 3.08 (t, J=7.1 Hz, 2H).

EXAMPLE 2(37)

[0855] 2-(3-(2-(5-methyl-2-(4-fluorophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

855

[0856] TLC: Rf 0.39 (chloroform:methanol=10:1);

[0857] NMR (CDCl3): δ 7.97 (dd, J=8.8, 5.2 Hz, 2H), 7.24-7.07 (m, 3H), 6.97 (m, 1H), 6.89 (d, J=7.6 Hz, 1H), 6.79 (dd, J=8.0, 1.8 Hz, 1H), 4.25 (t, J=7.1 Hz, 2H), 3.82 (s, 2H), 3.13 (s, 2H), 2.97 (t, J=7.1 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 2(38)

[0858] 2-(3-(2-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

856

[0859] TLC: Rf 0.30 (chloroform:methanol=10:1)

[0860] NMR (CDCl3): δ 7.53 (d, J=8.4 Hz, 1H), 7.44 (d, J=2.0 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H), 7.05 (s, 1H), 6.90-6.78 (m, 3H), 6.02 (s, 2H), 4.27 (t, J=7.4 Hz, 2H), 3.87 (s, 2H), 3.18 (s, 2H), 2,95 (t, J=7.4 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 2(39)

[0861] 5-(3-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenyl)pentanoic Acid

857

[0862] TLC Rf 0.63 (chloroform:methanol=9:1)

[0863] NMR (CDCl3): δ 8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.15 (m, 1H), 6.80-6.70 (m, 3H), 4.00 (t, J=6 Hz, 2H), 2.75 (t, J=7 Hz, 2H), 2.60 (m, 2H), 2.35 (m, 2H), 2.30 (s, 3H), 2.15 (m, 2H), 1.75-1.60 (m, 4H).

EXAMPLE 2(40)

[0864] 2-(3-(2-(5-methyl-2-(4-chlorophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

858

[0865] TLC: Rf 0.29 (chloroform:methanol=10:1);

[0866] NMR (CDCl3): δ 7.92 (d, J=8.8 Hz, 2H), 7.41 (d, J=8.8 Hz, 2H), 7.21 (t, J=7.9 Hz, 1H), 7.02 (m, 1H), δ 89 (d, J=8.0 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 4.27 (t, J=7.8 Hz, 2H), 3.86 (s, 2H), 3.16 (s, 2H), 2.97 (t, J=7.8 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 2(41)

[0867] 2-(3-(5-methyl-2-phenyloxazol-4-ylmethoxy)phenylmethylthio)acetic Acid

859

[0868] TLC: Rf 0.37 (chloroform:methanol=9:1)

[0869] NMR (CDCl3): δ 8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.25 (dd, J=7.5, 7.5 Hz, 1H), 7.05 (m, 1H), 6.95-6.85 (m, 2H), 5.05 (s, 2H), 3.80 (s, 2H), 3.15 (s, 2H), 2.45 (s, 3H).

EXAMPLE 2(42)

[0870] 2-(3-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenylmethylthio)acetic Acid

860

[0871] TLC: Rf 0.42 (chloroform:methanol=9:1)

[0872] NMR (CDCl3) δ 8.00-7.90 (m, 2H), 7.45-7.40 (m, 3H), 7.25 (dd, J=8, 8 Hz, 1H), 6.95-6.85 (m, 2H), 6.80 (m, 1H), 4.15 (t, J=6.5 Hz, 2H), 3.85 (s, 2H), 3.10 (s, 2H), 2.65 (t, J=7.5 Hz, 2H), 2.30 (s, 3H), 2.10 (m, 2H).

EXAMPLE 2(43)

[0873] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-methylpropanoic Acid

861

[0874] TLC: Rf 0.51 (chloroform:methanol=10:1)

[0875] NMR (CDCl3): δ 7.96-8.01 (m, 2H), 7.40-7.45 (m, 3H), 7.22 (dd, J=8.0, 8.0 Hz, 1H), 6.92-6.98 (m, 2H), 6.78 (m, 1H), 4.22 (t, J=6.6 Hz, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.36 (s, 3H), 1.57 (s, 6H).

EXAMPLE 2(44)

[0876] 2-(3-(2-(5-methyl-2-(2-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

862

[0877] TLC: Rf 0.38 (chloroform:methanol=10:1);

[0878] NMR (CDCl3): δ 7.89 (m, 1H), 7.33-7.17 (m, 4H), 6.99-6.79 (m, 3H), 4.29 (t, J=7.2 Hz, 2H), 3.83 (s, 2H), 3.12 (s, 2H), 2.99 (t, J=7.2 Hz, 2H), 2.61 (s, 3H), 2.39 (s, 3H).

EXAMPLE 2(45)

[0879] 2-(3-(2-(5-methyl-2-(3-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

863

[0880] TLC: Rf 0.39 (chloroform:methanol=10:1)

[0881] NMR (CDCl3): δ 7.79 (m, 2H), 7.37-7.17 (m, 3H), 7.03 (m, 1H), 6.88 (d, J=7.4 Hz, 1H), 6.81 (m, 1H), 4.28 (t, J=7.2 Hz, 2H), 3.86 (s, 2H), 3.16 (s, 2H), 2.98 (t, J=7.2 Hz, 2H), 2.40 (s, 3H), 2.39 (s, 3H).

EXAMPLE 2(46)

[0882] 2-(3-(2-(5-methyl-2-(4-methoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

864

[0883] TLC: Rf 0.43 (chloroform:methanol=10:1)

[0884] NMR (CDCl3): δ 7.92 (d, J=9.0 Hz, 2H), 7.20 (dd, J=7.9, 7.9 Hz, 1H), 7.05 (m, 1H), 6.95 (d, J=9.0 Hz, 2H), 6.78-6.90 (m, 2H), 4.27 (t, J=7.4 Hz, 2H), 3.86 (s, 2H), 3.85 (s, 3H), 3.17 (s, 2H), 2.96 (t, J=7.4 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 2(47)

[0885] 2-(3-(2-(5-methyl-2-(4-nitrophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

865

[0886] TLC: Rf 0.48 (chloroform:methanol=9:1)

[0887] NMR (CDCl3): δ 8.29 (d, J=9.0 Hz, 2H), 8.13 (d, J=9.0 Hz, 2H), 7.22 (dd, J=8.0, 8.0 Hz, 1H), 6.88-6.94 (m, 2H), 6.80 (dd, J=8.0, 1.6 Hz, 1H), 4.27 (t, J=6.5 Hz, 2H), 3.82 (s, 2H), 3.13 (s, 2H), 3.00 (t, J=6.5 Hz, 2H), 2.43 (s, 3H).

EXAMPLE 2(48)

[0888] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-5-chlorophenylmethylthio)acetic Acid

866

[0889] TLC: Rf 0.26 (chloroform:methanol:water=100:10:1)

[0890] NMR (CDCl3): δ 7.95-8.00 (m, 2H), 7.41-7.47 (m, 3H), 6.93 (m, 1H), 6.89 (m, 1H), 6.81 (dd, J=2.0, 2.0 Hz, 1H), 4.27 (t, J=7.2 Hz, 2H), 3.81 (s, 2H), 3.17 (s, 2H), 2.97 (t, J=7.2 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 2(49)

[0891] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)-2-methylphenylmethylthio)acetic Acid

867

[0892] TLC: Rf 0.29 (chloroform:methanol=10:1)

[0893] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.45-7.40 (m, 3H), 7.06 (t, J=8.0 Hz, 1H), 6.85-6.78 (m, 2H), 4.23 (t, J=6.5 Hz, 2H), 3.84 (s, 2H), 3.13 (s, 2H), 3.01 (t, J=6.5 Hz, 2H), 2.38 (s, 3H), 2.22 (s, 3H).

EXAMPLE 2(50)

[0894] 2-(1-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)ethylthio)acetic Acid

868

[0895] TLC: Rf 0.38 (chloroform:methanol=10:1);

[0896] NMR (CDCl3): δ 8.00-7.94 (m, 2H), 7.46-7.39 (m, 3H), 7.23 (t, J=7.8 Hz, 1H), 7.01 (brs, 1H), 6.93 (brd, J=8.0 Hz, 1H), 6.83-6.78 (m, 1H), 4.27 (t, J=7.2 Hz, 2H), 4.18 (q, J=7.0 Hz, 1H), 3.06 (d, J=15.6 Hz, 1H), 3.04(d, J=15.6 Hz, 1H), 2.96 (t, J=7.2 Hz, 2H), 2.38 (s, 3H), 1.58 (d, J=7.0 Hz, 3H).

EXAMPLE 2(51)

[0897] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)-1-methylethoxy)phenylmethylthio)acetic Acid

869

[0898] TLC: Rf 0.37 (chloroform:methanol=10:1)

[0899] NMR (CDCl3): δ 8.00-7.94 (m, 2H), 7.45-7.38 (m, 3H), 7.18 (t, J=7.2 Hz, 1H), 7.04 (brs, 1H), 6.89-6.77 (m, 2H), 4.77 (m, 1H), 3.83 (s, 2H), 3.16 (d, J=15.0 Hz, 1H), 3.10 (d, J=15.0 Hz, 1H), 3.01 (dd, J=14.2, 5.4 Hz, 1H), 2.63 (dd, J=14.2, 7.8 Hz, 1H), 2.35 (s, 3H), 1.34 (d, J=6.2 Hz, 3H).

EXAMPLE 2(52)

[0900] 2-(3-(2-(5-trifluoromethyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

870

[0901] TLC: Rf 0.23 (chloroform:methanol=20:1)

[0902] NMR (CDCl3): δ 8.10-8.01 (m, 2H), 7.58-7.42 (m, 3H), 7.22 (t, J=8.0 Hz, 1H), 6.96-6.87 (m, 2H), 6.81 (m, 1H), 4.31 (t, J=7.0 Hz, 2H), 3.81 (s, 2H), 3.20 (t, J=7.0 Hz, 2H), 3.10 (s, 2H).

EXAMPLE 2(53)

[0903] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenylmethylthio)acetic Acid

871

[0904] TLC: Rf 0.38 (hexane:ethyl acetate=1:3)

[0905] NMR (CDCl3): δ 8.00-7.91 (m, 2H), 7.38-7.33 (m, 3H), 7.06 (t, J=8.0 Hz, 1H), 6.83-6.67 (m, 3H), 4.18-3.94 (m, 2H), 3.67 (s, 2H), 3.15 (m, 1H), 3.08 (s, 2H), 2.31 (s, 3H), 1.34 (d, J=7.0 Hz, 3H).

EXAMPLE 2(54)

[0906] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)propanoic Acid.Sodium Salt

872

[0907] TLC: Rf 0.37 (chloroform:methanol=10:1)

[0908] NMR (CD3OD): δ 7.98-7.93 (m, 2H), 7.50-7.41 (m, 3H), 7.15 (t, J=7.8 Hz, 1H), 6.94-6.86 (m, 2H), 6.76 (m, 1H), 4.24 (t, J=6.6 Hz, 2H), 3.73 (d, J=13.2 Hz, 1H), 3.72 (d, 13.2 Hz, 1H) 3.27 (q, J=7.0 Hz, 1H), 2.96 (t, J=6.6 Hz, 2H), 2.37 (s, 3H), 1.34 (d, J=7.0 Hz, 3H).

EXAMPLE 2(55)

[0909] 2-(3-(2-(5-methyl-2-(4-ethylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

873

[0910] TLC: Rf 0.33 (water:methanol:chloroform=1:10:100)

[0911] NMR (CDCl3): δ 7.88 (d, J=8.5 Hz, 2H), 7.26 (d, J=8.5 Hz, 2H), 7.20 (dd, J=8.0, 8.0 Hz, 1H), 7.01 (d, J=2.5 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 6.80 (dd, J=8.0, 2.5 Hz, 1H), 4.26 (t, J=7.0 Hz, 2H), 3.84 (s, 2H), 3.15 (s, 2H), 2.97 (t, J=7.0 Hz, 2H), 2.68 (q, J=7.5 Hz, 2H), 2.37 (s, 3H), 1.25 (t, J=7.5 Hz, 3H).

EXAMPLE 2(56)

[0912] 2-(3-(2-(5-methyl-2-(2,2-difluoro-1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

874

[0913] TLC: Rf 0.31 (water:methanol:chloroform=1:10:100)

[0914] NMR (CDCl3): δ 7.75 (dd, J=8.5, 2.0 Hz, 1H), 7.69 (d, J=2.0 Hz, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 7.11 (d, J=8.5 Hz, 1H), 6.96 (d, J=2.5 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 6.80 (dd, J=8.0, 2.5 Hz, 1H), 4.25 (t, J=7.0 Hz, 2H), 3.83 (s, 2H), 3.14 (s, 2H), 2.97 (t, J=7.0 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(57)

[0915] 2-(3-(2-(5-methyl-2-(4-propylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

875

[0916] TLC: Rf 0.50 (water:methanol:chloroform=1:10:100)

[0917] NMR (CDCl3): δ 7.88 (d, J=8.5 Hz, 2H), 7.24 (d, J=8.5 Hz, 2H), 7.20 (dd, J=8.0, 8.0 Hz, 1H), 7.02 (d, J=2.5 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 6.80 (dd, J=8.0, 2.5 Hz, 1H), 4.27 (t, J=7.5 Hz, 2H), 3.8 (s, 2H), 3.16 (s, 2H), 2.97 (t, J=7.5 Hz, 2H), 2.62 (t, J=7.5 Hz, 2H), 2.37 (s, 3H), 1.65 (m, 2H), 0.94 (t, J=7.5 Hz, 3H).

EXAMPLE 2(58)

[0918] 2-(3-(2-(5-methyl-2-(4-isopropylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

876

[0919] TLC: Rf 0.53 (water:methanol:chloroform=1:10:100)

[0920] NMR (CDCl3): δ 7.89 (d, J=8.0 Hz, 2H), 7.29 (d, J=8.0 Hz, 2H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 7.06 (d, J=2.5 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 6.81 (dd, J=8.0, 2.5 Hz, 1H), 4.28 (t, J=7.5 Hz, 2H), 3.87 (s, 2H), 3.17 (s, 2H), 2.97 (t, J=7.5 Hz, 2H), 2.94 (m, 1H), 2.38 (s, 3H), 1.26 (d, J=7.0 Hz, 6H).

EXAMPLE 2(59)

[0921] 2-(3-(2-(5-methyl-2-phenylthiazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

877

[0922] TLC: Rf 0.32 (chloroform:methanol=10:1)

[0923] NMR (CDCl3): δ 7.88-7.82 (m, 2H), 7.45-7.34 (m, 3H), 7.21 (t, J=7.8 Hz, 1H), 6.98 (m, 1H), 6.92-6.77 (m, 2H), 4.33 (t, J=7.2 Hz, 2H), 3.83 (s, 2H), 3.20 (t, J=7.2 Hz, 2H), 3.12 (s, 2H), 2.47 (s, 3H).

EXAMPLE 2(60)

[0924] 2-(3-(2-(5-methyl-2-(−4-butylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

878

[0925] TLC: Rf 0.43 (chloroform:methanol=9:1)

[0926] NMR (CDCl3): δ 7.85 (d, J=7 Hz, 2H), 7.30-7.05 (m, 3H), 7.05 (brs, 1H), 6.90-6.75 (m, 2H), 4.30 (t, J=8 Hz, 2H), 3.85 (s, 2H), 3.20 (s, 2H), 2.95 (t, J=8 Hz, 2H), 2.60 (t, J=8 Hz, 2H), 2.40 (s, 3H), 1.60 (m, 2H), 1.35 (m, 2H), 0.95 (t, J=7 Hz, 3H).

EXAMPLE 2(61)

[0927] 2-(3-(2-(5-ethyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

879

[0928] TLC: Rf 0.63 (chloroform:methanol=5:1)

[0929] NMR (CDCl3): δ 7.96-8.01 (m, 2H), 7.40-7.47 (m, 3H), 7.21 (dd, J=7.8, 7.8 Hz, 1H), 7.04 (m, 1H), 6.88 (d, J=7.8 Hz, 1H), 6.81 (dd, J=7.8, 2.4 Hz, 1H), 4.28 (t, J=7.5 Hz, 2H), 3.86 (s, 2H), 3.17 (s, 2H), 2.98 (t, J=7.5 Hz, 2H), 2.75 (q, J=7.4 Hz, 2H), 1.31 (t, J=7.4 Hz, 3H).

EXAMPLE 2(62)

[0930] 2-(3-(2-(5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

880

[0931] TLC: Rf 0.33 (chloroform:methanol=15:1)

[0932] NMR (CDCl3): δ 7.21 (t, J=7.8 Hz, 1H), 6.97-6.75 (m, 3H), 4.26 (t, J=7.0 Hz, 2H), 3.82 (s, 2H), 3.12 (s, 2H), 3.02 (t, J=7.0 Hz, 2H), 2.42 (s, 3H), 2.33 (m, 3H).

EXAMPLE 2(63)

[0933] 2-(3-(2-(5-methyl-2-(4-pentylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

881

[0934] TLC: Rf 0.50 (chloroform:methanol=9:1)

[0935] NMR (CDCl3): δ 7.90 (d, J=8 Hz, 2H), 7.30-7.15 (m, 3H), 7.05 (br., 1H); 6.90-6.75 (m, 2H), 4.30 (t, J=8 Hz, 2H), 3.90 (s, 2H), 3.20 (s, 2H), 3.00 (t, J=8 Hz, 2H), 2.65 (t, J=8 Hz, 2H), 2.40 (s, 3H), 1.60 (m, 2H), 1.45-1.20 (m, 4H), 0.90 (t, J=7 Hz, 3H).

EXAMPLE 2(64)

[0936] 2-(3-(2-(5-methyl-2-(3-chloro-4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

882

[0937] TLC: Rf 0.63 (chloroform:methanol=5:1)

[0938] NMR (CDCl3): δ 7.95 (d, J=1.8 Hz, 1H), 7.76 (dd, J=8.0, 1.8 Hz, 1H), 7.29 (d, J=8.0 Hz, 1H), 7.21 (dd, J=7.8, 7.8 Hz, 1H), 6.99 (m, 1H), 6.89 (m, 1H), 6.80 (m, 1H), 4.26 (t, J=7.1 Hz, 2H), 3.84 (s, 2H), 3.15 (s, 2H), 2.97 (t, J=7.1 Hz, 2H), 2.40 (s, 3H), 2.38 (s, 3H).

EXAMPLE 2(65)

[0939] 2-(3-(2-(5-methyl-2-cyclohexyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

883

[0940] TLC: Rf 0.38 (chloroform:methanol=9:1)

[0941] NMR (CDCl3): δ 7.20 (dd, J=7.5, 7.5 Hz, 1H), 7.05 (br. 1H), 6.90-6.75 (m, 2H), 4.20 (t, J=8 Hz, 2H), 3.90 (s, 2H), 3.20 (s, 2H), 2.85 (t, J=8 Hz, 2H), 2.25 (s, 3H), 2.10-1.20 (m, 10H).

[0942] 2-(3-(2-(5-methyl-2-cyclohexyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid.Sodium Salt

884

[0943] TLC: Rf 0.22 (chloroform:methanol=10:1)

[0944] NMR (CDCl3): δ 6.96 (m, 1H), 6.76-6.66 (m, 2H), 6.58 (m, 1H), 4.00 (m, 2H), 3.48 (s, 2H), 3.07 (s, 2H), 2.74 (m, 2H), 2.62 (m, 1H), 2.15 (s, 3H), 2.01-1.89 (m, 2H), 1.80-1.15 (m, 8H).

EXAMPLE 2(66)

[0945] 2-(3-(2-(5-methyl-2-(4-(2-methylpropyl)phenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

885

[0946] TLC Rf 0.44 (chloroform:methanol=9:1)

[0947] NMR (CDCl3): δ 7.90 (d, J=7 Hz, 2H), 7.30-7.15 (m, 3H), 7.05 (m, 1H), 6.95-6.75 (m, 2H), 4.25 (t, J=7.5 Hz, 2H), 3.85 (s, 2H), 3.20 (s, 2H), 3.00 (t, J=7.5 Hz, 2H), 2.50 (d, J=8 Hz, 2H), 2.40 (s, 3H), 1.90 (m, 1H), 0.90 (d, J=8 Hz, 6H).

EXAMPLE 2(67)

[0948] 2-(3-(2-(5-methyl-2-(4-t-butylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

886

[0949] TLC: Rf 0.50 (chloroform:methanol=9:1)

[0950] NMR (CDCl3): δ 7.90 (d, J=9 Hz, 2H), 7.45 (d, J=9 Hz, 2H), 7.20 (dd, J=8, 8 Hz, 1H), 7.05 (br., 1H), 6.90-6.80 (m, 2H), 4.30 (t, J=7.5 Hz, 2H), 3.85 (s, 2H), 3.20 (s, 2H), 3.00 (t, J=7.5 Hz, 2H), 2.40 (s, 3H), 1.35 (s, 9H).

EXAMPLE 2(68)

[0951] 2-(3-(2-(5-methyl-2-(4-cyclohexylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

887

[0952] TLC: Rf 0.65 (chloroform:methanol=9:1)

[0953] NMR (CDCl3): δ 7.89 (d, J=8.5 Hz, 2H), 7.27 (d, J=8.5 Hz, 2H), 7.20 (dd, J=8.0, 8.0 Hz, 1H), 7.03 (m, 1H), 6.88 (d, J=8.0 Hz, 1H), 6.80 (dd, J=8.0, 2.2 Hz, 1H), 4.27 (t, J=7.5 Hz, 2H), 3.85 (s, 2H), 3.16 (s, 2H), 2.97 (t, J=7.5 Hz, 2H), 2.53 (m, 1H), 2.37 (s, 3H), 1.70-1.90 (m, 4H), 1.20-1.52 (m, 6H).

EXAMPLE 2(69)

[0954] 2-(3-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-ylmethoxy)phenylmethylthio)acetic Acid

888

[0955] TLC: Rf 0.40 (chloroform:methanol=10:1)

[0956] NMR (CDCl3): δ 7.54 (dd, J=8.0, 1.8 Hz, 1H), 7.46 (d, J=1.8 Hz, 1H), 7.21 (d, J=8.0 Hz, 1H), 7.07-7.02 (m, 1H), 6.96-6.82 (m, 3H), 6.02 (s, 2H), 5.00 (s, 2H), 3.78 (s, 2H), 3.11 (s, 2H), 2.42 (s, 3H).

EXAMPLE 2(70)

[0957] 2-(3-(5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethoxy)phenylmethylthio)acetic Acid

889

[0958] TLC: Rf 0.48 (chloroform:methanol=10:1)

[0959] NMR (CDCl3): δ 7.92 (d, J=8.5 Hz, 2H), 7.34-7.17 (m, 3H), 7.08-7.03 (m, 1H), 6.96-6.84 (m, 2H), 5.02 (s, 2H), 3.78 (s, 2H), 3.11 (s, 2H), 2.94 (sep., J=7.0 Hz, 1H), 2.44 (s, 3H), 1.26 (d, J=7.0 Hz, 6H).

EXAMPLE 2(71)

[0960] 2-(3-(2-(4-methyl-2-phenyloxazol-5-yl)ethoxy)phenylmethylthio)acetic Acid

890

[0961] TLC: Rf 0.38 (chloroform:methanol=10:1)

[0962] NMR (CDCl3): δ 8.00-7.95 (m, 2H), 7.49-7.37 (m, 3H), 7.22 (t, J=8.0 Hz, 1H), 6.95-6.76 (m, 3H), 4.23 (t,J=7.0 Hz, 2H), 3.81 (s, 2H), 3.15 (t, J=7.0 Hz, 2H), 3.10 (s, 2H), 2.22 (s, 3H).

EXAMPLE 2(72)

[0963] 2-(3-(2-(5-methyl-2-(3,4-dimethoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

891

[0964] TLC: Rf 0.62 (chloroform:methanol=5:1)

[0965] NMR (CDCl3): δ 7.57 (dd, J=8.5, 2.0 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H), 7.21 (dd, J=8.0, 8.0 Hz, 1H), 7.04 (m, 1H), 6.91 (d, J=8.5 Hz, 1H), 6.78-6.90 (m, 2H), 4.28 (t, J=7.5 Hz, 2H), 3.95 (s, 3H), 3.93 (s, 3H), 3.86 (s, 2H), 3.16 (s, 2H), 2.96 (t, J=7.5 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(73)

[0966] 2-(3-(2-(5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

892

[0967] TLC: Rf 0.39 (chloroform:methanol=9:1)

[0968] NMR (CDCl3): δ 8.00 (d, J=8 Hz, 2H), 7.30 (d, J=8 Hz, 2H), 7.20 (dd, J=7.5, 7.5 Hz, 1H), 7.00 (br. 1H) 6.90 (d, J=7.5 Hz, 1H), 6.80 (dd, J=7.5, 7.5 Hz, 1H), 4.25 (t, J=7 Hz, 2H), 3.85 (s, 2H), 3.15 (s, 2H), 3.00 (t, J=7 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 2(74)

[0969] 2-(3-(2-(5-methyl-2-(3,4,5-trimethoxyphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

893

[0970] TLC: Rf 0.39 (chloroform:methanol=9:1)

[0971] NMR (CDCl3): δ 7.25-7.15 (m, 3H), 7.05 (m, 1H), 6.90-6.75 (m, 2H), 4.25 (t, J=7.5 Hz, 2H), 3.95 (s, 6H), 3.90 (s, 3H), 3.85 (s, 2H), 3.15 (s, 2H), 2.95 (t, J=7.5 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 2(75)

[0972] 2-(3-(2-(5-methyl-2-(4-methylpiperazin-1-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

894

[0973] TLC: Rf 0.26 (water:methanol:chloroform=1:10:100)

[0974] NMR (CDCl3): δ 7.14 (dd, J=7.5, 7.5 Hz, 1H), 6.88 (d, J=7.5 Hz, 1H), 6.73 (dd, J=7.5, 2.0 Hz, 1H), 6.70 (d, J=2.0 Hz, 1H), 4.27 (t, J=6.5 Hz, 2H), 3.78 (s, 2H), 3.55 (t, J=5.0 Hz, 4H), 3.14 (s, 2H), 2.90 (t, J=6.5 Hz, 2H), 2.85 (t, J=5.0 Hz, 4H), 2.51 (s, 3H), 2.19 (s, 3H).

EXAMPLE 2(76)

[0975] 2-(3-(2-(5-methyl-2-(4-methylthiophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

895

[0976] TLC: Rf 0.33 (water:methanol:chloroform=1:10:100)

[0977] NMR (CDCl3): δ 7.88 (d, J=8.5 Hz, 2H), 7.27 (d, J=8.5 Hz, 2H), 7.20 (dd, J=8.0, 8.0 Hz, 1H), 7.03 (dd, J=2.5, 2.0 Hz, 1H), 6.88 (ddd, J=8.0, 2.0, 1.0 Hz, 1H), 6.80 (ddd, J=8.0, 2.5, 1.0 Hz, 1H), 4.27 (t, J=7.5 Hz, 2H), 3.85 (s, 2H), 3.16 (s, 2H), 2.96 (t, J=7.5 Hz, 2H), 2.51 (s, 3H), 2.37 (s, 3H).

EXAMPLE 2(77)

[0978] 2-(3-(2-(5-methyl-2-(pyridin-2-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

896

[0979] TLC: Rf 0.55 (chloroform:methanol=5:1)

[0980] NMR (CDCl3): δ 8.77 (ddd, J=4.9, 1.8, 0.8 Hz, 1H), 8.04 (ddd, J=8.0, 1.2, 0.8 Hz, 1H), 7.84 (ddd, J=8.0, 7.6, 1.8 Hz, 1H), 7.38 (ddd, J=7.6, 4.9, 1.2 Hz, 1H), 7.23 (dd, J=7.8, 7.8 Hz, 1H), 7.10 (m, 1H), 6.92 (m, 1H), 6.81 (m, 1H), 4.34 (t, J=7.0 Hz, 2H), 3.85 (s, 2H), 3.13 (s, 2H), 2.99 (t, J=7.0 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 2(78)

[0981] 2-(3-(2-(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

897

[0982] TLC: Rf 0.52 (chloroform:methanol=5:1);

[0983] NMR (CDCl3): δ 7.64 (dd, J=3.6, 1.2 Hz, 1H), 7.39 (dd, J=5.0, 1.2 Hz, 1H), 7.20 (dd, J=7.8, 7.8 Hz, 1H), 7.09 (dd, J=5.0, 3.6 Hz, 1H), 7.00 (m, 1H), 6.88 (m, 1H), 6.80 (m, 1H), 4.25 (t, J=7.4 Hz, 2H), 3.85 (s, 2H), 3.16 (s, 2H), 2.95 (t, J=7.4 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 2(79)

[0984] 2-(3-(2-(5-methyl-2-(3-nitro-4-methylphenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

898

[0985] TLC: Rf 0.40 (ethyl acetate)

[0986] NMR (CDCl3): δ 8.52 (s, 1H), 8.07 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.18 (m, 1H), 6.70-7.00 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 3.11 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.61 (s, 3H), 2.39 (s, 3H).

EXAMPLE 2(80)

[0987] 2-(3-(2-(5-methyl-2-(4-dimethylaminophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

899

[0988] TLC: Rf 0.47 (water:methanol:chloroform=1:10:100)

[0989] NMR (CDCl3): δ 7.84 (d, J=9.0 Hz, 2H), 7.20 (dd, J=8.0, 8.0 Hz, 1H), 7.11 (dd, J=2.0, 1.0 Hz, 1H), 6.87 (dd, J=8.0, 1.0 Hz, 1H), 6.80 (dd, J=8.0, 2.0 Hz, 1H), 6.71 (d, J=9.0 Hz, 2H), 4.29 (t, J=8.0 Hz, 2H), 3.88 (s, 2H), 3.19 (s, 2H), 3.02 (s, 6H), 2.94 (t, J=8.0 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 2(81)

[0990] 2-(3-(2-(5-methyl-2-cyclopentyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

900

[0991] TLC: Rf 0.44 (chloroform:methanol=9:1);

[0992] NMR (CDCl3): δ 7.20 (dd, J=7.5, 7.5 Hz, 1H), 7.10 (br., 1H), 6.85 (d, J=7.5 Hz, 1H), 6.80 (dd, J=7.5, 1.5 Hz, 1H), 4.20 (t, J=7.5 Hz, 2H), 3.85 (s, 2H), 3.20 (s, 2H), 3.15 (m, 1H), 2.85 (t, J=7.5 Hz, 2H), 2.25 (s, 3H), 2.20-1.60 (m, 8H).

[0993] Bis(2-(3-(2-(5-methyl-2-cyclopentyloxazol-4-yl)ethoxy)phenylmethylthio)acetic acid).ethylenediamine Salt

901

[0994] TLC: Rf 0.29 (chloroform:methanol=10:1)

[0995] NMR (DMSO-d6): δ 7.18 (t, J=8.0 Hz, 1H), 6.88-6.72 (m, 3H), 4.09 (t, J=6.8 Hz, 2H), 3.69 (s, 2H), 3.19-3.00 (m, 1H), 2.96 (s, 2H), 2.84 (s, 2H), 2.78 (t, J=6.8 Hz, 2H), 2.21 (s, 3H), 2.06-1.48 (m, 8H).

EXAMPLE 2(82)

[0996] 2-(3-(2-(5-methyl-2-(4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

902

[0997] TLC: Rf 0.46 (chloroform:methanol=10:1)

[0998] NMR (CDCl3): δ 7.85 (d, J=8.4 Hz, 2H), 7.27-7.14 (m, 3H), 6.89-6.75 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.38 (s, 3H), 2.35 (s, 3H).

EXAMPLE 2(83)

[0999] 2-(3-(2-(5-methyl-2-(4-ethylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

903

[1000] TLC: Rf 0.54 (chloroform:methanol=10:1)

[1001] NMR (CDCl3): δ 7.88 (d, J=8.2 Hz, 2H), 7.29-7.15 (m, 3H), 6.89-6.75 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.68 (q, J=7.6 Hz, 2H), 2.35 (s, 3H), 1.25 (t, J=7.6 Hz, 3H).

EXAMPLE 2(84)

[1002] 2-(3-(2-(5-methyl-2-(4-propylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

904

[1003] TLC: Rf 0.57 (chloroform:methanol=10:1)

[1004] NMR (CDCl3): δ 7.87 (d, J=8.2 Hz, 2H), 7.28-7.15 (m, 3H), 6.88-6.76 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.61 (t, J=7.5 Hz, 2H), 2.35 (s, 3H), 1.65 (sixtet, J=7.5 Hz, 2H), 0.94 (t, J=7.5 Hz, 3H).

EXAMPLE 2(85)

[1005] 2-(3-(2-(5-methyl-2-(4-isopropylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

905

[1006] TLC: Rf 0.52 (chloroform:methanol=10:1)

[1007] NMR (CDCl3): δ 7.88 (d, J=8.2 Hz, 2H), 7.32-7.15 (m, 3H), 6.88-6.76 (m, 3H), 4.19 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.93 (sept, J=7.2 Hz, 1H), 1.25 (d, J=7.2 Hz, 6H).

EXAMPLE 2(86)

[1008] 2-(3-(2-(5-methyl-2-(4-(2-methylpropyl)phenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

906

[1009] TLC: Rf 0.50 (chloroform:methanol=10:1)

[1010] NMR (CDCl3): δ 7.87 (d, J=8.2 Hz, 2H), 7.26-7.15 (m, 3H), 6.89-6.76 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.50 (d, J=7.0 Hz, 2H), 2.35 (s, 3H), 1.88 (m, 1H), 0.90 (d, J=6.6 Hz, 6H).

EXAMPLE 2(87)

[1011] 2-(3-(2-(5-methyl-2-(4-t-butylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

907

[1012] TLC: Rf 0.44 (chloroform:methanol=10:1)

[1013] NMR (CDCl3): δ 7.89 (d, J=8.2 Hz, 2H), 7.43 (d, J=8.2 Hz, 2H), 7.20 (t, J=8.0 Hz, 1H), 6.89-6.76 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.35 (s, 3H), 1.33 (s, 9H).

EXAMPLE 2(88)

[1014] 2-(3-(2-(5-methyl-2-cyclopropyloxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

908

[1015] TLC: Rf 0.39 (water:methanol:chloroform=1:10:100)

[1016] NMR (CDCl3): δ 7.18 (dd, J=8.0, 8.0 Hz, 1H), 7.00 (d, J=2.5 Hz, 1H), 6.86 (d, J=8.0 Hz, 1H), 6.77 (dd, J=8.0, 2.5 Hz, 1H), 4.19 (t, J=7.5 Hz, 2H), 3.83 (s, 2H), 3.15 (s, 2H), 2.84 (t, J=7.5 Hz, 2H), 2.22 (s, 3H), 2.06 (m, 1H), 1.10-0.95 (m, 4H).

EXAMPLE 2(89)

[1017] 2-(3-(2-(5-methyl-2-(4-(1,2,3-thiadiazol-4-yl)phenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

909

[1018] TLC: Rf 0.30 (chloroform:methanol=10:1)

[1019] NMR (CD3OD): δ 9.35 (d, J=0.8 Hz, 1H), 8.24 (d, J=8.2 Hz, 2H), 8.11 (d, J=8.2 Hz, 2H), 7.20 (t, J=7.6 Hz, 1H), 6.95-6.78 (m, 3H), 4.27 (t, J=6.2 Hz, 2H), 3.78 (s, 2H), 3.06 (s, 2H), 3.00 (t, J=6.2 Hz 2H), 2.41 (s, 3H).

EXAMPLE 2(90)

[1020] 2-(3-(2-(5-methyl-2-(4-(4-methyl-1,2,3-thiadiazol-5-yl)phenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

910

[1021] TLC: Rf 0.34 (chloroform:methanol=10:1)

[1022] NMR (CDCl3): δ 7.22 (t, J=8.0 Hz, 1H), 6.95-6.74 (m, 3H), 4.24 (t, J=6.2 Hz, 2H), 3.81 (s, 2H), 3.11 (s, 2H), 3.02 (s, 3H), 2.99 (t, J=6.2 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 2(91)

[1023] 2-(3-(2-(5-methyl-2-(4-methoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

911

[1024] TLC: Rf 0.67 (chloroform:methanol=10:1)

[1025] NMR (CDCl3): δ 7.90 (d, J=9.0 Hz, 2H), 7.20 (t, J=8.0 Hz, 1H), 6.93 (d, J=9.0 Hz, 2H), 6.89-6.76 (m, 3H), 4.19 (t, J=6.6 Hz, 2H), 3.84 (s, 3H), 3.59 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.34 (s, 3H).

EXAMPLE 2(92)

[1026] 2-(3-(2-(5-methyl-2-(3,4-dimethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

912

[1027] TLC: Rf 0.54 (chloroform:methanol=10:1)

[1028] NMR (CDCl3+CD3OD): δ 7.56 (dd, J=8.2, 2.0 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H), 7.22 (t, J=8.0 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.90-6.77 (m, 3H), 4.22 (t, J=6.6 Hz, 2H), 3.97 (s, 3H), 3.93 (s, 3H), 3.57 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(93)

[1029] 2-(3-(2-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

913

[1030] TLC: Rf 0.53 (chloroform:methanol=10:1)

[1031] NMR (CDCl3): δ 7.51 (dd, J=8.2, 1.8 Hz, 1H), 7.43 (d, J=1.8 Hz, 1H), 7.21 (t, J=7.6 Hz, 1H), 6.89-6.76 (m, 4H), 6.00 (s, 2H), 4.19 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.94 (t, J=6.6 Hz, 2H), 2.34 (s, 3H).

EXAMPLE 2(94)

[1032] 2-(3-(2-(5-methyl-2-(3,4,5-trimethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

914

[1033] TLC: Rf 0.47 (chloroform:methanol=10:1)

[1034] NMR (CDCl3): δ 7.21 (t, J=8.0 Hz, 1H), 7.20 (s, 2H), 6.89-6.76 (m, 3H), 4.21 (t, J=6.6 Hz, 2H), 3.91 (s, 6H), 3.88 (s, 3H), 3.60 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(95)

[1035] 2-(3-(2-(5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

915

[1036] TLC: Rf 0.57 (chloroform:methanol=10:1)

[1037] NMR (CDCl3): δ 8.00 (d, J=8.8 Hz, 2H), 7.30-7.16 (m, 3H), 6.89-6.76 (m, 3H), 4.21 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 2(96)

[1038] 2-(3-(2-(5-methyl-2-(2,2-difluoro-1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

916

[1039] TLC: Rf 0.53 (chloroform:methanol=10:1)

[1040] NMR (CDCl3): δ 7.74 (dd, J=8.4, 1.5 Hz, 1H), 7.68 (d, J=1.5 Hz, 1H), 7.22 (dd, J=9.4, 7.4 Hz, 1H), 7.09 (d, J=8.4 Hz, 1H), 6.89-6.76 (m, 3H), 4.21 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 2(97)

[1041] 2-(3-(2-(5-methyl-2-(4-trifluoromethylthiophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

917

[1042] TLC: Rf 0.47 (chloroform:methanol=10:1)

[1043] NMR (DMSO-d6): δ 8.02 (d, J=8.1 Hz, 2H), 7.81 (d, J=8.1 Hz, 2H), 7.20 (t, J=7.8 Hz, 1H), 6.86-6.80 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.74 (s, 2H), 3.09 (s, 2H), 2.94 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 2(98)

[1044] 2-(3-(2-(5-methyl-2-(4-cyanophenyl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

918

[1045] TLC: Rf 0.24 (hexane:ethyl acetate=1:1)

[1046] NMR (CDCl3): δ 8.08 (d, J=8.0 Hz, 2H), 7.72 (d, J=8.0 Hz, 2H), 7.22 (m, 1H), 6.76-6.98 (m, 3H), 4.26 (t, J=6.6 Hz, 2H), 3.83 (s, 2H), 3.13 (s, 2H), 2.99 (t, J=6.6 Hz, 2H), 2.42 (s, 3H).

EXAMPLE 2(99)

[1047] 2-(3-(2-(5-methyl-2-(furan-2-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

919

[1048] TLC: Rf 0.24 (hexane:ethyl acetate=1:1)

[1049] NMR (CDCl3) δ 7.52 (m, 1H), 7.20 (m, 1H), 6.74-7.03 (m, 4H), 6.51 (dd, J=3.4, 1.6 Hz, 1H), 4.25 (t, J=6.8 Hz, 2H), 3.82 (s, 2H), 3.13 (s, 2H), 2.97 (t, J=6.8 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 2(100)

[1050] 2-(3-(5-methyl-2-phenyloxazol-4-yl)methoxy)phenyl)acetic Acid

920

[1051] TLC: Rf 0.31 (chloroform:methanol=8:1)

[1052] NMR (CDCl3): δ 8.00 (m, 2H), 7.42 (m, 3H), 7.24 (m, 1H), 6.85-6.98 (m, 3H), 4.98 (s, 2H), 3.61 (s, 2H), 2.42 (s, 3H).

EXAMPLE 2(101)

[1053] 2-(3-(2-(5-methyl-2-phenylthiazol-4-yl)ethoxy)phenyl)acetic Acid

921

[1054] TLC: Rf 0.43 (chloroform:methanol=9:1)

[1055] NMR: δ 7.89-7.81 (m, 2H), 7.46-7.34 (m, 3H), 7.26-7.16 (m, 1H), 6.87-6.78 (m, 3H), 4.30 (t, J=6.8 Hz, 2H), 3.59 (s, 2H), 3.18 (t, J=6.8 Hz, 2H), 2.45 (s, 3H).

EXAMPLE 2(102)

[1056] 2-(3-(3-(5-methyl-2-phenyloxazol-4-yl)propoxy)phenyl)acetic Acid

922

[1057] TLC: Rf 0.50 (chloroform:methanol=8:1)

[1058] NMR (CDCl3): δ 7.97 (m, 2H), 7.41 (m, 3H), 7.22 (m, 1H), 6.74-6.92 (m, 3H), 3.94 (t, J=6.0 Hz, 2H), 3.61 (s, 2H), 2.68 (t, J=7.0 Hz, 2H), 2.27 (s, 3H), 2.11 (m, 2H).

EXAMPLE 2(103)

[1059] 2-(3-(2-(2-phenyloxazol-4-yl)ethoxy)phenyl)acetic Acid

923

[1060] TLC: Rf 0.39 (chloroform:methanol=8:1)

[1061] NMR (CDCl3): δ 8.01 (m, 2H), 7.55 (s, 1H), 7.43 (m, 3H), 7.23 (m, 1H), 6.85 (m, 3H), 4.25 (t, J=6.4 Hz, 2H), 3.60 (s, 2H), 3.07 (t, J=6.4 Hz, 2H).

EXAMPLE 2(104)

[1062] 2-(3-(2-(5-methyl-2-(4-cyclohexylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

924

[1063] TLC: Rf 0.62 (chloroform:methanol=5:1)

[1064] NMR (CDCl3): δ 7.88 (d, J=8.2 Hz, 2H), 7.25 (d, J=8.2 Hz, 2H), 7.21 (m, 1H), 6.78-6.87 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.52 (m, 1H), 2.35 (s, 3H), 1.70-1.95 (m, 4H), 1.20-1.53 (m, 6H).

EXAMPLE 2(105)

[1065] 2-(3-(2-(5-methyl-2-(3-chloro-4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

925

[1066] TLC: Rf 0.67 (chloroform:methanol=5:1)

[1067] NMR (CDCl3): δ 7.95 (d, J=1.7 Hz, 1H), 7.75 (dd, J=8.0, 1.7 Hz, 1H), 7.27 (d, J=8.0 Hz, 1H), 7.21 (m, 1H), 6.78-6.88 (m, 3H), 4.21 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.40 (s, 3H), 2.36 (s, 3H).

EXAMPLE 2(106)

[1068] 2-(3-(2-(5-methyl-2-(4-dimethylaminophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

926

[1069] TLC: Rf 0.55 (chloroform:methanol=5:1)

[1070] NMR (CDCl3): δ 7.83 (d, J=9.0 Hz, 2H), 7.09 (dd, J=8.0, 8.0 Hz, 1H), 6.76-6.87 (m, 3H), 6.70 (d, J=9.0 Hz, 2H), 4.18 (t, J=6.8 Hz, 2H), 3.60 (s, 2H), 3.01 (s, 6H), 2.94 (t, J=6.8 Hz, 2H), 2.32 (s, 3H).

EXAMPLE 2(107)

[1071] 2-(3-(2-(5-ethyl-2-phenyloxazol-4-yl)ethoxy)phenyl)acetic Acid

927

[1072] TLC: Rf 0.44 (chloroform:methanol=8:1)

[1073] NMR (CDCl3): δ 7.97 (m, 2H), 7.41 (m, 3H), 7.20 (m, 1H), 6.82 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.73 (q, J=7.6 Hz, 2H), 1.29 (t, J=7.6 Hz, 3H).

EXAMPLE 2(108)

[1074] 2-(3-(2-(5-methyl-2-(4-butylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

928

[1075] TLC: Rf 0.54 (chloroform:methanol=8:1)

[1076] NMR (CDCl3): δ 7.87 (d, J=8.2 Hz,2H), 7.22 (d, J=8.2 Hz, 2H),7.14-7.28 (m, 1H), 6.82 (m, 3H), 4.19 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.63 (t, J=7.6 Hz, 2H), 2.34 (s, 3H), 1.61 (m, 2H), 1.35 (m, 2H), 0.92 (t, J=7.2 Hz, 3H).

EXAMPLE 2(109)

[1077] 2-(3-(2-(5-methyl-2-(4-chlorophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

929

[1078] TLC: Rf 0.57 (chloroform:methanol=8:1)

[1079] NMR (CDCl3): δ 7.90 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 7.16-7.28 (m, 1H), 6.83 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 2(110)

[1080] 2-(3-(2-(5-methyl-2-(thiophen-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

930

[1081] TLC: Rf 0.70 (chloroform:methanol=5:1)

[1082] NMR (CDCl3): δ 7.59 (dd, J=3.6, 1.2 Hz, 1H), 7.36 (dd, J=4.8, 1.2 Hz, 1H), 7.21 (m, 1H), 7.07 (dd, J=4.8, 3.6 Hz, 1H), 6.77-6.87 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.34 (s, 3H).

EXAMPLE 2(111)

[1083] 2-(3-(2-(5-methyl-2-(furan-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

931

[1084] TLC: Rf 0.69 (chloroform:methanol=5:1)

[1085] NMR (CDCl3): δ 7.51 (m, 1H), 7.21 (m, 1H), 6.93 (d, J=3.5 Hz, 1H), 6.78-6.87 (m, 3H), 6.50 (dd, J=3.5, 1.9 Hz, 1H), 4.22 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 2(112)

[1086] 2-(3-(2-(5-methyl-2-(pyridin-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

932

[1087] TLC: Rf 0.67 (chloroform:methanol=5:1)

[1088] NMR (CDCl3): δ 8.71 (d, J=4.8 Hz, 1H), 8.05 (d, J=7.8 Hz, 1H), 7.79 (ddd, J=7.8, 7.8, 1.8 Hz, 1H), 7.32 (ddd, J=7.8, 4.8, 1.8 Hz, 1H), 7.21 (dd, J=7.8, 7.8 Hz, 1H), 6.78-6.87 (m, 3H), 4.26 (t, J=6.8 Hz, 2H), 3.61 (s, 2H), 2.99 (t, J=6.8 Hz, 2H), 2.41 (s, 3H).

EXAMPLE 2(113)

[1089] 2-(3-(2-(5-methyl-2-(2-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

933

[1090] TLC: Rf 0.68 (chloroform:methanol=5:1)

[1091] NMR (CDCl3): δ 7.90 (m, 1H), 7.18-7.30 (m, 4H), 6.80-6.87 (m, 3H), 4.24 (t, J=6.7 Hz, 2H), 3.60 (s, 2H), 2.98 (t, J=6.7 Hz, 2H), 2.64 (s, 3H), 2.37 (s, 3H).

EXAMPLE 2(114)

[1092] 2-(3-(2-(5-methyl-2-(3-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

934

[1093] TLC: Rf 0.71 (chloroform:methanol=5:1)

[1094] NMR (CDCl3): δ 7.74-7.81 (m, 2H), 7.17-7.35 (m, 3H), 6.78-6.87 (m, 3H), 4.21 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.39 (s, 3H), 2.36 (s, 3H).

EXAMPLE 2(115)

[1095] 2-(3-(2-(5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

935

[1096] TLC: Rf 0.54 (chloroform:methanol=8:1)

[1097] NMR (CDCl3): δ 8.08 (d, J=8.0 Hz, 2H), 7.67 (d, J=8.0 Hz, 2H), 7.17-7.24 (m, 1H), 6.83 (m, 3H), 4.23 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.98 (t, J=6.6 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 2(116)

[1098] 2-(3-(2-(5-methyl-2-(4-fluorophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

936

[1099] TLC: Rf 0.59 (chloroform:methanol=8:1)

[1100] NMR (CDCl3) δ 7.95 (m, 2H), 7.03-7.26 (m, 3H), 6.83 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.35 (s, 3H).

EXAMPLE 2(117)

[1101] 2-(3-(2-(5-methyl-2-(4-cyanophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

937

[1102] TLC: Rf 0.52 (chloroform:methanol=9:1)

[1103] NMR (CDCl3) δ 8.06 (d, J=8.6 Hz, 2H), 7.70 (d, J=8.6 Hz, 2H), 7.22 (m, 1H), 6.78-6.87 (m, 3H), 4.23 (t, J=6.4 Hz, 2H), 3.60 (s, 2H), 2.98 (t, J=6.4 Hz, 2H), 2.40 (s, 3H)

EXAMPLE 2(118)

[1104] 2-(3-(2-(5-methyl-2-(4-methyl-1,2,3-thiadiazol-5-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

938

[1105] TLC: Rf 0.54 (chloroform:methanol=9:1)

[1106] NMR (CDCl3): δ 7.23 (m, 1H), 6.78-6.88 (m, 3H), 4.23 (t, J=6.5 Hz, 2H), 3.60 (s, 2H), 3.02 (s, 3H), 2.98 (t, J=6.5 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 2(119)

[1107] 2-(3-(2-(5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

939

[1108] TLC: Rf 0.34 (chloroform:methanol=8:1)

[1109] NMR (CDCl3): δ 7.22 (m, 1H), 6.76-6.90 (m, 3H), 4.23 (t, J=6.4 Hz, 2H), 3.60 (s, 2H), 3.01 (t, J=6.4 Hz, 2H), 2.40 (s, 3H), 2.33 (s, 3H).

EXAMPLE 2(120)

[1110] 2-(3-(2-(5-methyl-2-(3-nitro-4-methylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

940

[1111] TLC: Rf 0.31 (chloroform:methanol=8:1)

[1112] NMR (CDCl3): δ 8.54 (d, J=1.6 Hz, 1H), 8.08 (dd, J=8.0, 1.6 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.17 (m, 1H), 6.66-6.90 (m, 3H), 4.21 (t, J=6.4 Hz, 2H), 3.59 (s, 2H), 2.97 (t, J=6.4 Hz, 2H), 2.63 (s, 3H), 2.39 (s, 3H).

EXAMPLE 2(121)

[1113] 2-(3-(2-(5-methyl-2-cyclohexyloxazol-4-yl)ethoxy)phenyl)acetic Acid

941

[1114] TLC: Rf 0.44 (chloroform:methanol=9:1)

[1115] NMR (CDCl3): δ 7.19 (dd, J=8.0, 8.0 Hz, 1H), 6.74-6.87 (m, 3H), 4.10 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.85 (t, J=6.6 Hz, 2H), 2.71 (m, 1H), 2.23 (s, 3H), 1.96-2.04 (m, 2H), 1.19-1.86 (m, 8H).

EXAMPLE 2(122)

[1116] 2-(3-(2-(5-methyl-2-cyclopentyloxazol-4-yl)ethoxy)phenyl)acetic Acid

942

[1117] TLC: Rf 0.46 (chloroform:methanol=9:1)

[1118] NMR (CDCl3): δ 7.19 (dd, J=7.9, 7.9 Hz, 1H), 6.74-6.87 (m, 3H), 4.11 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 3.14 (m, 1H), 2.86 (t, J=6.6 Hz, 2H), 2.24 (s, 3H), 1.56-2.12 (m, 8H).

EXAMPLE 2(123)

[1119] 2-(3-(2-(5-methyl-2-(4-pentylphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

943

[1120] TLC: Rf 0.44 (chloroform:methanol=8:1)

[1121] NMR (CDCl3): δ 7.87 (d, J=8.4 Hz, 2H), 7.22 (d, J=8.4 Hz, 2H), 7.20 (m, 1H), 6.75-6.90 (m, 3H), 4.19 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.62 (t, J=7.6 Hz, 2H), 2.35 (s, 3H), 1.62 (m, 2H), 1.23-1.44 (m, 4H), 0.89 (t, J=6.8 Hz, 3H).

EXAMPLE 2(124)

[1122] 2-(3-(2-(5-methyl-2-(pyridin-4-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

944

[1123] TLC: Rf 0.36 (chloroform:methanol=4:1)

[1124] NMR (DMSO-d6): δ 8.75 (d, J=6 Hz, 2H), 7.80 (d, J=6 Hz, 2H), 7.20 (dd, J=8, 8 Hz, 1H), 6.95-6.80 (m, 3H), 4.20 (t, J=7 Hz, 2H), 3.75 (s, 2H), 3.05 (s, 2H), 2.95 (t, J=7 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 2(125)

[1125] 2-(3-(2-(5-methyl-2-(pyridin-3-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

945

[1126] TLC: Rf 0.39 (chloroform:methanol=9:1)

[1127] NMR (DMSO-d6): δ 12.28 (brs, 1H), 9.07 (d, J=1.5 Hz, 1H), 8.65 (d, J=4.8 Hz, 1H), 8.24 (d, J=8.4 Hz, 1H), 7.52 (dd, J=8.4 Hz, 4.8 Hz, 1H), 7.21-7.16 (m, 1H), 6.82-6.79 (m, 3H), 4.18 (t, J=6.6 Hz, 2H), 3.50 (s, 2H), 2.93 (t, J=6.6 Hz, 2H), 2.37 (s, 3H).

EXAMPLE 2(126)

[1128] 2-(3-(2-(5-methyl-2-(pyridin-4-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

946

[1129] TLC: Rf 0.34 (chloroform:methanol=9:1)

[1130] NMR (DMSO-d6): δ 12.29 (brs, 1H), 8.69 (d, J=6.0 Hz, 2H), 7.80 (d, J=6.0 Hz, 2H), 7.21-7.16 (m, 1H), 6.82-6.78 (m, 3H), 4.19 (t, J=6.6 Hz, 2H), 3.50 (s, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(127)

[1131] 2-(3-(2-(5-methyl-2-(4-methylpiperazin-1-yl)thiazol-4-yl)ethoxy)phenyl)acetic Acid

947

[1132] TLC: Rf 0.40 (chloroform:methanol=3:1)

[1133] NMR (CDCl3): δ 7.00-7.20 (m, 2H), 6.70-6.85 (m, 3H), 4.19 (t, J=6.6 Hz, 2H), 3.46-3.55 (m, 4H), 2.91 (t, J=6.6 Hz, 2H), 2.75-2.83 (m, 4H), 2.47 (s, 3H), 2.24 (s, 3H).

EXAMPLE 2(128)

[1134] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethoxy)acetic Acid

948

[1135] TLC: Rf 0.31 (water:methanol:chloroform=1:10:100);

[1136] NMR (CDCl3): δ 7.98 (m, 2H), 7.50-7.40 (m. 3H), 7.24 (dd, J=8.0, 8.0 Hz, 1H), 7.00 (m, 1H), 6.95-6.80 (m, 2H), 4.62 (s, 2H), 4.26 (t, J=7.0 Hz, 2H), 4.11 (s, 2H), 2.99 (t, J=7.0 Hz, 2H), 2.39 (s, 3H).

EXAMPLE 2(129)

[1137] 2-(3-(2-(5-methyl-2-(pyridin-3-yl)oxazol-4-yl)ethoxy)phenylmethylthio)acetic Acid

949

[1138] TLC: Rf 0.41 (chloroform:methanol=4:1)

[1139] NMR (DMSO-d6): δ 9.05 (s, 1H), 8.65 (d, J=4 Hz, 1H), 8.25 (d, J=7 Hz, 1H), 7.55 (m, 1H), 7.20 (dd, J=7, 7 Hz, 1H), 6.95-6.80 (m, 3H), 4.20 (t, J=6 Hz, 2H), 3.80 (s, 2H), 3.10 (s, 2H), 2.95 (t, J=6 Hz, 2H), 2.40 (s, 3H).

EXAMPLE 2(130)

[1140] 2-(3-(2-(5-methyl-2-(4-methylthiophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

950

[1141] TLC: 0.44 (chloroform:methanol=8:1)

[1142] NMR (CDCl3): δ 7.87 (d, J=8.6 Hz, 2H), 7.26 (d, J=8.6 Hz, 2H), 7.21 (m, 1H), 6.75-6.89 (m, 3H), 4.20 (t, J=6.6 Hz, 2H), 3.59 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.51 (s, 3H), 2.35 (s, 3H).

EXAMPLE 2(131)

[1143] 2-(3-(2-(5-methyl-2-cyclopropyloxazol-4-yl)ethoxy)phenyl)acetic Acid

951

[1144] TLC: Rf 0.43 (chloroform:methanol=9:1);

[1145] NMR CDCl3): δ 7.25-7.10 (m, 1H), 6.86-6.74 (m, 3H), 4.10 (t, J=6.6 Hz, 2H), 3.58 (s, 2H), 2.82 (t, J=6.6 Hz, 2H), 2.20 (s, 3H), 2.04-1.98 (m, 1H), 1.01-0.94 (m, 4H).

EXAMPLE 2(132)

[1146] 2-(3-(2-(5-methyl-2-(4-nitrophenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

952

[1147] TLC: Rf 0.53 (chloroform:methanol=9:1)

[1148] NMR (CDCl3): δ 8.30 (d, J=9.0 Hz, 2H), 8.14 (d, J=9.0 Hz, 2H), 7.22 (dd, J=8.0, 8.0 Hz, 1H), 6.77-6.90 (m, 3H), 4.25 (t, J=6.6 Hz, 2H), 3.57 (s, 2H), 3.00 (t, J=6.6 Hz, 2H), 2.43 (s, 3H).

EXAMPLE 2(133)

[1149] 2-(3-(2-(5-methyl-2-(quinolin-2-yl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

953

[1150] TLC: Rf 0.51 (chloroform:methanol=9:1)

[1151] NMR (CDCl3) δ 8.16-8.28 (m, 3H), 7.83 (m, 1H), 7.75 (m, 1H), 7.57 (m, 1H), 7.22 (dd, J=8.2, 8.2 Hz, 1H), 6.78-6.87 (m, 3H), 4.29 (t, J=6.6 Hz, 2H), 3.61 (s, 2H), 3.04 (t, J=6.6 Hz, 2H), 2.46 (s, 3H).

EXAMPLE 2(134)

[1152] 2-(3-(2-(5-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

954

[1153] TLC: Rf 0.37 (chloroform:methanol=9:1)

[1154] NMR (CDCl3): δ 7.91 (dt, J=7.8, 1.2 Hz, 1H), 7.85-7.80 (m, 1H), 7.45 (t, J=7.8 Hz, 1H), 7.28-7.17 (m, 2H), 6.89-6.78 (m, 3H), 4.22 (t, J=6.6 Hz, 2H), 3.60 (s, 2H), 2.97 (t, J=6.6 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(135)

[1155] 2-(3-(2-(5-methyl-2-(2-trifluoromethoxyphenyl)oxazol-4-yl)ethoxy)phenyl)acetic Acid

955

[1156] TLC: Rf 0.42 (chloroform:methanol=9:1)

[1157] NMR (CDCl3): δ 8.06 (dd, J=7.8, 2.0 Hz, 1H), 7.49-7.31 (m, 3H), 7.27-7.17 (m, 1H), 6.88-6.78 (m, 3H), 4.23 (t, J=6.8 Hz, 2H), 3.60 (s, 2H), 2.98 (t, J=6.8 Hz, 2H), 2.38 (s, 3H).

EXAMPLE 2(136)

[1158] 2-(3-(2-(4-methyl-2-phenyloxazol-5-yl)ethoxy)phenyl)acetic Acid

956

[1159] TLC: Rf 0.44 (chloroform:methanol=9:1);

[1160] NMR (CDCl3) δ 8.00-7.93 (m, 2H), 7.46-7.37 (m, 3H), 7.28-7.18 (m, 1H), 6.90-6.78 (m, 3H), 4.22 (t, J=6.8 Hz, 2H), 3.61 (s, 2H), 3.14 (t, J=6.8 Hz, 2H), 2.20 (s, 3H).

EXAMPLE 2(137)

[1161] 2-(3-(2-(5-methyl-2-(1,3-dioxaindan-5-yl)oxazol-4-yl)ethoxy)phenylmethoxy)acetic Acid

957

[1162] TLC: Rf 0.20 (chloroform:methanol:water=100:10:1)

[1163] NMR (CD3OD): δ 7.49 (dd, J=8.4, 1.8 Hz, 1H), 7.38 (d, J=1.8 Hz, 1H), 7.22 (t, J=7.8 Hz, 1H), 6.97-6.79 (m, 4H), 6.01 (s, 2H), 4.54 (s, 2H), 4.26 (t, J=6.4 Hz, 2H), 4.06 (s, 2H), 2.93 (t, J=6.4 Hz, 2H), 2.33 (s, 3H).

EXAMPLE 3

[1164] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethylthio)phenyl)acetic Acid.Methyl Ester

958

[1165] 2-(5-methyl-2-phenyloxazol-4-yl)ethylbromide (136 mg) and 3-mercaptophenylacetic acid.methyl ester (78 mg) were dissolved in acetonitrile (5 ml) and thereto was added potassium carbonate and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into ice water and the mixture was extracted with ether. The extract was washed with an aqueous solution of sodium hydroxide, water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (chloroform ethyl acetate=200:150:1) to give the compound of the present invention (92 mg) having the following physical data.

[1166] TLC: Rf 0.33 (ethyl acetate:hexane=1:3)

[1167] NMR (CDCl3): δ 7.96 (m, 2H), 7.50-7.35 (m. 3H), 7.30-7.15 (m, 3H), 7.06 (m, 1H), 3.69 (s, 3H), 3.57 (s, 2H), 3.28 (t, J=7.0 Hz, 2H), 2.82 (t, J=7.0 Hz, 2H), 2.27 (s, 3H).

EXAMPLE 4

[1168] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)-2-methylpropanoic Acid.Ethyl Ester

959

[1169] To a solution of 3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzylthiol (1.15 g) in ethanol (35 ml) were added 2-bromo-2-methylpropanoic acid.ethyl ester (0.64 ml) and sodium methylate (290 mg) at 0° C. and the mixture was refluxed for 3 hours. The reaction mixture was cooled to room temperature and then filtered. The filtrate was poured into water and the aqueous layer was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=5:1) to give the compound of the present invention (1.69 g) having the following physical data.

[1170] TLC: Rf 0.46 (hexane:ethyl acetate=4:1);

[1171] NMR (CDCl3): δ 8.01-7.94 (m, 2H), 7.46-7.37 (m, 3H), 7.18 (t, J=8.0 Hz, 1H), 6.89-6.72 (m, 3H), 4.23 (t, J=6.8 Hz, 2H), 4.12 (q, J=7.0 Hz, 2H), 3.79 (s, 2H), 2.97 (t, J=6.8 Hz, 2H), 2.38 (s, 3H), 1.53 (s, 6H), 1.26 (t, J=7.0 Hz, 3H).

EXAMPLE 5˜EXAMPLE 5(1)

[1172] The following compounds of the present invention were obtained by the same procedure as shown in Example 2, using the compounds prepared in Example 3 or Example 4 in place of the compound prepared in Example 1, optionally followed by converting them to the corresponding salts by known methods.

[1173] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethylthio)phenyl)acetic Acid

960

[1174] TLC: Rf 0.50 (water:methanol:chloroform=1:10:100)

[1175] NMR (CDCl3): δ 7.94 (m, 2H), 7.45-7.35 (m. 3H), 7.30-7.15 (m, 3H), 7.07 (m, 1H), 3.58 (s, 2H), 3.25 (t, J=7.0 Hz, 2H), 2.81 (t, J=7.0 Hz, 2H), 2.25 (s, 3H).

EXAMPLE 5(1)

[1176] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)-2-methylpropanoic Acid

961

[1177] TLC: Rf 0.53 (hexane:ethyl acetate=1:3)

[1178] NMR (CDCl3): δ 8.00-7.94 (m, 2H), 7.46-7.41 (m, 3H), 7.15 (t, J=7.8 Hz, 1H), 7.08 (m, 1H), 6.84-6.74 (m, 2H), 4.29 (t, J=7.2 Hz, 2H), 3.88 (s, 2H), 2.99 (t, J=7.2 Hz, 1H), 2.38 (s, 3H), 1.58 (s, 6H).

[1179] 2-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenylmethylthio)-2-methylpropanoic Acid.Sodium Salt

962

[1180] TLC: Rf 0.53 (hexane:ethyl acetate=1:3)

[1181] NMR (CD3OD): δ 7.98-7.93 (m, 2H), 7.49-7.43 (m, 3H), 7.13 (t, J=7.4 Hz, 1H), 6.92-6.85 (m, 2H), 6.78-6.70 (m, 1H), 4.23 (t, J=6.6 Hz, 2H), 3.78 (s, 2H), 2.96 (t, J=6.6 Hz, 2H), 2.36 (s, 3H), 1.46 (s, 6H).

REFERENCE EXAMPLE 6

[1182] 3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzaldehyde

963

[1183] 2-(5-methyl-2-phenyloxazol-4-yl)ethanol (1.02 g), 3-hydroxybenzaldehyde (0.73 g) and triphenylphosphine (1.57 g) were dissolved in dichloromethane (10 ml) and thereto was added 1, 1′-(azodicarbonyl)dipiperidine (1.74 g) at 0° C. and the mixture was stirred at room temperature for 2 hours. To the reaction mixture was added hexane and the solid was filtered off. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (methanol:chloroform=1:100) to give the title compound (1.30 g) having the following physical data.

[1184] TLC: Rf 0.77 (methanol:chloroform=1:20)

[1185] NMR (CDCl3): δ 9.96 (s, 1H), 7.98 (m, 2H), 7.50-7.35 (m, 6H), 7.17 (m, 1H), 4.31 (t, J=6.0 Hz, 2H), 3.01 (t, J=6.0 Hz, 2H), 2.38 (s, 3H).

REFERENCE EXAMPLE 7

[1186] 3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)mandelonitrile

964

[1187] The compound prepared in Reference Example 6 (135 mg) and zinc iodide (13 mg) were dissolved in dichloromethane (3 ml). Thereto was added trimethylsilylnitrile (0.14 ml) at 0° C. and the mixture was stirred at 0° C. for 4 hours. To the reaction mixture were added cold water and a saturated aqueous solution of sodium bicarbonate and the organic layer was separated. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was dissolved in dioxane (3 ml) and thereto was added 2N hydrochloric acid (0.5 ml) and the mixture was stirred at room temperature overnight. The reaction mixture was poured into cold water and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the title compound (140 mg) having the following physical data.

[1188] TLC: Rf 0.27 (ethyl acetate:hexane=1:2);

[1189] NMR (CDCl3): δ 7.94 (m, 2H), 7.45-7.35 (m, 3H), 7.29 (dd, J=8.0, 8.0 Hz, 1H), 7.10-7.00 (m, 2H), 6.90 (m, 1H), 5.49 (d, J=6.0 Hz, 1H), 4.73 (d, J=6.0 Hz, 1H), 4.16 (t, J=6.5 Hz, 2H), 2.92 (t, J=6.5 Hz, 2H), 2.37 (s, 3H).

REFERENCE EXAMPLE 8

[1190] α-cyano-3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl chloride

965

[1191] The compound prepared in Reference Example 7 (93 mg) was dissolved in dichloromethane (3 ml), thereto were added thionyl chloride (61 ml) and dimethylformamide (1 drop) and the mixture was stirred at room temperature for 30 minutes. To the reaction mixture was added cold water and the solution was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the title compound (99 mg) having the following physical data.

[1192] TLC: Rf 0.74 (ethyl acetate:hexane=1:1)

[1193] NMR (CDCl3): δ 7.97 (m, 2H), 7.50-7.35 (m, 3H), 7.33 (dd, J=8.0, 8.0 Hz, 1H), 7.10-7.00 (m, 2H), 6.98 (m, 1H), 5.75 (s, 1H), 4.23 (t, J=6.5 Hz, 2H), 2.93 (t, J=6.5 Hz, 2H), 2.36 (s, 3H).

EXAMPLE 6

[1194] 5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2,4-thiazolidinedione

966

[1195] The compound prepared in Reference Example 8 (99 mg) was dissolved in ethanol (1 ml) and thereto was added thiourea (26 mg) and the mixture was refluxed for 3 hours. To the reaction mixture was added 2N hydrochloric acid (1.5 ml) and the mixture was refluxed overnight. The reaction mixture was poured into cold water and the solution was extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized from methanol to give the compound of the present invention (60 mg) having the following physical data.

[1196] TLC: Rf 0.31 (ethyl acetate:hexane=1:1);

[1197] NMR (d6-DMSO): δ 7.90 (m, 2H), 7.60-7.40 (m, 3H), 7.31 (dd, J=8.0, 8.0 Hz, 1H), 7.00-6.90 (m, 3H), 5.75 (s, 1H), 4.23 (t, J=6.5 Hz, 2H), 2.93 (t, J=6.5 Hz, 2H), 2.36 (s, 3H).

FORMULATION EXAMPLE

Formulation Example 1

[1198] The following components were admixed in a conventional method and punched out to give 100 tablets each containing 100 mg of active ingredient.

252-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)-10.0 gphenylmethyithio)acetic acidcarboxymethylcellulose calcium (disintegrating agent) 0.2 gMagnesium stearate (Lubricating agent) 0.1 gMicrocrystaline cellulose 9.7 g

FORMULATION EXAMPLE 2

[1199] The following components were admixed in a conventional method. The solution was sterilized in a conventional method, placed 5 ml portions into ampoules and freezedried to give 100 ampoules each containing 20 mg of active ingredient.

262-(3-(4-(4-methylphenyl)thiazol-2-ylmethoxy)- 2 gphenylmethylthio) acetic acidmannitol 5 gdistilled water1000 ml

[1200]

Number	Date	Country	Kind
10-058444	Mar 1998	JP
10-087560	Mar 1998	JP

	Number	Date	Country
Parent	09623913	Sep 2000	US
Child	10251805	Sep 2002	US

Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (2)

Divisions (1)